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1 General Introduction 
1.1 The ionotropic receptor family 
Ionotropic receptors play a substantial role in signal transmission in nerves, muscles and 
synapses. These membrane-located excitable elements are proteins capable of forming a pore 
through which ions can flow across either plasma membranes or membranes of intracellularly 
located organelles. The ion flow follows the concentration gradient, and can reach a very fast 
flow rate (e. g. 10 million ions/s at the acetylcholine receptor).1 Ionotropic channels can be 
subdivided into different classes based on their regulatory mechanisms. The two most 
prominent subfamilies are voltage-gated ion channels, which are regulated by changes in 
voltage, and ligand-gated ion channels, which are controlled by chemical transmitters (see 
Figure 1.1).  
 
 
Figure 1.1: Overview of the different subclasses of ionotropic receptors and their subtypes.2-6  
 
Other ion channels are opened for example after mechanic stimuli, by second messengers, 
changes in temperature or by light. Mechanotransduction is the conversion of mechanical forces 
into biochemical signals. It plays a very important role in the sensation of touch, hearing and 
1 General Introduction 
-2- 
 
pain. Very prominent examples are the Piezo channels Piezo1 and Piezo2, which were identified 
in 2010 in mouse as ion channels which open in response to pressure via a piezo-electrically 
driven glass probe.7 The classification of mechanically activated ion channels is difficult, because 
a lot of different cellular structures are involved in the process of mechanotransduction, and the 
representative structures often do not only respond to mechanical forces but also to other 
stimuli. Furthermore, predictable models of probable candidates like the Piezo channels indicate 
them to be very large proteins with 30 to 40 transmembrane domains. This topology lacks 
similarity to known ion channels, which are generally much smaller, as will be discussed in more 
detail further on.2 
Leaking ion channel is a term used for voltage-independent ion channels which allow ion 
trespass across membranes at normal resting potential. An example for this type of ion channel 
is the sodium leaking channel NALCN, which was discovered 1999 in rodents.8 It is reported to 
have high structural similarity to voltage-gated sodium and calcium channels, but is not 
susceptible to depolarization signals. Additionally, the channel activity is regulated by second 
messenger activity such as acetylcholine via muscarinic acetylcholine receptors.9 Therefore, the 
NALCN is an example for the capability of being activated by different stimuli.  
The two most prominent ones of those subfamilies are voltage-gated (VGICs) and ligand-gated 
ion channels (LGICs). VGICs are switched from closed to open state by changes in membrane 
potential. The first successfully cloned and sequenced VGICs were the voltage-gated Na+ channel 
(VGNC) from electroplax of Electrophorus electricus,10 the voltage-gated Ca2+ channel (VGCC) 
from rabbit skeletal muscle11 and the voltage-gated K+ channel (VGKC) from Drosophila.12 
Primary sequence analysis revealed VGNCs and VGCCs to be built by a single peptide (α-subunit) 
comprised of four homologous domains linked by three extra- and intracellular loops (see 
Figure 1.2).  
 
Figure 1.2: Topology of the human sodium channel α-subunits.13 
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The gating mechanism and general structure were confirmed by crystallization of the voltage-
gated sodium channel from Arcobacter butzleri (NavAb) in its closed state.14 Each of the four 
domains contains six transmembrane helical segments (TM) named S1 to S6, and can be 
subdivided into two parts, the voltage-sensing domain (VSD), reaching from S1 to S4, and the 
pore-forming domain, containing S5, S6 and its large amphiphilic extracellular loop (P-loop). The 
pore-forming domain is responsible for the selective permeability of ions through the cell 
membrane, while the VSD is involved in the regulation of channel opening upon membrane 
depolarization. All four domains are arranged in a pseudo-tetrameric fashion with the four pore-
forming domains building the ion passing pore. The most important feature in the VSD is S4, 
containing positively charged arginine and lysine residues roughly in every third position. It is 
suggested that in the case of membrane depolarization, those positively charged residues of the 
S4 domain are displaced towards the extracellular surface. This initiates a conformational 
change which is transferred to the pore-forming domains, resulting in the opening of the 
channel pore. This process is reversed upon membrane repolarization. The missing current 
sensitivity of leaking channels despite high structural similarity is attributed to a reduced 
number of positively charged amino acids in the S4 domain. During the depolarization state, the 
channel enters a state of inactivation. No matter how high the electrical stimulus, the channel is 
not capable of opening during this refractory period, due to the inactivation gate of the channel 
folding inside the pore. When normal membrane potential is restored and the sensory domain 
reaches its resting position, the channel’s opening capability is restored.13, 15  
Ligand-gated ion channels represent the second largest subfamily of ionotropic receptors. In 
contrast to voltage-gated ion channels, the opening of the channel pore is not linked to a change 
of the membrane potential but to the interaction of specific ligands, in most cases 
neurotransmitters, with their respective orthosteric site in the receptor protein. The binding of 
the ligand induces a conformational change leading to the opening of the pore. The resulting ion 
flow in VGIC is driven by the electrochemical gradient. Many LGIC can be found in the central 
nervous system, where they manage fast transmission between single cells. LGIC can roughly be 
divided into three different subclasses, the pentameric or Cys-loop ion channels, the tetrameric 
ionotropic glutamate receptors and the trimeric purinergic P2X receptors. The pentameric ion 
channels are the largest group of the three, including very prominent agents such as the 
nicotinic acetylcholine receptor (nACh), the 5-hydroxytryptamine receptor subtype 3 (5-HT3) and 
the γ-aminobutyric acid receptor subtype A (GABAA, see Figure 1.1).  
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Figure 1.3: Crystal structures of the human GABAA-beta3 homopentameric receptor (PDB code 
4COF) bound to the agonist benzamidine at 2.97 Å resolution and the AMPA-sensitive 
homomeric rat glutamate A2 receptor (PDB code 3KG2) in complex with the competitive 
antagonist ZK200775 at 3.6 Å resolution viewed (A) parallel to the membrane and (B) from a 
perpendicular point of view. Structures are presented as cartoon diagram with each single 
subunit colored differently.16-18  
 
The more common term Cys-loop ion channels is based on the presence of a large loop formed 
by disulfide-bridged cysteine residues in the extracellular domain. The crystal structure of the 
human GABAA receptor is presented as an example in Figure 1.3. A functional receptor protein is 
built of five identical or different subunits arranged perpendicular to the membrane. The N-
terminus of one single subunit is located extracellularly and contains around 200 amino acids. It 
is followed by three transmembrane domains named M1 to M3, and an extracellular loop 
bearing high divergence in size and amino acid sequence, mainly folded as β-sandwich sheets. 
The C-terminus is located extracellularly, and is preceded by a fourth transmembrane helix (M4). 
The ion channel pore is built by an inner ring of the second transmembrane domains M2 of each 
subunit. It is surrounded by an outer ring of 15 α-helices, the M1, M3 and M4 segments of all 
five subtypes, which separate the inner ring from the membrane. The amino acids of the M2 
domain are highly homologous, remitting in an arrangement of each identical residue in form of 
(A) 
(B) 
GABAA receptor AMPA-sensitive glutamate receptor 
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concentric rings. They are involved in the ion selectivity filter among other things. The center of 
the pore contains a ring of leucine and is maximally constricted due to hydrophobic interactions 
between neighboring helices, hindering ions from passing through. The binding of agonist 
induces a tilting movement of the upper sections of the M2 domains to the outward that results 
in a separation of the helices at midpoint, and opens the channel pore. The number of agonist 
binding sites varies between 2 to 5 depending on the receptor and its stoichiometry. They are 
localized in the extracellular loop, usually at the interface between adjacent extracellular 
domains of two subunits. The number of occupied binding pockets necessary for full channel 
opening depends on subtype and heterogeneity, e. g. the heteromeric muscle nACh receptor 
needs occupation of its both agonist binding sites for full efficacy.4, 19  
The second subclass of ligand-gated ion channels is the group of ionotropic glutamate receptors. 
Glutamate is the most important excitatory neurotransmitter in the central nervous system. The 
respective ion channel receptors can be further subdivided into three classes: α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), mainly permeable for sodium or calcium 
ions, depending on the stoichiometry, kainic acid (KA) and N-methyl-D-aspartate (NMDA), 
permeable for calcium.20 The crystal structure of the rat AMPA glutamate receptor is presented 
in Figure 1.3. The structure of all three subclasses is quite similar, despite their kinetic and 
pharmacological differences. The most detailed information results from the X-ray crystal 
structure of the rodent AMPA receptor.17 All subtypes assemble as tetrameric proteins of various 
stoichiometry. Only AMPA and selective kainate subtypes are forming homomers. The large 
extracellular amino terminal domain (ATD) includes the N-terminus and is followed by a ligand-
binding domain (LBD). The LBD contains the binding sites for agonists and antagonists and a 
transmembrane domain (TMD). The latter forms the actual ion channel. The AMPA receptor is 
much larger than the pentameric Cys-loop or the P2X receptors (see Figure 1.3). The tetrameric 
structure is kept together by the strong interactions in the TMD compartment, interactions 
between the front and back LBD subunits and interactions between the left and right ATD 
compartments. The channel opening is initiated by the binding of the agonist, in this case 
glutamate, to the LBD, which induces a conformational change. The TMD is built of three 
complete and one half α-helices of each subunit. The second transmembrane domain M2 of 
each subunit does not cross the membrane completely but folds back to the intracellular side of 
the receptor, thus forming the ion channel gate. Like many excitatory channels, glutamate 
receptors are prone to desensitization in the continuous presence of agonist to protect neurons 
from excessive excitation.5 
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ATP-gated ion channels, the P2X receptors, represent the third group of ligand-gated ion 
channels. Since the whole subfamily of P2X receptors is the main focus of this project, all 
subtypes are introduced comprehensively in the following chapter. 
 
1.2 Purinergic receptors 
1.2.1 P0, P1 and P2 receptors  
The story of purinergic signaling started in 1929, when Karl Lohman first isolated and identified 
pyrophosphoric acid and adenosine phosphates in fasciated muscle tissue.21 For a long time, ATP 
was considered to only be the main form of energy transfer inside living organisms, despite early 
hints of intracellular signal transduction processes induced by extracellular exposure to purine 
nucleotides.22 In 1972, Geoffrey Burnstock published evidence of ATP also acting as a 
cotransmitter in almost all nerves of the central and peripheral nervous system.23 ATP-mediated 
transmission was termed as “purinergic signaling”, and the first two classes of purine activated 
receptors, P1 and P2, were identified.24 The classification was based on the different activities of 
purine derivatives ATP, ADP, AMP, adenosine and methylxanthines like caffeine on the 
respective receptor subtypes and effects on second messenger systems, especially the adenylate 
cyclase.25 
 
 
Figure 1.4: Classification of purinergic receptors and their endogenous agonists. 
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Figure 1.4 illustrates all known purinergic receptor subtypes. P0 represent the youngest class of 
purinergic receptors with the recently discovered Ade1 and Ade2 receptors, both G-protein-
coupled and activated by the purine base adenine.26 P1 receptors are G-protein-coupled 
receptors and comprise four subtypes A1, A2A, A2B and A3, all activated by adenosine. The P2 class 
is further subdivided in ion channel P2X receptors, all activated by ATP,27, 28 and GPCR P2Y 
receptors activated by ATP, ADP, UTP, UDP or UDP-glucose. Eight P2Y subtypes (P2Y1, P2Y2, P2Y4, 
P2Y6 and P2Y11-14) are known, distinguishable (i) by the G-protein coupled to the receptor and 
therefore the effect on the associated second messenger system and (ii) the respective 
endogenous agonist.25, 29, 30  
 
1.2.2 P2X receptors 
P2X receptors are the only non-GPCR subclass in the purinergic receptor family. They are 
expressed ubiquitously in the whole body, but particularly in the central nervous system and in 
microglia cells, vas deferens, bladder, smooth muscle cells and pain sensing neurons.31-35 P2X 
receptors have been a central focus of research for a long time. Very particular interest lies in 
their occurrence in fast conducting excitatory neurons and their influence on the immune 
system and coagulation.36, 37 
 
1.2.3 P2X receptor topology 
The ATP-gated P2X receptors are the third main LGIC subfamily next to the pentameric Cys-loop 
channels and the tetrameric ionotropic glutamate receptors.6 Seven different subtypes have 
been identified. Their size lies between 384 (P2X4) and 595 (P2X7) amino acids.38 The tertiary 
structure of one subunit is composed of two hydrophobic transmembrane domains, positioning 
both N- and C-terminus intracellularly, and a large extracellular domain, containing ten highly 
conserved cysteine residues forming five disulfide bonds, 14 glycine residues, two to six 
potential glycosylation sites and the ATP binding sites. The binding of the agonist causes a 
conformational change that opens the ion pore and enables the flow of Ca2+, Na+ and K+ across 
the membrane.39 All P2X receptor subtypes except P2X7 enter a desensitized state upon 
prolonged exposure to the physiological agonist ATP, meaning that the receptor is temporarily 
unable to open despite the binding of the agonist. The kinetics of desensitization depends on the 
P2X receptor subtype. While P2X1 and P2X3 desensitize very rapidly, the process is noticeably 
slower for the remaining subtypes.35, 40, 41  
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Figure 1.5: Crystal structure of the homomeric truncated zebrafish P2X4 receptor in (A, C) its 
closed and (B, D) its open state while bound to ATP, viewed (A, B) parallel to the membrane and 
(C, D) from the extracellular site. Each single subunit is highlighted in a different color (blue, 
yellow, red).42 
 
Most information about the molecular architecture of P2X receptor stems from the crystal 
structure of the zebrafish P2X4 receptor (zfP2X4) in its closed and its open state.42, 43 Both 
confirmed the previously proposed trimeric assembly.44, 45 Homomeric receptors contain three 
subunits of the same type, receptor heteromers contain two different subunits in various 
(A) (B) 
(C) (D) 
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stoichiometry.46 The crystal structure allows the detailed molecular analysis of the three-
dimensional shape of one subunit itself and the fully assembled functional receptor. 
Kawate et al. crystallized the truncated homomeric zfP2X4 receptor in 2009 at a 3.1 Å resolution 
in its closed resting state with no bound antagonist.43 The receptor is shaped like a chalice with a 
large hydrophilic and glycosylated extracellular domain about 70 Å above and the 
transmembrane domains spanning roughly 28 Å through the membrane (see Figure 1.5). The 
transmembrane ion channel pore is composed of six α-helices. Each subunit contributes two α-
helices, both in antiparallel orientation towards each other and angled in an approximately 45° 
angle from the membrane axis. The three TM2 helices are oriented inwards, building the pore 
restriction in the closed resting state of the receptor, surrounded by the TM1 helices in a 
peripheral ring. The shape of one single subunit of one receptor is compared to a dolphin (see 
Figure 1.6), with transmembrane domains posing as the flukes and the extracellular region as 
the upper body domain. The core domain of the upper body contains two β-sheets, tightly knit 
together by strong interactions and therefore determining the high rigidity of the upper region. 
The body domain is augmented by the head domain, the dorsal fin and right and left flipper. The 
head domain contains three β strands and one α-helix. All three are mainly involved in the 
subunit-subunit-interface, along with the body domain. 
 
 
Figure 1.6: (A) Fold of one single and (B) intersubunit contacts of two zebrafish P2X4 subunits 
named A and B. The shape is compared to a dolphin. α-Helices (TM1 and 2, α2-5), β-sheets 
(β1-14), disulfide bonds (SS1-5) and glycosylation sites (g2 and g4) are indicated.43  
 
(A) (B) 
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Several mutagenesis studies, e. g. cysteine scanning mutagenesis, identified amino acid residues 
crucial for channel opening.47-52 Polar, aromatic and positively and negatively charged residues in 
the proposed ATP binding pocket and its immediate vicinity were exchanged. It was assumed 
that Mg2+ forms a complex with ATP, leading to the postulation that negatively charged amino 
acids like aspartate or glutamate could also contribute to ATP recognition by P2X receptors.53 
This could not be confirmed, making ATP in its fully negatively charged state the primary ionic 
form to activate P2X receptors.54, 55  
The ATP-binding sites were predicted to be located in the extracellular domain, about 45 Å from 
the ion channel domain, between two subunit interfaces. Every functional receptor contains 
three binding sites.47, 49-51, 56, 57 It was assumed that highly conserved positively charged amino 
acids following the pattern of a so-called Walker motif [GxxxxGKT] are involved in ATP 
recognition.47 This motif was previously identified in several other ATP-binding proteins.58 
Hattori et al. confirmed the postulated location by the successful crystallization of the zfP2X4 
receptor in its open state bound to ATP at 2.8 Å resolution, but identified a binding motif 
completely different from the Walker motif.42, 55  
 
Figure 1.7: Close-up view of the ATP-binding 
site with bound ATP. The glycerol (solvent) 
molecule involved in the recognition of the 
α-phosphate by K193 is shown as a red 
sphere. Hydrogen bonding is indicated by 
black dashed lines.55 
phosphate groups with positively charged amino acid residues lining the binding pocket. The 
most important residue in ATP recognition is Lys70 (K70) of the lower body of the second 
subunit. It resides in the center of the triphosphate U-shape and interacts with all three 
phosphates by the formation of salt bridges and intensive hydrogen bonding. The β-phosphate 
residue additionally interacts with Asn296 (N296) and Lys316 (K316) of the upper body domain 
of the first subunit. The latter also participates in interactions with the γ-phosphate, together 
The pocket consists of the head domain, upper 
body chain and left flipper of one subunit and 
the lower body and the dorsal fin of the 
second domain, respectively. Figure 1.7 
illustrates the exact binding conformation of 
ATP and the strictly conserved amino acids 
participating in ATP recognition. ATP adopts a 
U-shape, with the β- and γ-phosphate residues 
orientated towards the adenine ring. The base 
is buried head first into the binding pocket and 
the phosphate chain is oriented towards the 
outer surface. This conformation allows the 
intensive interaction of the negatively charged 
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with Lys72 (K72) of the second subunit and Arg298 (R298) of the first subunit. Both lysine 
residues K70 and K72 were identified as the highly conserved crucial binding motif in ATP 
recognition prior to the crystal structure, and confirmed in other P2X receptors in humans and 
rodents.48, 59-61 The α-phosphate was found to interact with Lys193 of the lower body domain of 
the second chain via a bridging molecule (glycerol in the crystal structure), that is suggested to 
be replaced by several water molecules under physiological conditions. The adenine base buried 
deep into the pocket is recognized by Thr189 (T189) and Lys70 (K70) of the lower body domain 
of the second subunit by the formation of hydrogen bonds with the side chains and the main 
carbonyl structures, respectively. Leu191 (L191) of the lower body domain and Ile232 (I232) of 
the dorsal fin of the second subunit additionally fix the adenine ring by hydrophobic interactions. 
The lack of activity of ADP and AMP at P2X receptors is explained by the insufficient interaction 
due to the shortened phosphate side chain, therefore weakening the bonding to the receptor.  
 
Figure 1.8: Reasonable mechanism of ATP-gated activation of the zebrafish P2X4 receptor. 
Sequential steps 1 to 5 are indicated.55 
 
The ATP binding induces an upper movement of the dorsal fin closer to the head domain and an 
outward movement of the left flipper. Due to the shape, it is often referred to as jaw tightening. 
Since both are coupled to the lower body domain, the movement is transferred and the whole 
lower body domain is flexed in an outward direction due to the rigidity of the contained β-
sheets. The connected TM domains are moved as well, widening the fenestrations and thus 
opening the ion channel pore (see Figure 1.8) allowing ions like Na+, K+ and Ca2+ to pass through.  
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1.2.4 P2X receptors – standard agonists 
Several derivatives of the physiological agonist ATP are also potent agonists at P2X receptors. 
The structures can be seen in Figure 1.9. EC50 values for all functional homomeric P2X receptor 
subtypes are summarized in Table 1.1. 
 
 
Figure 1.9: Structures of standard P2X receptor agonists. 
 
A very prominent feature is the relatively weak potency of the physiological agonist ATP at the 
homomeric P2X7 receptor, especially in comparison to the much higher activity of the ATP 
analog BzATP. The lacking activity of the methylene-swapped derivatives α,β- and β,γ-meATP at 
several subtypes indicate the importance of the phosphate side chain in agonist binding and 
recognition. 
 
 
α,β-MeATP 
β,γ-MeATP 
BzATP 
ATP 
2-MeSATP 
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Table 1.1: EC50 and IC50 concentrations of standard agonists and antagonists at homomeric P2X 
receptors. Data are presented as mean ± SEM.28, 40, 62-70  
 EC50 [µM] 
 P2X1 P2X2 P2X3 P2X4 P2X5 P2X7 
ATP 0.1-0.7 2-8 1.2-4.1 1-10 0.5-4 2000-4000 
BzATP 0.7-24 6-30 0.04-0.08 3 1-6 10 
α,β-meATP 0.1-1 > 100 1-2 4-300 1-12 > 300 
β,γ-meATP 2 > 300 > 300 > 300 10 > 300 
2-meSATP 0.1-1 1 0.3 10-100 0.5 200 
       
 IC50 [µM] or EC50Enhancement [µM]*, respectively 
Suramin 1-2 10 3 > 300 2-3 > 300 
RB-2 9-36 0.5 1.4a, b 3a 18.3 4.3 
TNP-ATP 0.006 2 0.001 1-15 0.6-0.7 > 30 µM 
PPADS 1 1-3 1.5 > 300 0.2-0.6 10-45 
a: EC50Enhancement of positive allosteric modulation at the respective receptor 
b: Enhancement only by the ortho-isomer (Cibacron Blue 3GA) 
 
1.2.5 P2X receptors – standard antagonists 
Early on, several weak, non-selective, nucleotide and non-nucleotide antagonists of P2X 
receptors were discovered. Anthraquinone- and ATP-derived structures are presented in 
Figure 1.10 and Table 1.1. 
 
 
Figure 1.10: Structures of standard P2X receptor antagonists. 
Suramin 
RB-2 TNP-ATP PPADS 
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Those compounds are not selective for any of the P2X receptors and show weak to potent 
inhibitory activity. The large polysulfonated suramin is capable of inhibiting not only P2X and P2Y 
receptors, but also G-proteins and various proteases including the HIV reverse transcriptase.71, 72 
Suramin, PPADS and RB-2 represent lead structures for the development of further potent P2X 
receptor inhibitors, which is discussed in more detail in chapter 3.1. 
 
1.2.6 The P2X1 receptor subtype 
The P2X1 receptor is particularly expressed in smooth muscle and blood cells. It plays a major 
role in the control of urinary tract and bladder function, of vasoconstriction, platelet aggregation 
and regulation of vas deferens.36, 73-78 The receptor was first cloned from rodent vas deferens 
and expressed in Xenopus oocytes in 1994, and was identified to be 399 amino acids long.79  
The physiological agonist at the P2X1 receptor is ATP. Its activity at the homomeric receptor is 
comparable to the synthetic ATP analog α,β-meATP (see Table 1.1). Upon agonist stimulation, 
the channel opens only for milliseconds. Simultaneously, a rapid desensitization of the receptor 
is observed, when agonist stimulation occurs longer than a few hundred milliseconds and the 
applied agonist concentration is higher than 1 µM.38 This process can be reversed, but 
resensitization takes much longer. Upon repeated agonist application in less than 10-minute 
intervals, the responsive currents are getting progressively smaller, and receptor internalization 
can be detected.28, 79, 80 These features influence the functional effects of ATP. In the human 
leukemia cell line HL60, P2X1 receptor expression could be observed, but measurable currents 
were only observed after pretreatment with apyrase. This phenomenon was ascribed to high 
extracellular ATP concentrations, caused by constant release by adjacent cells and leading to 
continuous desensitization of the P2X1 receptor. Apyrase cleaves the extracellular ATP, leading 
to resensitization.81 Similar effects can be observed concerning receptor internalization. The 
receptor reappears in the extracellular membrane when the extracellular ATP concentration is 
diminished.80 The desensitization can be reversed by introducing parts of the slow desensitizing 
P2X2 receptor into the structure of the P2X1 subunit, yielding receptor chimeras. This was 
detected using mutagenesis experiments to exchange the extracellular loop, one or both 
transmembrane domains as well as N- and C-terminus, respectively. Four variant amino acids 
located immediately before TM1, 20RMNL23, were identified to play a particular role in 
desensitization. When swapped to the respective P2X2 receptor sequence, desensitization 
slowed significantly.82 The exchange of the N-domain to the respective P2X2 receptor part 
diminished receptor desensitization from 90 ± 1 % to 2 ± 0.3 % during 10 second application of 
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ATP 100 µM. The respective C-domain exchange rendered a non-functional channel.83 Site-
directed mutagenesis and molecular modeling experiments at the P2X1 receptor formed a large 
part in structural elucidation of P2X receptor assembling and function, which could be proven by 
the two successful crystal structures (see chapter 1.2.2).47, 52, 60, 84 
The rapid desensitization occurs milliseconds after exposure to agonist and aggravates 
experimental characterization of the P2X1 receptor. In order to stabilize the receptor and enable 
functional experiments like measurement of calcium influx without influencing binding 
properties of the receptor, the whole first transmembrane domain including the N-terminal 
region of the human P2X1 receptor was exchanged to the respective part of the P2X2 receptor 
by PD Dr. Anke Schiedel in our lab. The mutant was then retrovirally transfected in 1321N1 
astrocytoma cells by Dr. Aliaa Abdelrahman, rendering a cell line stably expressing the human 
P2X1-2 chimera. In previous experiments, only the transmembrane parts or the respective 
termini were replaced, not the complete domain with the attached terminus.82, 83 We replaced 
the complete first transmembrane domain including the N-terminus (i) to stabilize the P2X1 
receptor to the level of the P2X2 receptor and (ii) to not influence the gating and ATP binding 
mechanism and guarantee a fully functional receptor, since the gating TM2 remained 
unchanged. This stable receptor mutant transfected in 1321N1 astrocytoma cells was used in all 
experiments discussed in this dissertation. When results at the P2X1 receptor are discussed, the 
P2X1-2 receptor is meant. 
 
1.2.6.1 P2X1 receptor antagonists 
Several potent P2X1 receptor antagonists could be identified. Figure 1.11 shows the structures 
of 8,8’-[carbonyl-bis(imino-4,1-phenylenecarbonylimino-4,1-pheylene-carbonyl-imino)]bis-1,3,5-
naphthalene trisulfonic acid (NF279), 8,8’-[carbonyl-bis(imino-3,1-phen-ylenecarbonylimino)]bis-
1,3,5-naphthalene-trisulfonic acid (NF023) and 4,4’,4’’,4’’’-[carbonylbis-(imino-5,1,3-
benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzene disulfonic acid (NF449), all truncated 
suramin derivatives with nanomolar inhibitory potency at the P2X1 receptor.85 Other P2X1 
receptor antagonists are PPADS derived MRS2220 and the benzimidazole-2-carboxamide 
derivative RO-0437626 (RO-1). Suramin-derived compounds are described to be competitive 
antagonists. PPADs-derived structures are described as acting non-surmountable with very slow 
receptor resensitization.86 RO-0437626 was the first P2X1 receptor antagonist proven to be 
selective towards P2X2, P2X3 and the heteromeric P2X2/3 receptor, but showed a relatively 
weak potency.87 
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Figure 1.11: Structures and inhibitory potency of suramin-derived P2X1 antagonists NF279, 
NF449 and NF023, PPADS-derived MRS2220 and RO-0437626, also known as RO-1.86-91  
 
 
NF279 
IC50 0.0019 ± 0.0008 µM 
NF449 
IC50 0.000288-0.0708 µM 
N023 
IC50 0.21-0.24 µM 
RO-0437626 (RO-1) 
IC50 3 µM 
MRS2220 
IC50 10.2 ± 2.6 µM 
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1.2.6.2 P2X1 receptor allosteric modulators 
One allosteric modulator of the P2X1 receptor has been identified until now. During the 
development of the PPADS-derived antagonists, one compound was found to potentiate ATP-
induced currents at the P2X1 receptor with an EC50Enhancement concentration of 5.9 ± 1.8 µM. The 
effect was selective towards the P2X2, P2X3 and P2X4 receptor.86 The structure of the 
compound, MRS2219, is presented in Figure 1.12. 
 
 
Figure 1.12: Structure and enhancing potency of PPADS-derived P2X1 positive allosteric 
modulator MRS2219.86  
 
1.2.7 The P2X2 receptor subtype 
The human P2X2 receptor was cloned from pituitary and pancreas, and is 471 amino acids 
long.92 It is expressed ubiquitously in the body, especially in the peripheral and the central 
nervous system, smooth muscle cells, pancreas and sensory nerves.93-95 Receptor homomers as 
well as heteromeric assembles can be found, mostly in combination with P2X3 or P2X6 subunits 
in various stoichiometry. The heteromeric P2X2/3 receptor contains one P2X2 and two P2X3 
subunits, while the respective P2X6 heteromer is formed by two P2X2 and one P2X6 subunit.96 
Mutagenesis studies on the P2X2 receptor contributed to clarification of P2X receptor topology. 
Examples are the identification of an important salt bridge between Glu63 (E63) and Arg274 
(R274) at the subunit interface in direct vicinity of the ATP binding site. This salt bridge is 
possibly involved in transferring the conformational change upon agonist binding to the ion 
pore. Another example is the identification of amino acids Thr336 (T336) and Thr339 (T339) as 
being a vital part of the closed channel gate.97, 98 
The activity of the P2X2 receptor can be modulated allosterically by low concentrations of 
transition metals zinc and copper. Copper is capable of enhancing ATP-gated currents of the rat 
P2X2 receptor more than 25-fold at 10 µM concentration. Site-directed mutagenesis studies 
revealed that the bivalent cations are not recognized by cysteine, but by histidine residues in the 
extracellular loop, namely His120, His192, His213 and His245. They are proposed to be part of a 
common allosteric metal binding site. There is evidence that copper and other metals like nickel 
MRS2219 
EC50Enhancement 5.9 ± 1.8 µM 
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and mercury potentiate the receptor.99 These findings are in contrast to the human P2X2 and 
the P2X1 receptor, where zinc shows concentration-dependent receptor inhibition. At P2X3, zinc 
also shows weak potentiation of ATP-induced current.100, 101 The P2X2 receptor shows 
desensitization, but much slower than the P2X1 receptor. It is therefore considered as stable and 
non-desensitizing, and is accessible to functional experiments, e. g. measurement of calcium 
influx.38 
 
1.2.7.1 P2X2 receptor antagonists 
Several non-selective antagonists of the P2X2 receptor homomer are known, including the 
already discussed compounds suramin, PPADS and TNP-ATP. Suramin and RB-2 were used as 
templates for the development of new and selective P2X2 receptor antagonists. Suramin-analog 
7,7’-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)carbonyl-
imino))bis-(1-methoxy-naphthalene)-3,6-disulfonic acid (NF770) is described to be more potent 
and selective towards the P2X2 receptor in rodents, and is described to inhibit the receptor in a 
competitive way.102 RB-2 derivatives PSB-1011 and PSB-10211 were presented in 2011 as the 
first potent and selective competitive rodent P2X2 receptor antagonists.103 Nicardipine, a 
dihydropyridine calcium channel blocker, was identified as an antagonist at the rat P2X2 
receptor with almost ninefold preference in comparison to the P2X4 receptor.104 Streptomycin 
and related aminoglycoside antibiotics are further approved drugs identified as weak P2X2 
receptor antagonists. Further analysis identified them as noncompetitive antagonists, which 
block the open channel and stabilize the receptor in an open non-conductive way.105  
 
1 General Introduction 
-19- 
 
 
 
Figure 1.13: Structures and inhibitory potency of P2X2 receptor antagonists NF770, PSB-10211, 
PSB-1011, streptomycin and nicardipine.102-105  
 
1.2.7.2 P2X2 receptor allosteric modulators 
Nicardipine derivative MRS2154 and anthraquinone compound sodium 1-amino-4-(3-phenoxy-
phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-10129) were identified as 
potent positive allosteric modulator (PAMs). They enhanced the ATP-induced currents of the 
P2X2 receptor when used in high nanomolar to low micromolar concentrations, demonstrating 
that inhibiting and enhancing effects lie close together structurally and cannot generally be 
applied to a whole library of similar compounds.103, 104 The structure and potency can be seen in 
Figure 1.14. 
 
NF770 
IC50 0.019 µM 
Nicardipine 
IC50 24 ± 5 µM 
Streptomycin 
IC50 71 ± 20 µM 
PSB-10211 (R = H)  
IC50 0.076-0.098 µM 
 
PSB-1011 (R = SO3H) 
IC50 0.068-0.090 µM 
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Figure 1.14: Structures of RB-2- and nicardipine-derived positive allosteric P2X2 modulators 
PSB-10129 and MRS2154.103, 104  
 
1.2.8 The P2X3 receptor subtype 
The cDNA of the P2X3 receptor was first cloned from dorsal root ganglion sensory neurons of 
the rat in 1995, and is 397 amino acids long.68 It is expressed on primary sensory neurons and 
other cells in the CNS as well as the bladder, and closely associated with genesis and 
transmission of neuropathic pain, which could be confirmed in a knock out mouse 
model.75, 106, 107 The receptor can be found on pre- and postsynaptic membranes of various 
ganglia of the somatosensory signal pathway, where ATP is released from neurons together with 
fast conducting glutamate and other neurotransmitters involved in forwarding of pain signals. 
The homomeric P2X3 receptor is a non-selective cation conducting channel with high 
permeability for calcium ions.108 It is further characterized by high ion permeability in its open 
state and fast desensitization followed by a long regeneration period, which is observed after 
exposure to the physiological agonist ATP.68 Sokolova et al. promoted two types of 
desensitization observed in rodent sensory neurons. The first one was a fast process occurring 
after 50 msec by 10 µM ATP, and the second one a slow process after 35 sec by 0.01 µM ATP, 
which inhibited the receptors without previous activation. The latter was termed high affinity 
desensitization (HAD). The effect is attributed to the high affinity of ATP at the P2X3 receptor.109 
The recovery from desensitization is agonist-specific and takes seconds to minutes. 
Furthermore, it is dependent on the temperature (the higher the temperature, the faster the 
recovery) and the extracellular ion concentration (acceleration by increased calcium and 
decreased magnesium concentrations).110 Naproxen, a non-steroidal anti-inflammatory drug, is 
capable of accelerating the desensitization process of recombinant P2X3 receptors. This is 
considered to be a possible explanation for its effectiveness against migraines.111 The recovery 
time depends on the agonist. Resensitization occurs very fast when the receptor is stimulated 
with β,γ-meATP, but is unusually slow when 2-meSATP is used.109  
PSB-10129 
EC50Enhancement 0.489 ± 0.090 µM 
MRS2154 
EC50Enhancement 0.3-10 µM 
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The discovery that the functional properties of recombinant P2X3 receptors, e. g. the different 
responses to agonist α,β-me-ATP, do not properly correlate with P2X receptors tested in dorsal 
root ganglions is explained by the formation of heteromeric assemblies of two different 
subtypes.108 These receptor heteromers have a different pharmacological properties and do not 
desensitize. P2X2/3 receptors were the first identified and the best characterized P2X 
heteromer. The stoichiometry was initially found to be fixed of one P2X2 and two P2X3 
subunits.49, 112 Recently, evidence has been presented that this ratio is not exclusive and that the 
stoichiometry also depends on the expression level of both receptor subunits.113 The assembly of 
heteromeric receptors appears not to be controlled by the extracellular loop, but by the 
transmembrane domain, in particular TM2 and the intracellular region located directly before 
it.114 The structural differences subsequently also influence agonist and antagonist 
pharmacology. Potent ligands like agonist [γ-32P]8-Azido-ATP or antagonists Ip5I and RO-85 are 
active at the homomeric, but not the heteromeric receptor.46, 115-117  
Desensitization of the homomeric P2X3 receptor hinders functional experiments like patch-
clamp or measurement of calcium influx. Heteromeric assembly allows no experimental 
estimation of the P2X3 properties of new potential ligands, since the heteromeric P2X2/3 
receptor shows a complete different pharmacology. Several studies were conducted to create 
stable receptor mutants with no change of receptor pharmacology. Neelands et al. exchanged 
the N-terminal region and the associated transmembrane domain to the respective part of the 
P2X2 receptor. Patch-clamp experiments demonstrated that agonists ATP and α,β-meATP 
activate the receptor to the same extent, but the kinetic of desensitization of the P2X2-3 
receptor chimera is much slower than for the homomeric receptor.62 The long recovery time was 
attributed to the high affinity of both agonists, which bind effectively to the receptor in 
concentrations below those required for successful receptor activation. The return to normal 
excitability is delayed by the slow dissociation of the agonist.69 
The N-terminal region seems to be responsible for the fast desensitization kinetics of the P2X3 
receptor. The comparison of the primary receptor of the N-terminus of rat P2X2 and P2X3 
receptors showed that 20 out of 47 amino acids of both subunits are identical By side-directed 
mutagenesis of single and longer parts of different amino acids, it was discovered that the 
exchange of three amino acids located directly before the transmembrane domain against the 
respective P2X2 equivalent is sufficient to slow the desensitization process significantly. Further 
experiments revealed that changing the serine in position 15 of the native rat P2X3 receptor to 
valine or other hydrophobic amino acids like isoleucine or phenylalanine is enough to 
significantly reduce receptor desensitization to the level of the P2X2 receptor. Agonist and 
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antagonist affinity was proposed to not be affected by the site-directed mutagenesis.118 Dr. Ralf 
Hausmann kindly provided the non-desensitizing valine mutant S15V of the rat P2X3 receptor 
stably transfected in 1321N1 astrocytoma cells. This cell line was used in all experiments 
discussed in this dissertation. When results at the P2X3 receptor are mentioned, the S15VrP2X3 
receptor mutant is meant.  
The stabilizing effect of the same mutation could also be seen for the human P2X3 receptor, but 
since the attempt to stably transfect the construct into 1321N1 astrocytoma cells failed 
repeatedly, it was not available for testing. 
 
1.2.8.1 P2X3 receptor antagonists 
Several selective antagonists of the P2X3 receptor have already been described. The first small 
potent drug-like competitive P2X3 receptor antagonist discovered was A-317491 with Ki 
concentrations in the low nanomolar range at human and rat P2X3 and P2X2/3 receptors, 
respectively. It is highly selective over other P2 or neurotransmitter receptors (IC50 > 10 µM).
119 
The (S)-enantiomer was potent, the (R)-configurated derivative called A-317344 was completely 
inactive. Another potent and selective P2X3 antagonist is AF-353, also called RO-4, a small drug-
like and highly selective non-competitive P2X3 and P2X2/3 receptor antagonist. The compound 
is structurally related to the antibacterial drug trimethoprim, which itself does not have any 
inhibitory potency at the P2X3 receptor.120 IC50 values were determined for human and rat P2X3 
and human P2X2/3 receptors. It was deemed the better in vivo tool over A-317491 due to 
improved bioavailability and higher plasma-free fraction.121 The structure was further optimized 
by introduction of features with increased polarity, leading to the potent antagonist AF-906 
(RO-51). AF-906 shows inhibitory potency in the low nanomolar range at both human P2X3 and 
P2X2/3 receptors.122 AF-219, an aryloxy-pyrimidinediamine, has been described as a potent 
allosteric P2X3 receptor antagonist and was recently evaluated in clinical phase II studies for 
treatment of chronic cough, osteoarthritic joint pain and asthma. Until now, the structure of the 
compound is undisclosed.123  
Another very potent antagonist is thienopyrazole derivative RO-85. The compound is slightly 
more potent at the rat than the human P2X3 receptor, but selective not only toward the other 
P2X receptor subtypes but also towards heteromeric P2X2/3 receptors. The high metabolic 
stability and good bioavailability make it a valid candidate for clinical testing.117 Another potent 
P2X3 antagonist is MK-3901, which was successfully tested in a chronic inflammatory and 
neuropathic pain experimental model and is also reported to have good bioavailability.124 The 
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suramin-derived compound NF110 was shown to inhibit P2X3 with low nanomolar potency and 
was found to be less potent at P2X1, P2X2, P2X4 and P2X7, despite the high structural similarity 
to P2X1 receptor antagonist NF449.125  
Spinorphin is a very effective non-competitive antagonist of human P2X3 receptor with 
subnanomolar affinity and was selective towards mouse P2X1 and human P2X7 receptor.126 All 
mentioned antagonists and respective IC50 and Ki values are shown in Figure 1.15. 
 
 
 
Figure 1.15: Structures and inhibitory potency of P2X3 antagonists A-317491, MK-3901, AF-353 
(RO-4), AF-906 (RO-51), RO-85 and spinorphin.117, 119, 121, 122, 124-126  
A-317491 
Ki 0.022-0.092 µM 
MK3901 
IC50 0.024 µM 
AF-353 (RO-4) 
IC50 0.0087-0.0389 µM 
 
AF-906 (RO-51) 
IC50 0.00200-0.00501 µM 
 
RO-85 
IC50 0.0316-0.398 µM 
 
Spinorphin 
IC50 0.00083 ± 0.00022 µM 
 
NF110 
Ki 0.036 ± 0.007 µM 
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1.2.8.2 P2X3 receptor allosteric modulators 
Cibacron Blue 3GA, the purified ortho-isomer of RB-2 (see Figure 1.10), was identified as a PAM 
of human and rat P2X3 receptor by Alexander et al. in 1999.127 It enhanced the ATP-induced 
calcium influx and transmembrane currents three- to seven times higher than the normal level 
with low micromolar potency (EC50Enhancement 1.4 ± 0.5 µM). The enhancing effect is not 
dependent on the agonist, since it is also observed when the receptor is stimulated with the ATP 
analogs BzATP, 2-meSATP or α,β-me-ATP. 
 
1.2.9 The P2X4 receptor subtype 
The P2X4 receptor was first cloned from rat hippocampus. Furthermore, the mRNA of the 
receptor was found ubiquitously in purkinje cells, spinal cord motor neurons and medulla 
oblongata.128 It is described to be the widest distributed P2X receptor in the organism, and is 
expressed in central and peripheral nervous system including activated microglia, epithelia, 
smooth muscle cells in bladder, intestines and uterus, arteries, uterine endometrium, 
osteoclasts, kidney, lung, heart, liver, pancreas, B lymphocytes and fat cells.129, 130 A knockout 
mouse model tested in different pain and inflammation models showed the association of the 
P2X4 receptor with genesis and forwarding of neuropathic pain, inflammatory-associated pain 
and tactile allodynia.131 Furthermore, it was found to be upregulated in case of neuronal injury 
or inflammation caused by various transcriptional and translational controlling factors, e. g. the 
CC chemokine receptor (CCR2), CC chemokine CCL21, fibronectin and the transcription factor 
interferon regulatory factor 8 (IRF8).132 CCR2 was further identified as a regulator of P2X4 
receptors trafficking from lysosomes to the cell surface via exocytosis. Stimulation of CCR2 with 
endogenous ligands CCL2 or CCL12 increased the levels of cell surface-located P2X4 receptors. A 
decrease was observed under the influence of CCR2 antagonist RS-504393.133 Neuropathic pain 
is a debilitating pain condition and mainly caused not by noxious stimuli, but by neuronal 
damage. Pain treatment as applied for pain caused by external stimuli (e. g. NSAIDs and opioids) 
is ineffective for neuropathic pain. The lack of potent drugs makes it an interesting field for 
scientific research and the design of novel, selective and effective drug-like ligands. 
Furthermore, P2X4 receptors were found to be associated with the enzyme endothelial nitric 
oxide synthase (eNOS) in murine ventricular myocytes. The stimulation of P2X4 receptors was 
found to stimulate the activity of eNOS, resulting in increased levels of cardiac NO, 
demonstrating cardioprotection in heart failure and improvement of cardiac function.134  
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1.2.9.1 P2X4 receptor antagonists 
The rat P2X4 receptor is not inhibited by classic standard antagonists such as suramin and PPADS 
in concentrations up to 300 µM. In contrast, the mouse and human orthologues have a weak 
sensitivity to PPADS, and Coomassie Brilliant Blue G (BBG) is also a weak antagonist, as well as 
RB-2.28 TNP-ATP is the most potent competitive, though non-selective antagonist (see Table 1.1). 
Since antidepressants have been proven to be effective against neuropathic pain states, a 
selection of antidepressant compounds have been tested for inhibitory potency at the P2X4 
receptor. Paroxetine was identified as a potent allosteric antagonist of rat and human P2X4 
receptors with low micromolar potency. Furthermore, it was demonstrated to be an effective 
drug in a neuropathic pain model. The antinociceptive effect could not be attributed to the 
serotonin receptor pathway.135 Amitriptyline, a tricyclic antidepressant clinically approved for 
the treatment of neuropathic pain, is only a weak inhibitor of P2X4 receptors. Due to its lack of 
potency, P2X4 receptor inhibition is not considered as the defining factor for efficacy against 
neuropathic pain.136  
 
 
 
Figure 1.16: Structure and potency of P2X4 antagonists BBG, paroxetine, BX430, PSB-12054, 
PSB-12062, N,N-diisopropylcarbamazepine and 5-BDBD. The potency of BBG at the P2X7 
receptor is further discussed in chapter 1.2.12.1.64, 135, 137-140  
 
BBG 
IC50 (P2X4) 3.16 ± 0.75 µM 
IC50 (P2X7) 0.01-0.265 µM 
Paroxetine 
IC50 1.87-2.45 µM 
 
BX430 
IC50 0.54 µM 
 
PSB-12054 
IC50 0.189-2.10 µM 
 
PSB-12062 
IC50 0.928-1.76 µM 
 
N,N-Diisopropyl-
carbamazepine 
IC50 3.44-54.6 µM 
 
5-BDBD 
IC50 1.2 µM 
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Benzodiazepine derivative 5-BDBD is a selective antagonist of the P2X4 receptor. The 
information of its mode of action is inconclusive. References for competitive and allosteric 
binding of 5-BDBD are known.137, 141 Another lead structure for successful and selective P2X4 
antagonism is phenoxazine. A compound library of effective N-substituted derivatives was 
synthesized. They enabled structure-activity relationships at the P2X4 receptor for the first time. 
The structure of the most active compound PSB-12054 inhibited the P2X4 receptor with 
nanomolar potency and was at least tenfold selective towards human P2X1, P2X2, P2X3, and 
P2X7 receptors. One disadvantage of the compound is its poor water solubility. The closely 
related derivative PSB-12062 is more water-soluble with potency and selectivity similar to PSB-
12054.64 Structurally distantly related anticonvulsant drug carbamazepine and derivatives were 
identified as potent P2X4 receptor antagonists as well. The most effective compound of the 
series was N,N-diisopropylcarbamazepine. The compound was fairly selective towards human 
P2X2 and P2X7, but not P2X1 and P2X3 receptors (IC50 P2X1 5.32 ± 1.91 µM and P2X7 
7.18 ± 2.86 µM, respectively).138 The newest P2X4 receptor-selective phenylurea antagonist 
BX430 was recently discovered by screening the Canadian Chemical Biology Network library 
using calcium imaging and whole cell patch clamp experiments. BX430 inhibited the P2X4 
receptor with high nanomolar potency. The compound is described to be soluble in physiological 
solutions and stable at room temperature, and to be selective towards human P2X1-3, P2X5 and 
P2X7 receptors.139  
 
1.2.9.2 P2X4 receptor allosteric modulators 
Ethanol was identified as an allosteric antagonist of the P2X4 receptor. The inhibitory effect can 
only be seen at high concentrations (100 mM), which makes ethanol not very interesting as a 
P2X4 receptor antagonist. However, there are several genomic findings including the decrease of 
P2X4 receptor mRNA expression in the brain of alcohol-preferring rats indicating that P2X4 
receptor activation may play a role as a reducer of alcohol intake and preference.142 Therefore, 
the activated P2X4 receptors may contribute to sobriety and reduction of alcohol use disorders. 
The broad-spectrum antiparasitic drug ivermectin has been identified as a positive allosteric 
modulator of the P2X4 receptor with high nanomolar to low micromolar potency in 1999 (see 
Figure 1.17).143 Ivermectin is a macrolide drug isolated from Streptomyces avermectinius as a 
mixture of two compounds Ivermectin H2B1a and ivermectin H2B1b, and is approved for the 
treatment of onchocerciasis and in a topical form for rosacea. Further investigations identified 
ivermectin as an effective drug to reduce alcohol intake and preference by antagonizing ethanol-
induced inhibition of P2X4 receptors, which could be verified in an animal model.144-146 The 
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positive allosteric modulation can be observed at other ion channels like the glutamate-gated 
chloride channel, γ-aminobutyric acid type-A receptor, glycine receptor or neuronal α7-nicotinic 
receptor.147 Ivermectin is perorally bioavailable, widely distributed in the body, especially in cell 
membranes due to its high lipophilicity. It also penetrates past the blood brain barrier into the 
CNS.148 Low concentrations of ivermectin increase the ATP-induced signal at the P2X4 receptor, 
higher concentrations retard channel closing and receptor desensitization during sustained ATP 
presence and thereby temporarily induce pore dilation.147, 149 Those different effects were 
explained by the existence of two different binding sites for ivermectin at the P2X4 receptor, 
one with high affinity in the high nanomolar and one with lower affinity in the lower micromolar 
range.147, 150 This theory is not proven since binding site of ivermectin has not yet been fully 
identified. There is evidence that the transmembrane domains are involved in ivermectin 
recognition. Several residues apparently involved in ivermectin recognition could be identified 
by side-directed mutagenesis.151  
Other PAMs of the P2X4 receptor are d-tubocurarine, a muscle relaxant first isolated from 
Chondrodendron tormentosum, RB-2, the standard antagonist at the P2X2 receptor, and i.v. 
anesthetic propofol. The allosteric effects of d-tubocurarine were identified while characterizing 
the rat P2X4 receptor using the radioligand [35S]ATPγS. D-tubocurarine increased radioligand 
binding when used in concentrations above 10 µM.152 Cibacron Blue 3GA is a weak inhibitor 
especially at the P2X2 receptor. The compound is derived from anthraquinone, and was selected 
as the lead structure for the development of a broad variety of P2X receptor ligands (see 
chapter 3.1). The positive allosteric modulation is expressed in increased responses of rat P2X4 
receptors to ATP. Cells were preincubated with 3-30 µM Cibacron Blue 3GA prior to ATP 
stimulation. The increase could be attributed to enhanced ATP potency without affecting the 
maximum signal.153 Propofol is known as an allosteric enhancer at the GABAA receptor, which is 
considered responsible for its general anesthetic and anticonvulsant effect. It was found to 
enhance ATP-evoked signal at rat P2X4 receptors when used in concentrations higher than 
50 µM, and was selective towards rat P2X2 and P2X2/3 receptors.154 Hasaka et al. confirmed this 
observation, but enhancement of ATP-induced signal was observed at much lower propofol 
concentrations (0.3-3 µM). Higher concentrations were observed to inhibit ATP-induced P2X4 
receptor currents in mouse microglia cells.155 The activity of propofol at the P2X4 receptor was 
deemed responsible for excitatory side effects of propofol administration.154  
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Figure 1.17: Structure and potency of positive allosteric P2X4 modulators. The potency of 
ivermectin and propofol at the P2X7 receptor is discussed in chapter 1.2.12.2.143, 152, 154-156  
 
1.2.10 The P2X5 receptor subtype 
The P2X5 receptor was first discovered in rat celiac ganglia along with the P2X6 receptor.157 In 
humans, it was first discovered in the fetal brain in a truncated form.158 It was later identified to 
miss exon 10, which encounts for the major part of the second transmembrane domain.159 When 
compared to the other P2X receptor subtypes, the expression of P2X5 receptors in the body is 
limited. It was found in mesencephalic nucleus of the trigeminal nerve, cervical spinal cord, 
purkinje cells of the cerebellum, heart, adrenal gland and retina.28, 157, 160, 161 There is evidence 
that the P2X5 receptor is found in epithelial cancer cells and in the immune system, especially 
thymus.158, 162 The receptor presentation on the membrane is usually poor. The function of the 
receptor is not yet fully cleared in humans. 
The P2X5 receptor shows fast rapid currents and slow desensitization upon prolonged exposure 
to ATP. The recovery from the desensitized state is also very slow.159 The receptor is sensitive to 
Ivermectin 
EC50Enhancement (P2X4) 0.25 µM, 2 µM 
EC50Enhancement (P2X7) 0.056 µM, > 10 µM  
(two postulated binding sites) 
R = CH2CH3: Ivermectin H2B1a (main component, > 90 %) 
R = CH3: Ivermectin H2B1b (minor component, < 10 %) 
d-Tubocurarine 
EC50Enhancement 3-30 µM 
Propofol 
EC50Enhancement (P2X4) 0.3-50 µM 
EC50Enhancement (P2X7) 40-60 µM 
Cibacron Blue 3GA 
EC50Enhancement > 10 µM 
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standard agonists ATP and 2-meSATP with low micromolar potency. The rat receptor does not 
react to α,β-meATP, and the potency at the human orthologue is comparable to the other 
agonists, although α,β-meATP and BzATP act as a partial agonist.67, 159  
Standard antagonists PPADS, TNP-ATP, suramin and RB-2 are active at the rat P2X5 receptor 
with diminishing potency. The human variety was inhibited by PPADS, Brilliant Blue G and 
suramin.28 The P2X5 receptor was found to form a heteromeric receptor together with the P2X1 
subunit. The so-called P2X1/5 receptor displays properties of both subtypes. The current 
desensitizes slowly and the ATP potency is similar to the P2X1 receptor. The potency of agonist 
α,β-meATP is increased to the level of the P2X1 receptor.163 Furthermore, the P2X1/5 heteromer 
was found to be highly sensitive to the P2X1 antagonist NF449 (see Figure 1.11), while the 
inhibitory potency of TNP-ATP was reduced in comparison to its potency at the homomeric P2X1 
receptor.28, 67, 164  
Recently, heteromeric receptors of P2X2 and P2X5 subunits in various stoichiometry were 
discovered. The identified functional properties include pore dilation, membrane blebbing and 
phosphatidylserine exposure. All features were previously associated solely with the P2X7 
receptor.165 The sensitivity to ATP and BzATP was slightly reduced in comparison to the 
homomeric P2X2 receptor, while the inhibitory potency of TNP-ATP was found to be increased, 
and α,β-meATP had no effect.46, 165  
 
1.2.11 The P2X6 receptor subtype 
The P2X6 subunit was identified along with the P2X5 receptor in 1996 in rat celiac ganglia, a 
protein of 379 amino acids.157 High mRNA expression was found in cerebellar Purkinje cells, 
ependymal, CA1 region of hippocampus, spinal motor neurons, uterus, ovary and bronchial 
epithelia.28, 157, 166 The first characterization after discovery via patch clamp experiments showed 
quick currents after stimulation with ATP, 2-MeSATP and ADP, α,β-meATP was not active.157 
Another study at recombinant P2X6 receptors transfected in human embryonic kidney cells 
reported sensitivity to ATP and α,β-meATP with low nanomolar potency in the absence of any 
other P2X receptor subunit (EC50 0.5 µM and 0.6 µM, respectively). Standard antagonists TNP-
ATP and PPADS were also active (IC50 0.8 µM and 22 µM, respectively), but not suramin.
167 
Currents upon stimulation were observed only in a small fraction of the cells. Membrane-located 
P2X6 receptors were confirmed by western blot analysis in ATP-responsive cells, but the protein 
was more heavily glycosylated than in non-responsive cells.168 The receptor shows poor 
membrane presentation and accumulates in the endoplasmic reticulum.169 The P2X6 subunit is 
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unable to oligomerize to build a functional homomeric receptor, which was attributed to an 
uncharged sequence of 14 amino acids in the N-terminal region that is unique among P2X 
receptors.169 While evidence of homomeric P2X6 receptors is inconclusive, heteromeric 
assembly with P2X2 or P2X4 subunits is documented.46, 170, 171 The P2X2/6 receptor has lower 
ATP potency and lower pH tolerance than the homomeric P2X2 receptor and shows slow 
desensitization kinetics.170 One functional receptor contains  two P2X2 and one P2X6 subunits, 
respectively.96  
The P2X6 receptor also easily forms heteromers with the P2X4 receptor. The functional 
properties of the heteromer closely resemble those of the P2X4 receptor, including weak 
potency of α,β-meATP, similar potency of ATP and 2-meSATP and inhibition by suramin and 
RB-2.171  
 
1.2.12 The P2X7 receptor subtype 
The P2X7 receptor was originally cloned from rat brain. It is identical to the previously described 
P2XZ receptor, which was found responsible for the formation of membrane pores in 
macrophages upon exposure to high ATP concentrations.172 The human orthologue was 
discovered shortly after in monocytes.173 The topology of the receptor matches all previously 
discovered P2X subunits. However, the amino acid sequence, specifically the C-terminal region, 
is much longer than in all other subtypes. The complete subunit is 595 amino acids long. The C-
terminal domain is important for correct oligomerization and posttranslational modification of 
the receptor, and contains several motifs for protein- and lipid interaction and a cysteine-rich 
amino acid section.174 It is orientated solely intracellularly and does not possess any length of 
hydrophobic residues spanning through the membrane.172 The mRNA is excessively found in 
bone marrow cells including granulocytes, monocytes, B-lymphocytes, spleen, heart, placenta, 
testes, liver, epithelial cells, osteoblasts, microglia and several neuronal cells.28, 173, 175 The 
receptor is further differentiated from the other P2X subtypes by its low sensitivity to the 
physiological agonist ATP. The rat receptor is activated by 0.1 to 100 µM ATP, while the human 
receptor requires higher concentrations (see Table 1.1).28 BzATP is around 100-fold more potent 
at the P2X7 receptor than ATP (see Table 1.1). 2-MeSATP is also a weak agonist, while 
α,β-meATP and β,γ-meATP are not active. Prolonged exposure to agonist also induces a higher 
permeation pathway in the cell membrane, which can induce cell death. It also enables 
permeability of compounds of high molecular mass like YO-PRO1, a fluorescent dye, or cations 
like N-methyl-D-glucamine or quinolinum.173, 176 It is not yet fully cleared how the higher 
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permeability is achieved. The most likely explanation is a dilation of the ion channel, building a 
pore-like structure with high conducting ability.28, 172  
The P2X7 receptor is highly expressed in cells of the immune system. It is associated with 
inflammatory processes and promotes the release of several proinflammatory interleukins 
including IL-1β and IL-18.177, 178 This process is caused by high amounts of ATP released passively 
by cell death or by cells under extreme stress. High extracellular ATP concentrations are known 
to cause cell death via activation of P2X7 receptors. A participation of P2X7 receptor, in some 
cases even its overexpression, could be demonstrated for several inflammatory diseases like 
Crohn’s disease, ulcerative colitis, neuroinflammatory processes or necrosis.177, 179-181 An orally 
available antagonist of the P2X7 receptor, AZD9056, was recently assessed in a phase IIa study 
for efficacy and safety against Crohn’s disease. The drug was found to significantly improve pain 
and general well-being of patients suffering from Crohn’s disease.182 The receptor is also 
involved in cancer progression, though its role remains inconclusive.178  
 
1.2.12.1 P2X7 receptor antagonists 
Several antagonists of the P2X7 receptor are known. A selection is presented in Figure 1.18. 
Brilliant Blue G is a weak non-competitive antagonist at human P2X7 as well as at P2X4, with an 
at least threefold preference for rat P2X7 receptor.140, 183 KN-62 is a very potent non-competitive 
antagonist at the human, but not the rat P2X7 receptor.184, 185 Triazole- and tetrazole-based 
compounds were also identified as potent more drug-like P2X7 inhibitors, namely A-438079 and 
A-839977. A-438079 was identified as the most potent compound out of a 1-benzyl-5-
aryltetrazol library at both human and rat P2X7 receptors. The efficacy was verified in a model of 
neuropathic pain.186 A-839977 inhibited human, rat and mouse P2X7 receptors at nanomolar 
concentrations. The antihyperalgesic effect could be confirmed in vivo in the CFA model of 
inflammatory pain.187 AZ10606120 was developed as a radioligand for P2X7 and labeled with 
[3H]. The compound binds to P2X7 in a non-competitive way. It is reversible, saturable and could 
be influenced by addition of classic P2X7 receptor antagonists.188 AACBA, also known as 
GSK314181, is an adamantane derivative that inhibits both rat and human P2X7 at low 
nanomolar concentrations. The effect was found to be more prophylactic than therapeutic in 
chronic pain models.189  
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Figure 1.18: Structure and potency of P2X7 receptor antagonists KN-62, MRS2540, A-438079, A-
839977, A-740003, AZ10606120, AACBA, JNJ-47965567, AZ11645373, prochlorperazine, 
trifluoperazine and trifluopromazine. Structure and potency of BBG is presented in 
Figure 1.16.140, 184, 186-193  
 
KN62 
IC50 0.034 ± 0.003 µM 
A-438079 
IC50 0.126-0.316 µM 
A-839977 
IC50 0.020-0.150 µM 
 
A-740003 
IC50 0.018-0.04 µM 
 
AZ10606120 
KD 0.0014 ± 0.00015 µM 
 
AACBA (GSK314181) 
IC50 0.018-0.029 µM 
 
JNJ-47965567 
IC50 0.005 µM 
 
AZ11645373 
KB 0.005-0.020 µM 
 
Prochlorperazine 
IC50 1.2 µM 
 
Trifluoperazine 
IC50 1.8 µM 
 
Triflupromazine 
IC50 > 50 µM 
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AACBA and AZ10606120 both contain an adamantane amide partial structure. The potency of 
cyanoguanidine derivative A740003 is comparable to AACBA at human and rat P2X7 receptors. It 
is also described to be selective towards P2 and other cell surface receptors, e. g. 5-HT, 
adenosine, adrenergic, dopamine, acetylcholine and opioid receptors. The orthosteric P2X7 
antagonist also potently reduces the release of IL-1β in human macrophage THP-1 cells.190 Cyclic 
imide P2X7 antagonist AZ116453373 is very selective towards human P2X1, P2X3, P2X4, P2X5 as 
well as rat P2X2 and P2X2/3 receptors. It inhibits P2X7 receptors in THP-1 cells in nanomolar 
concentrations. In contrast to the previously discussed antagonists, it is selective towards the rat 
P2X7 receptor.191 N-(cyclohexlmethyl)-benzamides were identified as weak P2X7 antagonists by 
high-throughput screening. JNJ-47965567 is the product of a series of structural modifications. It 
inhibited human P2X7 receptors in low nanomolar concentrations and was six-to tenfold 
selective towards rat and mouse orthologues.192 Further pharmacological characterization 
demonstrated good permeability into the central nervous system. The efficacy against mania 
and neuropathic pain could be elucidated in an animal model.194  
Inhibitory potency is also demonstrated for already approved drugs like antipsychotics 
prochlorperazine, trifluperazine and trifluopromazine. The first two inhibit P2X7 receptors in low 
micromolar concentrations, the latter is less potent. All three are allosteric antagonists at the 
P2X7 receptor.193  
 
1.2.12.2 P2X7 receptor allosteric modulators 
Several positive allosteric modulators of the P2X7 receptor have been characterized so far. 
Polymyxin B was identified as an enhancer of P2X7 activity when the receptor was stimulated 
with ATP. The effect expressed itself in increased membrane permeabilization and elevated 
cytotoxicity by otherwise nontoxic ATP concentrations.195 Another drug reported to enhance 
ATP-induced human but not murine P2X7 receptor signaling is ivermectin, which has already 
been discussed as a PAM at the P2X4 receptor in chapter 1.2.9.2. The antiparasitic drug 
potentiated P2X7 receptor signaling at saturating and subsaturating ATP concentrations.156 
Injectable narcotics like propofol (see chapter 1.2.9.2), ketamine and thiopental reversibly 
increase P2X7 receptor activity. Their potency could not be correlated with lipophilicity, and 
thiopental showed inhibition when used in low concentrations.196 The antihistamine clemastine 
was recently identified as another PAM at P2X7 receptors. Clemastine was found to bind from 
the extracellular site. A facilitated pore dilation and increased sensitization to the physiological 
agonist ATP were reported as responsible for clemastine-induced allosteric enhancement.197  
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Figure 1.19: Structures of positive allosteric P2X7 modulators polymyxin B, clemastine, ketamine 
and thiopental. Structure and potency of ivermectin and propofol are presented in 
Figure 1.17.156, 195-197 
 
Polymyxin B 
EC50Enhancement 2.07-6.90 µM 
Ketamine 
EC50Enhancement 570-1790 µM 
Thiopental 
EC50Enhancement 76-160 µM 
Clemastine 
EC50Enhancement 10 µM 
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1.3 Objective 
Not many potent and selective inhibitors with drug-like properties are known for any of the P2X 
receptor subtypes. Such tools are necessary for the in vivo study of respective P2X receptors, 
and for the development of new and potent drugs for the broad variety of diseases P2X 
receptors are associated with. Many of the identified compounds have several disadvantages 
concerning solubility, polarity, metabolism or toxicity, exacerbating their suitability of being valid 
drug candidates. Recently, Dr. Ralf Hausmann succeeded in stabilizing the rat P2X3 receptor by 
one single mutation that did not affect ATP binding. The first aim of this study was 
demonstrating that the stably transfected rat P2X3 receptor mutant is suitable for high 
throughput screening by determination of the Z’ factor and the screening an anthraquinone 
library and further characterizing of hit compounds. Following the successful transfection of all 
human P2X receptors except the P2X5 and P2X6 subtypes by Dr. Aliaa Abdelrahman and Stefanie 
Weyer, the establishment of an assay measuring calcium influx, high throughput screening and 
hit selectivity studies was possible. The search for novel and selective ligands includes the 
screening of a 440 compound approved drug and inorganic polyoxometalate library at all readily 
cloned P2X receptor subtypes. The hits are further characterized by determination of potency 
and for some by determination of inhibition mechanism. The general aim of this study is the 
identification of novel potent hits at P2X receptors out of different compound libraries, their 
characterization and assessment with regard to their suitability as potential drugs. 
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2 Material and methods 
2.1 Material 
2.1.1 Chemicals 
ATP Carl Roth GmbH & Co. KG, Karlsruhe 
Calcium chloride [CaCl2] Sigma Aldrich Chemie GmbH, Taufkirchen 
Carbachol Sigma Aldrich Chemie GmbH, Taufkirchen 
D-glucose Sigma Aldrich Chemie GmbH, Taufkirchen 
DMSO AppliChem GmbH, Darmstadt 
DMSO for cell culture AppliChem GmbH, Darmstadt 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco® Invitrogen GmbH, Darmstadt 
EDTA-sodium Carl Roth GmbH & Co. KG, Karlsruhe 
Ethanol absolute VWR International GmbH, Darmstadt 
FCS Sigma Aldrich Chemie GmbH, Taufkirchen 
FLIPR® Calcium-4 Explorer Kit Molecular Devices Corporation, Sunnyvale CA 
(USA) 
FLIPR® Calcium-5 Bulk Kit (10 x 10) Molecular Devices Corporation, Sunnyvale CA 
(USA) 
FLIPR® Calcium-5 Explorer Kit Molecular Devices Corporation, Sunnyvale CA 
(USA) 
Fluo-4 AM cell permanent dye 10 x 50 µg Invitrogen GmbH, Darmstadt 
Geneticin® (G 418) 100 mg/ml Invitrogen GmbH, Darmstadt 
Glacial acetic acid Carl Roth GmbH & Co. KG, Karlsruhe 
HEPES Carl Roth GmbH & Co. KG, Karlsruhe 
Hydrochloric acid 37 % AppliChem GmbH, Darmstadt 
Isopropanol absolute ZVE Universität Bonn 
Magnesium chloride [MgCl2] Sigma Aldrich Chemie GmbH, Taufkirchen 
Magnesium sulfate [MgSO4] Sigma Aldrich Chemie GmbH, Taufkirchen 
MTT AppliChem GmbH, Darmstadt 
Penicillin-streptomycin (10 000 I.E./ml, 10 
mg/ml) 
Gibco® Invitrogen GmbH, Darmstadt 
Phenol red solution 0.5 % Sigma Aldrich Chemie GmbH, Taufkirchen 
Plasmocin 2.5 mg/ml Invitrogen GmbH, Darmstadt 
Pluronic F-127 Sigma Aldrich Chemie GmbH, Taufkirchen 
Potassium chloride [KCl] Fluka, Sigma Aldrich Chemie GmbH, 
Taufkirchen 
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Potassium dihydrogen orthophosphate 
[KH2PO4] 
Sigma Aldrich Chemie GmbH, Taufkirchen 
Purelab® Plus water ELGA LabWater, Celle 
Sodium bicarbonate [NaHCO3] Sigma Aldrich Chemie GmbH, Taufkirchen 
Sodium chloride [NaCl] Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium dihydrogen phosphate [NaH2PO4] Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium hydroxide solution 1 M Sigma Aldrich Chemie GmbH, Taufkirchen 
TRIS-HCl Carl Roth GmbH & Co. KG, Karlsruhe 
Trypsin 2.5 % in HBSS Lonza Group Ltd., Schweiz 
 
2.1.2 Consumable supplies 
Corning® 3340 CellBind 96 well plates, sterile Sigma Aldrich Chemie GmbH, Taufkirchen 
Combitips advanced® for Eppendorf 
Multipette® E3 5 ml, 2.5 ml and 1 ml 
Eppendorf AG, Hamburg 
Disposable pipettes 1, 5, 10 and 25 ml Sarstedt, Nümbrecht 
Falcons 15 ml, 120 x 17 mm Sarstedt, Nümbrecht 
Falcons 50 ml, 114 x 28 mm Sarstedt, Nümbrecht 
Microtubes 2 ml Axygen Scientific, Union City 
Pipette tips 10, 100 and 1000 µl Sarstedt, Nümbrecht 
Pipette tips 5000 µl Sarstedt, Nümbrecht 
TipOne filter tips sterile 10, 100 and 1000 µl STARLAB GmbH, Hamburg 
Reservoirs, nonsterile 50 ml VWR International GmbH, Darmstadt 
Reservoirs, sterile 50 ml VWR International GmbH, Darmstadt 
Ritips® 0.5 ml, 1 ml, 2.5 ml and 5 ml Ritter GmbH Medical, Schwabmünchen 
Rotilabo® microtest plates, V profile, 96 Well Carl Roth GmbH & Co. KG, Karlsruhe 
Safe Seal® microtubes 1.5 and 5 ml Eppendorf AG, Hamburg 
Tissue culture 96 well plates, sterile Greiner Bio-one GmbH, Frickenhausen 
Tissue Culture Flask 25, 75 und 175 cm2 Sarstedt, Nümbrecht 
 
2.1.3 Devices 
Accu-Jet® pipetting controller Brand, Wertheim 
Analytical balance 440-47N (max. 2000 g) Kern & Sohn GmbH, Balingen-Frommern 
Analytical balance CP225D Sartorius, Göttingen 
Axiovert 25 microscope Carl Zeiss AG, Oberkochen 
Biometra® Thermocycler Biometra GmbH, Göttingen 
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Neubauer Counting chamber 
10 mm2/0,0025 mm2 
Paul Marienfeld GmbH & Co. KG, Lauda 
Königshofen 
Eppendorf Easypet®3 pipetting aid Eppendorf AG, Hamburg 
Eppendorf Multipette® E3 Eppendorf AG, Hamburg 
Eppendorf Multipette® plus Eppendorf AG, Hamburg 
Eppendorf Research® plus pipettes 0.5-10 µl, 
2-20 µl, 10-100 µl, 20-200 µl, 100-1000 µl and 
500-5000 µl 
Eppendorf AG, Hamburg 
Eppendorf Xplorer® electronic pipettes 0.5-
10 µl, 10-100 µl and30-300 µl 
Eppendorf AG, Hamburg 
FlexStation® 3 multi-mode microplate reader Molecular Devices Corporation, Sunnyvale CA 
(USA) 
Freezer -20°C Bosch GmbH, Stuttgart 
Sanyo Ultra Low Freezer -80°C Ewald Innovationstechnik GmbH, Bad 
Nenndorf 
Fridge Bosch GmbH, Stuttgart 
Hund microscope Helmut Hund GmbH, Wetzlar 
IKA® Vortex 3 vortexer IKA®-Werke GmbH & Co. KG, Staufen 
Jouan IG 650 incubator Thermo Fisher Scientific, Waltham 
Micro 200 centrifuge Hettich Holding GmbH & Co.oHG, Kirchlengern 
NOVOstar® fluorescence plate reader BMG Labtech GmbH, Ortenberg 
NUNC® BIOFLOW workbench Nunc GmbH & Co. KG, Langenselbold 
NUNC® Safe flow 1.2 workbench Nunc GmbH & Co. KG, Langenselbold 
pH 197 measuring instrument Wissenschaftlich-Technische Werkstätten 
GmbH, Weilheim 
pH electrode SenTix 41 Wissenschaftlich-Technische Werkstätten 
GmbH, Weilheim 
Purelab® Plus water purification plant ELGA LabWater, Celle 
RCT Basic hot plate stirrer IKA Labortechnik, Staufen 
Rotofix 32 centrifuge Hettich, Tuttlingen 
Scaltec SBC 42 balance (min. 0,02 g, max. 
120 g) 
Scaltec Instruments GmbH, Göttingen 
Systec 3850 ELV autoclave Systec, Wettenberg 
Ultrasonic bath Bandelin electronic, Berlin 
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2.1.4 Compounds and compound libraries 
Anthraquinone derivatives synthesized by Dr. Younis Baqi in the group of 
Prof. Dr. Müller, University of Bonn 
Drug library  Internal compound library (http://mueller-
group.pharma.uni-bonn.de/bibliothek) 
Polyoxometalate library (polyoxotungstates, 
PEGylated polyoxotungstates, rhenium cluster 
compounds, vanadium clusters) 
Synthesized in the group of Prof. Dr. Kortz, 
University of Bremen, Prof. Dr. Wang, 
University of Tianjin, Prof. Dr. Stephan, 
Research Center Dresden-Rossendorf, or 
purchased from Sigma Aldrich Chemie GmbH 
TNP-ATP Tocris Bioscience, Bristol, UK 
RB-2 Sigma Aldrich Chemie GmbH, Taufkirchen 
AF-353 Afferent Pharmaceuticals, Inc., San Mateo, CA, 
USA 
BBG Sigma Aldrich Chemie GmbH, Taufkirchen 
 
2.1.5 Solutions and reagents 
Calcium-4/Calcium-5 
dilution ready for use 
(Explorer kit) 
Component A (dye) 
Component B (buffer) 
1 vial 
10 ml 
Solution is 
prepared 
according to 
company 
instruction 
Calcium-5 dilution ready 
for use (Bulk kit) 
Calcium-5 stock solution 
(Bulk kit) 
HBSS 
1 ml 
 
ad 10 ml 
Prepared 
directly before 
use according to 
company 
instruction 
Calcium-5 stock dilution 
(Bulk kit) 
Component A (dye) 
HBSS 
1 vial 
10 ml 
Solution is 
prepared 
according to 
company 
instruction, 
stored at -20°C 
Carbachol solution 
100 µM 
Carbachol stock solution 
HBSS buffer 
0.01 ml 
ad 0.1 ml 
Stored at -20°C 
Carbachol stock solution 
1 mM 
Carbamoylcholine chloride 
HBSS buffer  
1.83 mg 
1 ml 
Stored at -20°C 
Cell culture medium for 
1321N1 astrocytoma 
cells transfected with 
plasmid pQCXIP 
FCS  
Penicillin-streptomycin 
(10.000 I.E./ml, 10 mg/ml) 
Puromycin 10mg/ml  
DMEM®  
50 ml 
 
5 ml 
0.11 ml (2 µg/ml) 
500 ml 
Stored at 4°C 
Cell culture medium for 
1321N1 astrocytoma 
cells transfected with 
plasmid pLXSN 
FCS 
Penicillin-streptomycin 
(10.000 I.E./ml, 10 mg/ml 
G418 (100 mg/ml) 
DMEM® 
50 ml 
 
5 ml 
2 ml (200 µg/ml) 
500 ml 
Stored at 4°C 
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Cell culture medium for 
non-transfected 1321N1 
astrocytoma cells 
FCS  
Penicillin-streptomycin 
(10.000 I.E./ml, 10 mg/ml) 
DMEM®  
50 ml 
 
5 ml 
500 ml 
Stored at 4°C 
EDTA 0.1 M stock 
solution 
EDTA 
Purelab® Plus 
3.7 g 
ad 100 ml 
pH is adjusted 
to 7.6, stored at 
room 
temperature 
EDTA 0.6 mM solution PBS 
EDTA 0.1 M stock solution 
2000 ml 
12 ml 
Autoclave at 
120°C and 2 bar 
pressure, then 
leave to cool 
down to room 
temperature 
Fluo-4 AM 3 µM dilution 
ready for use 
Fluo-4 AM 1 mM stock 
solution 
Pluronic F127 stock solution 
25 % 
HBSS buffer 
 
0.012 ml 
0.012 ml 
 
ad 4.0 ml 
Prepared 
directly before 
use 
Fluo-4 AM stock solution 
1 mM 
Fluo-4 AM (Mr 1097 g/mol) 
DMSO 
50 µg (1 aliquot) 
45.6 µl 
Stored at -20°C, 
protected from 
light 
Hank’s buffered salt 
solution (HBSS) 
CaCl2 (anhyd.) 
MgCl2 
MgSO4 
KCl 
KH2PO4 
NaHCO3 
NaCl 
Na2HPO4 
D-Glucose 
Autoclaved Purelab® Plus 
water 
0.14 g 
0.0476 g 
0.0494 g 
0.4 g 
0.06 g 
0.35 g 
8 g 
0.048 g 
1 g 
 
1000 ml 
pH is adjusted 
to 7.3 using 
NaOH 1 M or 
HCl 1 M, stored 
at 4°C 
Medium for freezing 
at -176°C in liquid 
nitrogen 
DMSO for cell culture 
FCS 
1 ml 
ad 10 ml 
Stored at -20°C 
MTT solution MTT 
PBS 
5 mg 
1 ml 
dissolved using 
ultrasonic bath, 
protected from 
light, prepared 
directly before 
use 
Phosphate-buffered 
saline (PBS) 
NaCl 
Na2HPO4-2 H2O 
KH2PO4 
KCl 
Purelab®Plus 
8,0 g 
1,4 g 
0,2 g 
0,2 g 
1000 ml 
pH is adjusted 
to 7.4 using 
NaOH 1 M or 
HCl 1 M, 
autoclaved at 
121°C and 2 bar 
pressure, then 
stored at 4°C 
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Pluronic® F127 stock 
solution 25 % 
Pluronic® F127 
DMSO 
0.2 g 
0.8 ml 
Dissolved at 
37°C, then 
stored at room 
temperature 
Trypsin 0.05 %/EDTA 
0.6 mM solution 
EDTA 0.6 mM solution 
Trypsin 2.5 % solution 
Phenol red indicator 0.5 % 
solution 
2000 ml 
40 ml 
1.5 ml 
aliquoted in 
50 ml falcons, 
stored at 4°C 
 
2.1.6 Pipetting schemes 
2.1.6.1 ATP solutions used for determination of inhibitory potency 
 P2X1 P2X2 P2X3 P2X4 P2X7 
       
ATP amount 
weighed [mg] 
0.5511 0.5511 0.5511 0.5511 5.511 11.022 
HBSS [ml] 1 1 1 1 1 1 
Concentration 
[mM] 
1 1 1 1 10 20 
Dilution 0.1 ml 
(1 mM) + 
0.9 ml HBSS 
(100 µM) 
 
0.1 ml 
(1 mM) + 
0.9 ml 
HBSS 
0.1 ml (1 
mM) + 
0.9 ml HBSS 
(100 µM) 
 
0.1 ml 
(1 mM) + 
0.9 ml 
HBSS 
- - 
Final dilution 0.01 ml 
(100 µM) + 
0.99 ml 
HBSS 
- 0.01 ml 
(100 µM) + 
0.99 ml 
HBSS 
- - - 
Final 
concentration 
in the well 
[µM] 
0.1 1 0.1 1 1000 2000 
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2.1.6.2 ATP solutions used for determination of enhancing potency 
 P2X1 P2X2 P2X3 P2X4 P2X7 
      
ATP amount 
weighed [mg] 
- - 0.5511 - 55.11 
HBSS [ml] - - 1 - 1 
Concentration 
[mM] 
- - 1 - 50 
Dilution 1 
(full receptor 
stimulation) 
- - 0.1 ml (1 mM) 
+ 0.9 ml HBSS  
- - 
Final 
concentration 
in the well 1 
[µM] 
- - 10 - - 
Dilution 2 
(EC50 receptor 
stimulation) 
- - 0.005 ml 
(100 µM) + 
0.995 ml HBSS 
- 50 µl 
(50 mM) + 
50 µl HBSS 
Final 
concentration 
in the well 2 
[µM] 
- - 0.1 - 2500 
 
2.1.6.3 Standard dilution scheme of ATP (50 mM stock solution) 
Dilution Real concentration 
[µM] 
Final concentration in 
the well [µM] 
Production 
All dilutions produced from 5 mM stock solution 
D1 50 000 5000 20µl stock/well 
D2 25 000 2500 50 µl stock + 50 µl HBSS 
D3 20 000 2000 40 µl stock + 60 µl HBSS 
D4 15 000 1500 30 µl stock + 70 µl HBSS 
D5 10 000 1000 20 µl Stock + 80 µl HBSS 
D6 8000 800 16 µl stock + 84 µl HBSS 
D7 7000 700 14 µl stock + 86 µl HBSS 
D8 5000 500 10 µl stock + 90 µl HBSS 
D9 4000 400 8 µl stock + 92 µl HBSS 
D10 3000 300 6 µl stock + 94 µl HBSS 
D11 1000 100 10 µl D5 + 90 µl HBSS 
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2.1.6.4 Standard dilution scheme of P2X receptor agonists (1 mM stock solution) 
Dilution Real concentration 
[µM] 
Final concentration in 
the well [µM] 
Production 
All dilutions produced from 1 mM stock solution 
D1 1000 100 10 µl stock + 90 µl HBSS 
D2 300 30 30 µl D0 + 70 µl HBSS 
D3 100 10 10 µl D0 + 90 µl HBSS 
D4 30 3 10 µl D2 + 90 µl HBSS 
D5 10 1 10 µl D3 + 90 µl HBSS 
D6 5 0.5 5 µl D3 + 95 µl HBSS 
D7 6 0.6 6 µl D3 + 94 µl HBSS 
D8 3 0.3 10 µl D4 + 90 µl HBSS 
D9 1 0.1 10 µl D5 + 90 µl HBSS 
D10 0.5 0.05 10 µl D6 + 90 µl HBSS 
D11 0.3 0.03 10 µl D8 + 90 µl HBSS 
D12 0.1 0.01 10 µl D9 + 90 µl HBSS 
D13 0.03 0.003 10 µl D11 + 90 µl HBSS 
D14 0.01 0.001 10 µl D12 + 90 µl HBSS 
D15 0.003 0.0003 10 µl D13 + 90 µl HBSS 
D16 0.001 0.0001 10 µl D14 + 90 µl HBSS 
 
2.1.6.5 Dilutions of standard antagonists for the determination of Z’-factor 
 P2X1 P2X2 P2X3 P2X4 P2X7 
      
Antagonist TNP-ATP RB-2 AF-353 BBG BBG 
Mr [g/mol] 1123.04 840.10 436.68 854.02 854.02 
Amount 
weighed for 
10 mM stock 
solution [mg] 
predisolved in 
water, 10 mM 
8.401 4.367 8.540 8.540 
DMSO added 
for 10 mM 
stock 
solution [ml] 
- 1 1 1 1 
Dilution 2 µl stock 
solution/well, 
supplemented 
with 2 µl 
DMSO 
2 µl stock 
solution/well 
1 µl stock 
solution + 
9 µl DMSO 
2 µl stock 
solution/well 
2 µl stock 
solution/well 
Final 
concentration 
in the well 
[µM] 
100 100 10 100 100 
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2.1.6.6 Standard dilution scheme for test compounds (10 mM stock solution) 
Dilution Real concentration 
[µM] 
Final concentration in 
the well [µM] 
Production 
All dilutions produced from 10 mM stock solution 
D1 10 000 100 2 µl stock solution/well 
D2 5000 50 4 µl stock solution + 4 µl DMSO 
D3 3000 30 3 µl stock solution + 7 µl DMSO 
D4 1000 10 1 µl stock solution + 9 µl DMSO 
D5 500 5 1 µl D2 + 9 µl DMSO 
D6 300 3 1 µl D3 + 9 µl DMSO 
D7 100 1 1 µl D4 + 9 µl DMSO 
D8 50 0.5 1 µl D5 + 9 µl DMSO 
D9 30 0.3 1 µl D6 + 9 µl DMSO 
D10 10 0.1 1 µl D7 + 9 µl DMSO 
D11 1 0.01 1 µl D10 + 9 µl DMSO 
D12 0.1 0.001 1 µl D11 + 9 µl DMSO 
D13 0.01 0.0001 1 µl D12 + 9 µl DMSO 
 
2.1.6.7 Standard dilution scheme for test compounds (1 mM stock solution) 
Dilution Real concentration 
[µM] 
Final concentration in 
the well [µM] 
Production 
All dilutions produced from 1 mM stock solution 
D1 1000 100 20 µl stock solution/well 
D2 500 50 40 µl stock solution + 40 µl HBSS 
D3 300 30 30 µl stock solution + 70 µl HBSS 
D4 100 10 10 µl D1 + 90 µl HBSS 
D5 50 5 10 µl D2 + 90 µl HBSS 
D6 30 3 10 µl D3 + 90 µl HBSS 
D7 10 1 10 µl D4 + 90 µl HBSS 
D8 5 0.5 10 µl D5 + 90 µl HBSS 
D9 3 0.3 10 µl D6 + 90 µl HBSS 
D10 1 0.1 10 µl D7 + 90 µl HBSS 
D11 0.1 0.01 10 µl D10 + 90 µl HBSS 
D12 0.01 0.001 10 µl D11 + 90 µl HBSS 
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2.1.6.8 Standard dilution scheme for test compounds (0.1 mM stock solution) 
Dilution Real concentration 
[µM] 
Final concentration in 
the well [µM] 
Production 
All dilutions produced from 0.1 mM stock solution 
D1 1000 10 20 µl stock solution/well 
D2 500 5 40 µl stock solution + 40 µl HBSS 
D3 300 3 30 µl stock solution + 70 µl HBSS 
D4 100 1 10 µl D1 + 90 µl HBSS 
D5 50 0.5 10 µl D2 + 90 µl HBSS 
D6 30 0.3 10 µl D3 + 90 µl HBSS 
D7 10 1 10 µl D4 + 90 µl HBSS 
D8 5 0.5 10 µl D5 + 90 µl HBSS 
D9 3 0.3 10 µl D6 + 90 µl HBSS 
D10 1 0.1 10 µl D7 + 90 µl HBSS 
D11 0.1 0.01 10 µl D10 + 90 µl HBSS 
D12 0.01 0.001 10 µl D11 + 90 µl HBSS 
 
All dilutions were freshly prepared before each experiment. 
 
2.2 Methods 
2.2.1 Cell culture 
All experiments discussed in the following paragraph were performed in human 1321N1 
astrocytoma cells stably transfected with human P2X1, P2X2, P2X4 P2X7 or rat P2X3 receptor, 
via retroviral vector system, respectively. The cells were cultured at 37°C and 5 % CO2 in tissue 
culture flask 25, 75 und 175 cm2, respectively, using Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10 % FCS, 100 U/ml penicillin G, 100 µg/ml streptomycin, and a selection 
antibiotic dependent on the retroviral system used for receptor transfection (G418 800 µg/ml 
for human P2X1, P2X2, P2X4 and P2X7 receptor and Puromycin 2 µg/ml for P2X3 receptor). 
The transfection of 1321N1 astrocytoma cells with P2X1, P2X2, P2X4 and P2X7 was performed 
by Dr. Aliaa Abdelrahman, Scarlett Weigel and Stefanie Weyer. Briefly, the cDNA of the 
respective receptor was cloned into the retroviral vector pLXSN, which was then cotransfected 
into GP+envAM12 mouse fibroblast packaging cells together with the viral expression vector 
pVSV-G. Afterwards, the packaging cells produce retroviruses carrying the desired receptor DNA, 
which are capable of infecting 1321N1 astrocytoma cells, and insert the receptor gene into its 
genome. Due to the lack of viral replicating enzymes and proteins, the viruses cannot replicate 
after cell infection. Successfully transfected cells were selected by supplementing the cell culture 
medium with selection antibiotic (G418 800 µg/ml). The P2X3 receptor was transfected by PD 
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Dr. Ralf Hausmann. The protocol used for the transfection was the same as for the other P2X 
receptors. Instead of pLXSN, the retroviral vector pQCXIP, containing the gene for puromycin 
resistance, was used. For the selection of successfully transfected cells, puromycin 6 µg/ml was 
added to the cell culture medium. 
Since the human P2X1 and P2X3 receptors both desensitize rapidly after stimulation with agonist 
(see chapters 1.2.6 and 1.2.8), chimeras of both receptors were used to enable their 
characterization using functional experiment setups. For the P2X1 receptor, the first 
transmembrane domain was exchanged to the analog of the P2X2 receptor, while one amino 
acid of the P2X3 receptor, serine in position 15, was exchanged to valine. In both cases, a 
stabilization of the receptor without a change of its respective binding properties was obtained. 
Both chimera cell lines (human P2X1 and rat P2X3) were used in all described experiments. 
To provide good and stable results in experiments, monoclones with high receptor expression of 
each cell line were selected. The original cell pool was diluted to a final cell count of 1 cell/200 µl 
and seeded in sterile tissue culture 96 well plates with a final count of 1 cell/well. Cells were 
incubated at 37°C and 5 % CO2 for several days. Only wells containing one colony were 
transferred to sterile tissue culture 24 well plates. The level of receptor expression was 
determined by calcium influx measurement after ATP injection. Buffer and carbachol injection 
served as negative and cell viability control, respectively. Only the monoclone with the highest 
fluorescence signal was selected for further experiments, as high fluorescence signal is 
associated with high receptor expression. 
Backups of all cell lines were frozen at -80°C and -176°C in liquid nitrogen. For the latter, a 
mixture of pure FCS supplemented with 10 % DMSO was used as a cryoprotector. Cells were 
splitted at least once a week to prevent overgrowth, also before each experiment, using 0.5-2 ml 
of trypsin-EDTA solution to detach the cells from the bottom of the flask. The amount depends 
on the size of the flask, 0.5 ml for 25 cm2, 1 ml for 75 cm2 and 2 ml for 175 cm2. Since most of the 
experiments required exact cell amounts, cells were counted using a counting chamber before 
seed in respective assay plates. 
 
2.2.2 Measurement of calcium influx in transfected 1321N1 astrocytoma cells 
P2X receptors are transmembrane ion channels permeable for divalent cations, especially Ca2+ 
ions. This feature was utilized to perform functional experiments characterizing the influence of 
potential ligands on transmembrane calcium influx in transfected 1321N1 astrocytoma cells 
after agonist stimulation.  
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All experiments are conducted in living cells. Special fluorescent dyes are utilized to measure the 
intracellular calcium concentration. The fluorescence intensity of these dyes is enhanced upon 
formation of complexes with Ca2+ ions. Fluo-4 as acetoxymethyl ester for cells transfected with 
human P2X2, P2X4 and P2X7, and Calcium-4 and Calcium-5 for cells transfected with human 
P2X1 and P2X3, respectively, were used. Fluo-4 AM is cleaved after entering the cell by 
nonspecific esterases. The negatively charged cleaved form is presented in Figure 2.1. 
 
 
Figure 2.1: Structure of Ca2+-complexing fluorescent dye Fluo-4 in its dissociated, negatively 
charged form. 
 
Calcium-4 and Calcium-5 are Ca2+-sensitive fluorescent dyes provided in form of ready for use 
assay kits developed by Molecular Devices. The company does not provide any information 
about the structure of the dye. The system includes a masking agent, which blocks any 
fluorescence of Calcium-4 and Calcium-5 molecules, who did not cross the cell membrane. This 
leads to reduction of background fluorescence, fluorescence interference caused by 
spontaneous calcium influxes and loss of cells, since any washing steps are no longer necessary. 
 
2.2.2.1 Experimental setup 
2.2.2.1.1 Testing for inhibitory and enhancing activity 
Day 1 
Transfected 1321N1 astrocytoma cells were seeded in Corning 3340 black 96 well plates with 
clear bottom at a concentration of 40 000 cells/well. In order to let the cells attach to the 
bottom, the plate was incubated overnight at 37°C and 5 % CO2.  
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Day 2 
Calcium-4 and Calcium-5 dye is prepared according to the instructions provided by Molecular 
Devices. The explorer kit requires the dilution of component A (dye) with 10 ml of component B 
(assay buffer). The bulk kit needs the dilution of the dye in 10ml HBSS buffer to prepare a stock 
solution of Calcium-5 dye. 1 ml of the stock solution is then diluted ad 10 ml with HBSS buffer for 
the final assay dye. The solutions were mixed thoroughly for at least two minutes. The medium 
of the cells in the assay plate is removed and cells are incubated with 100 µl dye/well at 37°C in 
the dark for one hour.  
Fluo-4 AM 3 µM solution is prepared as described in chapter 2.1.5. Cells are incubated with 40 µl 
dye/well for one hour in the dark at room temperature while shaking at 200 rpm. After 
discarding the dye and washing with 50 µl HBSS, cells were incubated with 180 µl HBSS 
buffer/well supplemented with various concentrations of test compounds at room temperature 
for 30 minutes. The compound dilutions were freshly prepared for each experiment. The 
pipetting scheme for preparation of compound dilutions is presented in chapter 2.1.4. 178 µl of 
HBSS and 2 µl of each compound dilution were added to the respective well, rendering a final 
DMSO concentration of 1 %/well. 
The EC50 and EC80 values of ATP were determined prior to any testing of potential antagonists 
every time a freshly defrozen cell line was used. This is necessary to compensate for any changes 
in receptor expression due to the stress cells have to endure because of the freezing process. 
The EC50 and EC80 values of ATP remained unchanged for P2X1, P2X2, P2X3 and P2X4, but a 
decrease was observed after defreezing for cells transfected with the P2X7 receptor. The ATP 
concentration used for stimulation was increased from 1 mM to 2 mM. The former 
concentration was used for the POM experiments, the latter for the drug library experiments 
and the selectivity experiments of anthraquinone derivatives. 
The 10 mM stock solutions of POMs, except the five polyoxotungstates from Prof. Wei Wang 
from University of Tianjin, China, were prepared in HBSS buffer due to insufficient solubility in 
organic solvents. The stock solutions of the polyoxotungstate derivatives from China were 
prepared in DMSO. PV5, P8W48, KB1 and KB2, could not be dissolved completely neither in buffer 
nor in DMSO at such high concentrations, therefore less concentrated stock solutions in HBSS 
were prepared for those compounds (1 mM for PV5, KB1 and KB2, and 0.1 mM for P8W48). The 
respective pipetting schemes are presented in chapters 2.1.6.6, 2.1.6.7 and 2.1.6.8. 
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Each well was incubated with 20 µl of respective solution on top of 160 µl of buffer 
supplemented with 2 µl of DMSO to reach the final DMSO concentration of 1 %/well to allow the 
testing of higher compound concentrations of these stock solutions. 
Each well incubated with test compound was stimulated with the same agonist concentration 
for determination of inhibitory potency. The physiological agonist ATP was the used agonist for 
all P2X receptor subtypes. The concentration prepared for stimulation matched the EC80 value 
determined previously for each receptor cell line by injecting various concentrations of ATP after 
incubating with 1 % DMSO instead of test compounds. The ATP dilutions used for determination 
of EC50 and EC80 depended on the transfected receptor tested. Dilution concentrations and 
preparation for each receptor are summarized in chapter 2.1.6.1. At least seven different 
concentrations were tested for dose-response experiments. 
Pure HBSS buffer was injected as negative control. All solutions for injection were provided in a 
V-profile microtest plate loaded with 40 µl/well to prevent loss of volume. Further control 
solutions tested in duplicates in each experiments are ATP (positive control, standard 
stimulation concentration, preincubation with 1 % DMSO instead of test compound), carbachol 
100 µM (preincubation with 1 % DMSO) and a standard antagonist provided in high enough 
concentrations to guarantee complete inhibition of the receptor (added for preincubation 
instead of test compound). The antagonist used depended on the receptor cell line tested in the 
respective experiment. The used antagonists and their preparation are summarized in 
chapter 2.1.6.5. Carbachol is an agonist at muscarinic acetylcholine receptors. These receptors 
are physiologically expressed in 1321N1 astrocytoma cells and impart the release of Ca2+ ions 
from intracellular storage organs. This provides an increase of Ca2+-dependent fluorescence 
independent from the transfected P2X receptor and renders a positive control to prove the 
functionality of the assay principle and the vitality of the cells. 
Fluorescence intensity was measured after 30 minutes incubation with test compound or DMSO 
before and after injection of agonist using the fluorescent imaging plate reader NOVOstar®. 
20 µl of agonist were injected into each well, rendering a total assay volume of 200 µl/well. The 
fluorescence in each well is measured for a total time of 35.6 seconds. In between injection of 
two wells, the injection needle is flushed with Purelab® Plus water to prevent contamination. 
The program settings used in each experiment are summarized in Table 2.1. 
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Table 2.1: Advanced settings of NOVOstar® for measurement of calcium influx using fluorescent 
dyes Fluo-4, Calcium-4 and Calcium-5. 
Measurement parameter Fluo-4, Calcium-4 and Calcium-5 
Excitation wavelength 485 nm, bandwidth 25 nm 
Emission wavelength 520 nm, bandwidth, 20 nm 
Number of flashes  
(Validation) 
10 (10) 
Gain variable 
Timeframe 1 (2) 0-4 s (11.6-35.6 s) 
Number of intervals 60 (4) 
Time interval 0.4 (1.0) 
Injection time 11.6 s 
Injection volume 20 µl 
Pump speed 65 µl/s 
Position delay 0.2 s 
Temperature RT 
Basic fluorescence 22 000-28 000 fluorescent counts 
Washing steps after injection 3 
Washing solution Purelab® Plus 
 
Some compounds showed ATP-induced receptor enhancing properties during initial 
experiments. The concentration-dependency of the effect was determined analog to the 
determination of inhibitory potency by preincubating cells with various concentrations of test 
compounds for 30 minutes prior to the stimulation by one single concentration of agonist ATP. 
The concentration selected for cell stimulation represents the respective EC50 concentration of 
ATP. Additional experiments with fully stimulated receptors were conducted for P2X3 receptors 
for further characterization. The ATP concentration used in these experiments was 10 µM. All 
concentrations and preparation of solutions are summarized in chapter 2.1.6.2. 
 
2.2.2.1.2 Testing for agonistic activity  
Most of the test compounds were examined for their inhibitory potency, but some indicated 
agonistic properties during initial screening experiments. The experimental setup was modified 
for further investigation. Cells were incubated without test compound for 30 minutes and then 
injected with various concentration of test compound as agonist, instead of preincubating with 
the test compound and then stimulating with agonist. ATP was used as a positive control.  
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2.2.2.1.3 Determination of inhibition mechanism 
The determination of inhibition mechanism became of great interest for several potent hits. 
Cells were incubated for 30 minutes with a single concentration of selected test compound 
based on the previously determined inhibitory dose-response curves. Five different 
concentrations of test compound were tested in duplicates on one 96 well plate of cells, plus 
duplicates DMSO 1 % as positive control. Cells were stimulated with various ATP concentrations 
to create shift curves. The nature of the shift provides an indication how the test compounds 
affects receptor activation upon agonist presence. When full activation of receptor is reached 
even under influence of high inhibitor concentration, and the EC50 value of agonist is shifted to 
higher concentrations than the control, competitive receptor inhibition is indicated. The same 
EC50 value, but a decrease of agonist potency upon full stimulation points to an allosteric 
inhibition mechanism of the antagonist. 
 
2.2.2.2 Data analysis 
Data evaluation required a two-step completion. The first step was executed in Microsoft® Excel. 
The first four measurement points of each calcium assay were taken prior to agonist injection 
and therefore discarded for the determination of fluorescence signal increase. Since ion 
channels provide a very fast response upon agonist stimulation, the very first fluorescence value 
measured after agonist stimulation was taken as starting point and subtracted from each 
following figure. This feature was programmed in Microsoft® Excel to be executed for each value 
obtained for each well. Only the sheer fluorescence increase was used for further data analysis. 
It was calculated by subtraction of the basic fluorescence out of each value. The mean was 
calculated out of all values obtained for one well. It was used for further dose-response analysis 
using GraphPad® Prism 4.02 for Windows (GraphPad® Software, San Diego, California, USA). All 
means obtained for test compounds were set in relation to the negative control (buffer) posing 
as 0 % receptor activity and the positive control (ATP), posing as 100 % receptor activity. 
Compound concentration values were then logarithmized, and curve fitting analysis was 
conducted, using sigmoidal dose response with variable slope, based on the logistic equation: 
 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +  
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10((𝑙𝑜𝑔𝐸𝐶50−𝑋)×𝐻𝑖𝑙𝑙 𝑠𝑙𝑜𝑝𝑒)
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Top and Bottom represent 100 and 0 % receptor activation, respectively, while X represents the 
concentration of the used ligand. No constraints were selected. Each experiment was repeated 
three times. The mean curve was calculated by averaging the mean data of each experiment, 
followed by sigmoidal dose response analysis with variable slope. This calculation was selected 
for every dose-response experiment, including testing for inhibitory potency and enhancement 
dose-dependency.  
The bell-shaped curve analysis was selected for compounds showing inhibition in high and 
enhancement in low concentrations, using GraphPad® Prism 5.03 (GraphPad® Software, San 
Diego, California, USA). It follows the equation: 
 
𝑌 = 𝐷𝑖𝑝 +
𝑃𝑙𝑎𝑡𝑒𝑎𝑢1 − 𝐷𝑖𝑝
1 + 10((𝐿𝑜𝑔𝐸𝐶50_1−𝑋)×𝑛𝐻1))
+
𝑃𝑙𝑎𝑡𝑒𝑎𝑢2 − 𝐷𝑖𝑝
1 + 10((𝑙𝑜𝑔𝐸𝐶50_2−𝑋)×𝑛𝐻2))
 
 
Plateau1 and Plateau2 are the plateaus at the left and right end of the curve. Dip represents the 
plateau level in the middle of the curve, LogEC50_1 and LogEC50_2 are the concentrations that 
give half-maximal stimulatory and inhibitory effects, and nH1 and nH2 represent the unitless Hill 
slopes. 
ATP shift curves were conducted in order to gain more insight in the inhibition mechanism of the 
most interesting hits. The Gaddum/Schild analysis was selected for determination whether the 
shift of the ATP curve fits with competitive antagonism. The equations are: 
 
𝐸𝐶50 = 10𝑙𝑜𝑔𝐸𝐶50 
𝐿𝑜𝑔𝐸𝐶 = 𝐿𝑜𝑔 [𝐸𝐶50 × (1 + (
𝐵
10(−1×𝑝𝐴2)
)
𝑆𝑐ℎ𝑖𝑙𝑑 𝑆𝑙𝑜𝑝𝑒
)] 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + 
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10((𝑙𝑜𝑔𝐸𝐶−𝑋)×𝐻𝑖𝑙𝑙 𝑠𝑙𝑜𝑝𝑒)
 
 
Bottom and top represent the minimum and maximum responses, and X is the concentration of 
the used ligand in both sigmoidal dose response and Gaddum/Schild equations, respectively. The 
calculation of the dose ratio (DR) was needed for the linear regression. The dose ratio is defined 
as the quotient of the agonist EC50 concentration influenced by antagonist and the control 
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agonist EC50 concentration. The concentration of antagonist is then plotted against DR-1 to 
create the linear regression of the Schild plot. 
Some compounds tested in ATP shift curve experiment did not show a shift of EC50 value, but a 
concentration-dependent reduction of the maximal ATP effect. The fluorescence signal induced 
by the highest ATP concentration used in the experiment was calculated for those compounds. 
The buffer control was based as 0 % and the respective highest ATP concentration as 100 %. The 
unpaired Student’s t-test of the respective means was conducted in order to determine whether 
the influence of the compound on the maximal ATP effect was statistically significantly different 
from the fluorescence increase caused by the highest ATP concentration of the control. The 
difference between mean pEC50 of ATP control and mean pEC50 of ATP influenced by respective 
test compound concentration was deemed significant, when the calculated P value was lower 
than 0.05. For all experiments, the two-tailed P value was selected. The same analysis was used 
to determine significance of maximal ATP effect of the control and after preincubation with 
respective test compound. Significant differences of the mean (P < 0.05) were marked with (*), 
very significant differences (p < 0.01) with (**) and highly significant differences (p < 0.001) with 
(***). 
The unpaired Student’s t-test was also selected for the analysis of the data collected for the 
fluorescence signal enhancement caused by some test compounds. The pEC50Enhancement values 
and the enhancement of maximal ATP effect were analyzed with the same protocol as described 
for pEC50 values and maximal ATP effect determined out of ATP shift curves for inhibitory 
compounds. The ATP control was calculated from the results of the highest ATP concentration 
used in the respective experiment. It was perched at 100 % for the calculation of enhancement, 
the buffer control as 0 %. The ATP control was subtracted from the values of each sample to 
demonstrate the magnitude of enhancement.  
The validity of each experiment at each receptor was determined by calculation of Z’-factor as 
described by Zhang et al. in 1999.198 The Z’ factor is calculated by the following equation, with σ 
representing the standard deviation and μ the mean of the positive (index p) and negative 
control (index n), respectively.  
 
𝑍′ = 1 −  
|3 × 𝜎p + 3 × 𝜎n|
|𝜇p − 𝜇n|
 
 
2 Material and Methods 
-54- 
 
The ATP values without addition of any inhibitor or test component were used as positive 
control. The negative control was calculated from the data obtained by preincubation with a 
standard antagonist. The concentration was selected high enough to completely block any 
receptor activity. When it was not possible to apply a standard antagonist on the assay plate, the 
buffer control was taken as the negative control instead. The Z’-factors from all experiments 
were averaged for each receptor and the standard error of the mean was calculated. At a Z’-
factor higher than 0.5, the separation band between positive and negative control is large and 
the assay is deemed as suitable for high-throughput screening. 
 
2.2.3 Measurement of compound toxicity and cell viability 
Cell viability experiments were conducted to determine cytotoxicity of potent test compounds 
and to eliminate the possibility of positive calcium influx results due to cell toxicity. The 
experiment is based upon 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a 
yellow tetrazolium salt, being reduced to purple formazan, as illustrated in Figure 2.2. 
 
Figure 2.2: Conversion of MTT to formazan. 
 
The reduction is catalyzed by oxidoreductase enzymes that are primarily expressed in cellular 
mitochondria. Since the enzyme is only active in living cells, the amount of purple dye produced 
is directly proportional to the quantity of living cells in the well. 
 
2.2.3.1 Experimental setup 
Day 1 
Non-transfected 1321N1 astrocytoma cells were seeded in sterile tissue culture 96 well plates 
with a concentration of 2000 cells/well in a final volume of 180 µl (POMs) or 99 µl (all other 
compounds) and incubated overnight at 37°C and 5 % CO2.  
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Day 2 
The dilutions of test compounds were prepared as discussed in chapter 2.2.2.1. The pipetting 
schemes can be found in chapters 2.1.6.6, 2.1.6.7 and 2.1.6.8. The dilutions for POMs were 
prepared in cell culture medium containing 10 % DMSO. All other compounds were diluted in 
pure DMSO. 5-Fluorouracil, a known cytotoxic cancer drug, was included in each experiment as a 
positive control. Cells were then supplemented with 20 µl (POMs) or 1 µl test compound, or 
pure DMSO (negative control), respectively, and then incubated for 72 hours at 37°C and 5 % 
CO2. The final DMSO concentration in the well never exceeded 1 %. Each compound 
concentration was measured in duplicates in three independent experiments. 
Day 5 
One hour prior to the end of the 72 hour incubation period, each well was supplemented with 
40 µl (POMs) or 20 µl (all other compounds) of freshly prepared MTT solution 5 mg/ml in PBS. 
Incubation was then continued to the end at 37°C and 5 % CO2, so that still alive cells could 
transform the yellow tetrazolium salt to purple formazan. The medium was removed and 100 µl 
of DMSO was added to each well to lyse the cells. The plate was shaken at 200 rpm for 2 minutes 
to dissolve the formazan crystals produced in mitochondria. UV absorbance of the purple 
formazan was measured using FlexStation 3 at 570 nm. A second measurement was conducted 
directly afterwards to eliminate background absorbance. The full settings of the measurement 
are summarized in Table 2.2. 
 
Table 2.2: Advanced settings of FlexStation3 for measurement UV absorbance of produced 
purple Formazan during MTT cell viability experiment 
Measurement parameter Settings 
Read mode Absorbance 
Wavelength LM1: 570 nm 
LM2: 690 nm 
Assay plate 96 well standard clear bottom 
Wells to read Entire plate 
Compound transfer None 
Automix No 
Calibration On 
Settle time Off 
Priority: wavelength or column column 
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2.2.3.2 Data analysis 
Data analysis was performed analog to results of calcium influx measurement using Microsoft® 
Excel and GraphPad® Prism 4.02. The EC50 value was determined using sigmoidal dose-response 
analysis with variable slope. No constraints were defined. The results of each well obtained via 
UV measurement at 690 nm were subtracted from the respective results obtained at 570 nm to 
eliminate background fluorescence of residual medium and cell components. The data was then 
transferred to GraphPad® Prism 4.02. The EC50 value is here defined as the concentration of test 
compound, at which half of the cells are dead after 72 hours exposure. 
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3 Characterization of the S15V mutant of rat P2X3 receptor 
3.1 Introduction 
Anthraquinones are chemical derivatives of anthracene and represent a class of natural 
products. They are either produced by the polyketide or the shikimate pathway. Anthraquinones 
synthesized by the latter often carry hydroxyl residues in positions 1 and 8 as well as methyl in 
position 3. The hydroxyl residues also represent glycosylation sites. Anthraquinones and 
dianthrones are important contents of plants including senna, frangula, aloe and rhubarb, and 
have been known for their laxative purposes for a long time.199 Naturally glycosylated, the 
glycosides behave as prodrugs and are metabolized in the colon. This leads to the release of the 
aglycones that are responsible for the laxative effect by causing an increase of secretion and 
motility in the colon.  
Anthraquinone derivatives are also used as anticancer drugs. The most prominent 
representative is mitoxantrone, an alkaline substituted anthracendione, which is utilized in the 
therapy of lymphoma, leukemia, breast and prostate cancer.200 It acts as an intercalate 
substance and inhibits the activity of topoisomerase II. Alongside cancer, it is also approved for 
the treatment of multiple sclerosis.201 The use in both indications is limited by 
cardiotoxicity.200, 202  
The anthraquinone derivative RB-2 is a weak antagonist and allosteric modulator at P2 
receptors.66, 203 RB-2 is an anthraquinone-chlorotrizinyl reactive dye and was formerly used in 
textile industry and in the purification process of proteins by affinity chromatography.204 A 
truncated version of RB-2 was selected as a lead structure for the development of new potent 
antagonists of P2 receptors. The library contains 165 amino and 26 desamino derivatives. It was 
originally developed for the pharmacological testing at the P2Y2 and the P2Y12 receptors.
205, 206 
The aim was the identification of a new and potent ligand with antithrombotic efficacy. P2Y12, a 
Gi-coupled GPCR, plays an important role in blood platelet function and regulation.
207 All 
investigated compounds display an aminoanthraquinone- or desaminoanthraquinone core with 
a sulfonic acid group in position 2 and various residues with great structural differences in 
position 4 linked via an amino bridge. The synthesis of the compounds has been described in 
detail.208-210 Briefly, 4-bromo-substituted anthraquinone derivatives are coupled with the 
appropriate amine by microwave-assisted Ullmann reaction in phosphate buffer (pH 6-7) in the 
presence of Cu0. The synthesis scheme is presented in Figure 3.1, and Figure 3.2 gives an 
overview of the different basic structures of the tested compounds. 
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Figure 3.1: Microwave-assisted Cu(0)-catalyzed synthesis of 4-phenylamino-substituted 1-amino-
2-sulfoanthraquinone derivatives in phosphate buffer.208 
 
A variety of different substitutions is available, which facilitates the study of structure-activity 
relationships. This compound library has previously been identified to contain potent 
antagonists of P2X2, P2Y2, P2Y12 receptors, ecto-5’-nucleotidase and ectonucleoside 
triphosphate diphosphohydrolases. They display high inhibitory potency with nanomolar IC50 
and Ki concentrations, respectively.
103, 205, 206, 211-214  
A total of 26 compounds are available in their deaminated form, where the amino residue in 
position 1 was replaced with hydrogen. Most of them are derivatives displaying scaffold C. The 
purpose of eliminating the amino function in position 1 was to characterize its influence on 
compound binding and efficacy.  
Hausmann et al. succeeded in creating a stable non-desensitizing rat P2X3 receptor mutant by 
exchanging serine in position 15 to valine, as is described in detail in chapter 1.2.8.118 The 
receptor was transfected retrovirally into 1321N1 astrocytoma cells, creating a stably expressing 
cell line. The aim of this study was to evaluate the created cell line and determine its suitability 
for high-throughput screening by testing the anilinoanthraquinone library via measurement of 
calcium influx. Since Cibacron Blue 3GA is an identified PAM of the P2X3 receptor, the effect of 
structural derivatization on compound activity was also evaluated.127  
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Figure 3.2: Basic scaffolds of tested aminoanthraquinone derivatives. Residues are presented in 
chapters 3.4.1 and 3.4.2. 
 
3.2 Z’-factor for determination of assay quality 
The Z’-factor was calculated to determine assay quality and therefore the accuracy of the 
results. When the Z’-factor is higher than 0.5, the assay system is considered acceptable for high-
throughput screening.198 The Z’-factor was calculated for each experiment, using the mean and 
standard deviation of all positive and all negative controls. The data obtained of all experiments 
was used to calculate the average Z’-factor. A total number of 75 values were included in this 
analysis. The average Z’-factor for the measurement of calcium influx in the 1321N1 astrocytoma 
cell line stably transfected with the P2X3 receptor was 0.64 ± 0.02. Therefore, the assay is 
suitable for high-throughput screening. 
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3.3 Potency of standard agonists and antagonists 
The affinity and potency of several standard agonists and antagonists towards the S15V mutant 
of the rat P2X3 receptor (P2X3) stably expressed in 1321N1 astrocytoma cell lines were 
determined as a first step. Eleven cell monoclones were successfully selected and cultured to 
find cells with high receptor expression. Two different concentrations (0.1 µM and 1 µM) of the 
physiological agonist ATP were used for initial stimulation experiments. Carbachol and HBSS 
buffer were used as positive and negative controls, respectively. Three of those monoclones 
showed high fluorescence signal increase between 6000 and 18 000 fluorescence counts. The 
monoclone giving the highest signal (monoclone 7) was used in all further experiments. 
 
3.3.1 Standard agonists 
Several standard agonists, α,β-meATP, BzATP and 2-meSATP (structures see Figure 1.9), whose 
affinity and potency is well described at P2X receptors, were selected for further receptor 
characterization.  
The physiological agonist ATP showed an EC50 value of 0.0514 ± 0.0096 µM. The results indicate 
a higher affinity as previously determined via patch clamp experiments (1.2 µM,68 1.6 ± 0.1 µM69 
or 4.1 ± 0.53 µM70 at human and 2.6 ± 0.9 µM69 at rat P2X3). However, they are lower than those 
obtained in radioligand binding studies (IC50 0.00316 against [
35S]ATPγS).215 Both human and rat 
P2X3 wild type receptors show rapid desensitization milliseconds after agonist stimulation, so 
the adequate estimation of agonist affinity by functional experiments like measurement of 
calcium influx or patch clamp experiments proves to be difficult.216 The high affinity data of 
radioligand binding experiments suggest a very high potency of ATP at wild type P2X3 receptors. 
Pratt et al. suggest the possibility of two classes of binding sites, a low-affinity activator and a 
high-affinity inhibitory site on the receptor as an explanation for this phenomenon.69 According 
to this theory, the high affinity of ATP to the latter and its slow dissociation traps the receptor in 
its desensitized state and defines the unusually slow recovery rate. 
The EC50 value of ATP determined with the P2X3 receptor mutant lies below the reported 
functional and binding data of the P2X3 receptor wild type and was determined to be around 
five times more potent than reported by Hausmann et al. by measurement of calcium influx. The 
same is true for the potent ATP analog α,β-meATP.118  
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Figure 3.3: Mean dose-response curves of standard agonists at the P2X3 receptor (mean ± SEM, 
n = 3-7). 
 
Additionally, BzATP and 2-meSATP, further potent standard agonists at wild type P2X3 receptors, 
were tested. BzATP proved to be slightly more potent at the P2X3 receptor than ATP. This was 
previously reported by Bianchi et al., although again with higher values (see Table 3.1).63 The 
most active agonist was 2-meSATP with an EC50 value of 0.00925 ± 0.00109 µM. It was almost 30 
times more potent than reported previously for the wild type receptor.28 Discrepancies like this 
could be attributed to receptor desensibilization distorting its sensitivity to stimulation. Despite 
the high potency of 2-meSATP, ATP was selected as standard agonist for stimulation 
experiments due to lower cost.  
 
Table 3.1: Agonistic potency of standard agonists (mean ± SEM, n = 3-7) and described in the 
literature at the P2X3 receptor.28, 63, 118  
Agonist EC50 ± SEM [µM] EC50 [µM] from literature 
ATP 0.0514 ± 0.0096 0.280-0.339 
BzATP 0.0241 ± 0.0024 0.03-0.08 
α,β-meATP 0.0859 ± 0.0064 0.354-2 
2-meSATP 0.00925 ± 0.00109 0.3 
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3.3.2 Standard antagonists 
Several well-known standard antagonists were tested at the P2X3 receptor. Suramin, RB-2, TNP-
ATP and the P2X3 receptor-selective compounds AF-353 and NF110 were available for testing. 
The results are presented in Figure 3.4. The most potent standard antagonist was TNP-ATP, 
which was capable of blocking calcium flux in low nanomolar concentrations (see Table 3.2). This 
result correlates to previously reported data of patch clamp experiments at rat P2X3 receptors, 
where an IC50 value of ~0.002 µM was determined.
28 RB-2 and Suramin were proven to be 
relatively weak antagonists. The results for suramin are comparable to the ones already 
reported, but RB-2 was previously identified as a weak allosteric modulator.28, 63 RB-2 is a 
mixture of meta/para sulfonate substitution at the last phenyl residue. The substitution pattern 
at the last ring is most likely responsible for the diversion, since only the ortho-isomer acts as a 
PAM at the P2X3 receptor. 
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Figure 3.4: Mean dose-response curves of standard antagonists at the P2X3 receptor stimulated 
with ATP 0.1 µM (mean ± SEM, n = 3-7). 
 
Gever et al described AF-353 as a potent and selective non-competitive P2X3 receptor 
antagonist.121 The results at the P2X3 receptor indicate a lower IC50 value (0.389 ± 0.100 µM). 
Since the compound is described to inhibit the receptor in a non-competitive way, it is possible 
that the amino acid exchange to stabilize the receptor lead to an alteration of the antagonist 
binding pocket, resulting in a loss of potency.  
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NF110 was initially described as the first suramin-derived antagonist who preferably inhibits the 
P2X3 receptor over the P2X1 receptor in a competitive manner with an IC50 value of 
0.090 ± 0.018 µM.125 In our experiments, the compound was found to be approximately tenfold 
less potent. The mode of inhibition of NF110 was determined via patch clamp experiments at 
the heteromeric P2X2/3 receptor subtype due to its non-desensitizing properties upon ATP 
stimulation. The different pharmacology of the heteromeric receptor (see chapter 1.2.8) could 
explain the observed discrepancy. 
 
Table 3.2: Inhibitory potency of standard antagonists (mean ± SEM, n = 3-7) and described in the 
literature at the P2X3 receptor.28, 121, 125 
Antagonist IC50 ± SEM [µM] IC50 ± SEM [µM] from 
literature 
RB-2 2.88 ± 0.12 1.4a, b 
AF-353 (RO-4) 0.389 ± 0.100 0.00891 
Suramin 4.41 ± 2.04 3 
TNP-ATP 0.0190 ± 0.0036 0.001 
NF110 1.57 ± 0.55 0.090 ± 0.018 
a: EC50Enhancement of positive allosteric modulation 
b: Enhancement only by the ortho-isomer (Cibacron Blue 3GA) 
 
3.4 Potency of amino- and desaminoanthraquinone derivatives 
The next step in the characterization of the P2X3 receptor represented the screening of a 
comprehensive compound library to prove its suitability for high-throughput screening via 
measurement of calcium influx. The selected derivatives were already identified to be potent 
inhibitors of the P2X2 receptor and they contain a high variety of structural modifications for 
extensive structure-activity-relationship studies.103 A compound library of 165 anthraquinone- 
and 26 desaminoanthraquinone derivatives was selected for screening and determination of 
dose-response curves.  
The first step was a screening experiment, where a single concentration (10 µM) was tested at 
least three times in duplicates. The results are presented in Figure 3.5. Since many compounds 
seemed to be highly active, dose-response curves to determine the IC50 concentration were 
conducted for all compounds which inhibited the P2X3 receptor more than 80 %. Moreover, a 
lot of compounds apparently enhanced the maximal ATP effect, resulting in receptor inhibition 
mathematically lower than zero. Both effects were examined further in additional experiments. 
In the following chapters, structure-activity relationships of compounds with inhibitory and ATP-
enhancing potency demonstrated. 
3 Results and Discussion 
-64- 
 
-250
-200
-150
-100
-50
0
50
100
150
200
in
h
ib
it
io
n
 (
%
)
 
Figure 3.5: Inhibition of the P2X3 receptor by 165 anthraquinone ( ) and 26 desamino-
anthraquinone compounds ( ) in a single concentration of 10 µM (mean, n = 3-5). Compounds 
YB038, YB087, YB120, YB149 and YB160 are marked ( ), since they were selected for further 
experiments (mean ± SEM, n = 3-5). Dashed line: compounds with an inhibition value ≥ 80 % 
or ≤ -100 % were submitted to dose-response curve determination. 
 
3.4.1 Inhibitory potency  
During the initial screening experiments, 39 anthraquinone- and 5 desaminoanthraquinone 
derivatives were found to inhibit the P2X3 receptor to over 80 % at a final concentration of 
10 µM (see Figure 3.5). For of those hits, concentration-response curves were conducted.  
 
3.4.1.1 Scaffold C, D and E of aminoanthraquinones 
The results of the screening and dose-response experiments are summarized in Table 3.3 for 
compounds based on scaffold C, Table 3.4 for scaffold D and Table 3.5 for scaffold E. Smaller 
substituents introduced in position 4 of the aminoanthraquinone core proved to be suitable for 
inhibitors of the P2X3 receptor.  
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Table 3.3: Inhibitory potency of aminoanthraquinone derivatives with basic scaffold C at the 
P2X3 receptor (mean ± SEM, n = 3-5). 
Scaffold 
 
 
Compound R1 R2 R3 R4 IC50 ± SEM 
[µM] 
YB025 (Acid Blue 25) H H H H > 10 (-24 %) 
YB022 H H Cl H n. c.a (106 %) 
YB034 H H Br H 5.89 ± 2.01b 
YB036 H H CH3 H n. c.
a (83 %) 
YB073 H H CH2CH3 H 8.90 ± 1.12
b 
YB011 H H OH H > 10 (-21 %) 
YB045 H H SO3H H > 10 (-72 %) 
YB015 H H OCH3 H > 10 (-61 %) 
YB019 H H NH2 H > 10 (-42 %) 
YB054 H CH3 OH H 7.04 ± 1.43
b 
YB037 H COOH NH2 H n. c.
a (148 %) 
YB059 H CH3 H CH3 n. c.
a (101 %) 
YB005 COOH H H H > 10 (10 %) 
YB009 SO3H H H H > 10 (-5 %) 
YB004 COOH H H Cl > 10 (-5 %) 
YB007 COOH H Cl H > 10 (6 %) 
YB006 H COOH H H > 10 (-34 %) 
YB008 H H COOH H > 10 (-50 %) 
YB010 OH H H H > 10 (19 %) 
YB016 (PSB-0716) OCH3 H H H > 10 (-46 %) 
YB020 NH2 H H H > 10 (-36 %) 
a: n. c. no convergence (nonlinear regression fit of the data was not possible) 
b: curve was extrapolated 
 
The sole aniline derivative YB025 was not active, but the introduction of several residues in 
different positions of scaffold C lead to an increase of inhibitory potency. Small residues like 
halogen (chlorine in YB022 and bromine in YB034), a methyl (YB036) or an ethyl group (YB073) 
were tolerated in the para-position, whereas compounds with a hydroxyl (YB011), a sulfonic acid 
(YB045), a methoxy (YB015), an amino (YB019) or a carboxymethyl substituent in this position 
showed no inhibitory activity. The concentration-response curves for the active compounds 
confirmed the initial results for the bromine residue (YB034, IC50 5.89 ± 2.01 µM). The 
determination of the IC50 value for the chlorine substituent was not successful. A fluorine 
3 Results and Discussion 
-66- 
 
residue in the para-position displayed a very different effect, which will be discussed in detail 
later on in chapter 3.4.2. 
 
Table 3.4: Inhibitory potency of aminoanthraquinone derivatives with basic scaffold D at the 
P2X3 receptor (mean ± SEM, n = 3-5). 
Scaffold 
 
 
Compound X IC50 ± SEM [µM] 
YB030 O 7.92 ± 1.74a 
YB039 (PSB-0739) NH n. c.b (98 %) 
a: curve was extrapolated 
b: n.c. no convergence (nonlinear regression fit of the data was not possible) 
 
The combination of two different substituents in different positions on the aniline residue of 
scaffold C led to inhibitory potency at the P2X3 receptor. When the previously proven inactive 
hydroxyl group in the para-position is combined with a methyl residue in the meta-position, 
inhibition of the P2X3 receptor can be observed (YB054, IC50 7.04 ± 1.43 µM). Its potency is 
similar to the introduction of an amino- and a carboxylic acid function in the same positions. The 
introduction of those residues in meta-position of each other was tolerated as well (YB037). Two 
methyl substituents in meta-position (YB059) also led to inhibition of the receptor at 10 µM 
screening concentration, but these results could not be confirmed in concentration-response 
experiments. Positioning a carboxylic acid (YB005) or a sulfonic acid function (YB009) in the 
ortho-position of the aniline ring abolished any inhibitory effect of the compounds. This result 
was consistent in combination with chlorine in different positions (see compounds YB004 and 
YB007).The transposition of the carboxylic acid residue in the meta- or para-position of the 
aniline ring did not improve these results (see compounds YB006 and YB008). Generally, the 
introduction of small hydrophilic residues (compounds YB010, YB016 and YB020) in the ortho-
position was not tolerated by the P2X3 receptor. 
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Table 3.5: Inhibitory potency of aminoanthraquinone derivatives with basic scaffold E at the 
P2X3 receptor (mean ± SEM, n = 3-5). 
Scaffold 
 
 
Compound R IC50 ± SEM [µM] 
YB117 
 
7.71 ± 0.17a 
YB118 
 
> 10 (77 %) 
YB120 
 
2.39 ± 1.00a 
YB119 
 
5.99 ± 0.52a 
YB121 
 
> 10 (40 %) 
YB123 
 
> 10 (45 %) 
YB126 
 
> 10 (-52 %) 
YB122 
 
6.89 ± 0.79a 
a: curve was extrapolated 
 
The linker between the sulfoaniline and the second benzene moiety was varied in scaffold D. 
Both nitrogen and oxygen showed high inhibitory potency during initial screening at 10 µM, but 
only for the oxygen linker IC50 values could be calculated. 
Scaffold E was varied by introducing different residues in the para-position of the carboxyaniline 
moiety in position 4 of the aminoanthraquinone core. The cyclohexylamino residue (YB117) was 
more potent than its cyclopentyl analog (YB118). No inhibitory activity could be observed for the 
pyrrolidin-1-yl group (YB126) in the initial screening experiments. The exchange of the cyclohexyl 
residue to a benzyl function (YB120) led to a slight increase in potency, but still in the lower 
micromolar range. This proved to be the most active compound of all of these three scaffolds. 
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The concentration-response curves measured via calcium influx experiment and via patch clamp 
(thanks to PD Dr. Ralf Hausmann from the Institute of Toxicology and Pharmacology, University 
of Aachen) of three independent experiments are presented in Figure 3.6 as an example for all 
conducted dose-response curves with active compounds based on scaffold C, D and E. The 
respective IC50 values were 2.39 ± 1.00 µM for measurement of calcium influx and 2.60 µM for 
patch clamp experiments. The results are reproducible by different methods, and it seems 
unlikely that any fluorescence of the compounds themselves interfered with the calcium influx 
experiment. 
 
 
 
 
 
 
 
 
Figure 3.6: Mean dose-response curves and structure of YB120 at the P2X3 receptor 
(mean ± SEM, n = 3), determined by (A) measurement of calcium influx ( , curve was 
extrapolated) and (B) by patch clamp experiments ( ). The patch clamp-derived data was 
provided by PD Dr. Ralf Hausmann. Data is presented as mean ± SEM from 5-6 independent 
experiments. 
 
The elongation to a phenylethyl moiety (YB119) did not improve the inhibitory effect. Non-cyclic 
aliphatic residues like an isobutyl (YB121) or isopropyl (YB123) function attached via N to the 
carboxyaniline residue showed weak to no activity. Only the non-branched short ethyl group 
weakly inhibited the P2X3 receptor similar to the other active aminoanthraquinone derivatives. 
 
3.4.1.2 Scaffold A and B of aminoanthraquinones 
The addition of a second phenyl residue in the para-position of the aminoaniline moiety was the 
first step to a series of compounds displaying constant inhibitory activity at the P2X3 receptor. 
The results are presented in Table 3.6. 
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Table 3.6: Inhibitory potency of aminoanthraquinone derivatives with basic scaffold A at the 
P2X3 receptor (mean ± SEM, n = 3). 
Scaffold 
 
 
Compound X IC50 ± SEM [µM] 
YB017 CH2 5.98 ± 2.09
a 
YB018 O > 10 (-49 %) 
YB027 S > 10 (-44 %) 
YB026 NH 6.28 ± 2.31a 
a: curve was extrapolated 
 
First, the influence of the linker between the two phenyl residues in scaffold A was investigated. 
A methylene group (YB017), nitrogen (YB026), oxygen (YB018) and sulfur (YB027) were tested. 
Only the methylene and the amino linker showed suitable inhibitory potency at the P2X3 
receptor. 
Scaffold B was obtained by introducing a carboxyl group in position 3 of the first aniline ring. It 
was the starting point for a whole series of compounds displaying various residue patterns on 
the second aniline moiety. All compounds except YB103 were shown to be full antagonists of the 
P2X3 receptor with IC50 values between 2 and 8 µM, respectively. Short residues like chlorine, 
fluorine, methyl, methoxy or ethoxy groups were tolerated in all positions of the second aniline 
ring, but did not lead to an improvement of inhibitory activity below the micromolar range. The 
only residue not tolerated was an ethyl function in position 2 (YB103). Since the ethoxy residue 
in the same position did not abolish inhibitory potency, it is possible that anything bulkier than a 
methyl residue needs a polar structure like oxygen for full inhibition of the P2X3 receptor.  
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Figure 3.7: Inhibitory potency of aminoanthraquinone derivatives with basic scaffold B at the 
P2X3 receptor (mean ± SEM, n = 3). 
Scaffold 
 
 
Compound R1 R2 R3 R4 IC50 ± SEM 
[µM] 
YB100 H H H H 3.29 ± 0.37 
YB103 H H H CH2CH3 > 10 (-42 %) 
YB101 H CH3 H H 7.56 ± 0.90
a 
YB102 H H CH3 H 3.50 ± 0.20 
YB104 H H Cl H 2.62 ± 0.37 
YB105 H H H OCH3 2.47 ± 0.25 
YB106 H H OCH3 H 2.81 ± 0.41 
YB107 H H H Cl 2.38 ± 0.30 
YB108 H F H H 2.82 ± 0.12 
YB110 CH3 H CH3 H 5.35 ± 2.30
a 
YB111 CH3 H H CH3 3.41 ± 0.77 
YB113 H CH3 H CH3 3.33 ± 0.78 
YB114 H H CH3 CH3 3.48 ± 0.50 
YB115 H H H OCH2CH3 6.33 ± 0.11
a 
YB116 H OCH2CH3 H H 3.52 ± 0.90 
YB124 H H H F 3.62 ± 0.54a 
YB125 H H F H 7.12 ± 1.07a 
YB139 H H Cl H 6.83 ± 1.17a 
a: curve was extrapolated 
 
One of the most active compounds was YB106 with an IC50 value of 2.81 ± 0.41 µM (see 
Figure 3.8). Small residues in various positions of the second aniline ring did not further improve 
the inhibitory potency. No compounds with larger residues like phenyl or benzyl or longer 
aliphatic groups were available for testing. With the exception of position 2, the introduction of 
such functions in other positions of the second aniline ring might further improve inhibition 
potency. Nonetheless, scaffold B was proven to be a successful lead structure for the 
development of potent aminoanthraquinone-based inhibitors of the P2X3 receptor. 
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Figure 3.8: Mean dose-response curve and structure of scaffold B anthraquinone derivative 
YB106 at the P2X3 receptor (mean ± SEM, n = 3). 
 
3.4.1.3 Determination of inhibition mechanism 
The inhibitory potency of anthraquinone derivatives proved to be weak, but in order to 
determine the mechanism of inhibition, ATP concentration-response experiments with and 
without various concentrations of an anthraquinone-based inhibitor were conducted. One of the 
most active compounds, scaffold E-based compound YB120, was selected as an example for the 
whole series of anthraquinone derivatives. The results are presented in Figure 3.9. 
 
 
 
 
 
 
 
 
Figure 3.9: (A) Mean ATP dose-response curves, (B) ATP pEC50 values and (C) maximal ATP 
effect (%) at 10 µM ATP characterizing the influence of most active inhibitory scaffold E 
derivative YB120 0.5 µM ( ), 1 µM ( ), 5 µM ( ), 10 µM ( ) and 15 µM (×) at the P2X3 receptor. 
Cells were incubated with compounds prior to stimulation with ATP 0.0001-10 µM, respectively. 
Buffer containing 1 % DMSO without compound was used as control ( ). Data is presented as 
mean ± SEM from 3-6 independent experiments. 
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Before testing the high concentration of 15 µM YB120, a fluorescence test was necessary to 
eliminate any interfering fluorescence signal. No increase of basic fluorescence prior to ATP 
injection could be detected. The obtained results were therefore included in the data analysis 
and interpretation.  
The concentrations of YB120 used in this experiment were selected based on the previously 
determined IC50 value of 2.39 ± 1.00 µM. None of the concentrations tested affected the 
maximal ATP effect with statistical significance (see Figure 3.9). However, the pEC50 values of 
ATP were slightly shifted towards higher concentrations. 
Since the maximal ATP effect is sparsely affected, the shift of EC50 value indicates YB120 to be a 
competitive antagonist of the P2X3 receptor. A Schild plot was conducted to further analyze the 
effect. The results are presented in Table 3.7. 
 
Table 3.7: pA2, Hill slope and Schild slope of Gaddum/Schild EC50 shift analysis for anthraquinone 
derivative YB120 at the P2X3 receptor. Data was calculated from the mean of 3-6 independent 
experiments. 
 pA2 Hill slope Schild slope 
YB120 4.98 1.20 3.95 
 
PA2 is defined as the logarithm of the concentration of antagonist needed to shift the ATP dose-
response curve by a factor of 2.The Schild slope quantifies how well the shifts match the 
prediction of competitive interaction. When the inhibitor binds in a competitive mode, the 
Schild slope is 1.0. If the shift of ATP dose-response curve to the right is greater than predicted, 
the Schild slope is greater than 1, when it is less than predicted, it is less than 1. Here, the Schild 
slope is greater than 1. The lack of fluorescence signal decrease and the slight shift of EC50 to the 
right are hints for orthosteric antagonism, but the analysis was inconclusive. The lack of 
fluorescence signal decrease and the slight shift of EC50 values to the right are hints for 
competitive receptor inhibition, but the results of the analysis did not confirm the initial 
observation. In the literature, a competitive mode of inhibition for the anthraquinone 
derivatives at P2X2 receptors has been determined previously via patch clamp experiments in 
Xenopus oocytes.103 Since aminoanthraquinone derivative Cibacron Blue 3GA is postulated as an 
allosteric modulator of P2X3 receptor, it is possible that YB120 is capable of interacting with the 
P2X3 receptor by different binding sites.127 This could be a cause f or the inconclusive Schild plot 
data. 
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3.4.1.4 Desaminoanthraquinone derivatives 
A series of deaminated anthraquinone compounds was tested in order to determine the 
importance of the amino function in position 1 of the anthraquinone core. Not all anthraquinone 
compounds were available in the deaminated form. Table 3.8 and Table 3.9 contain the results 
of the most interesting substitutes.  
 
Table 3.8: Inhibitory potency of desaminoanthraquinone derivatives with basic scaffold C at the 
P2X3 receptor (mean ± SEM, n = 3-5). The data of the aminated derivative is repeated for better 
comparison. 
Scaffold 
 
 
 
Compound R1 R2 IC50 ± SEM [µM] 
of aminated 
compound 
IC50 ± SEM [µM] 
of deaminated 
compound 
daYB025 H H > 10 (-24 %) > 10 (-24 %) 
daYB016 CH3 H > 10 (-46 %) > 10 (-14 %) 
daYB010 OH H > 10 (19 %) 4.86 ± 0.64a 
daYB022 H Cl n. c.b (106 %) > 10 (61 %) 
daYB034 H Br 5.89 ± 2.01a 7.69 ± 0.80a 
daYB036 H CH3 n. c.
b (83 %) > 10 (32 %) 
a: curve was extrapolated 
b: n. c. no convergence 
 
When comparing the results of deaminated compounds available with their respective aminated 
counterpart (see chapters 3.4.1.1 and 3.4.1.2, respectively), most of them remained inactive at 
the P2X3 receptor. The deamination seemed to have no effect on the compound’s potency. A 
distinct affinity improvement could be observed upon deamination only for compounds 
daYB010 and daYB041 (inhibition values for YB010 and YB041 were 19 ± 18 and 18 ± 36 %, 
respectively). 
The subsequently determined IC50 value of the deaminated compounds remained in the same 
range between 1 and 10 µM as observed for all other active anthraquinone derivatives. By 
contrast, the activity of YB034 remained unaffected by the loss of the amino function. Unlike the 
aminated form, concentration-response curves for deaminated daYB039 could be generated, 
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but the potency of the compound was comparable to the rest of the anthraquinone series. 
These observations indicate that the amino group in position 1 of the anthraquinone core seems 
not to be essential for antagonistic potency, since neither presence nor absence have a 
significant influence on compound affinity to the P2X3 receptor. Position 1 could be a suitable 
position for the introduction of other residues to improve activity and selectivity towards the 
P2X3 receptor. 
 
Table 3.9: Inhibitory potency of desaminoanthraquinone derivatives at the P2X3 receptor. 
Compound daYB039 is based on scaffold D (mean ± SEM, n = 3-5). The data of the aminated 
derivative is repeated for better comparison. 
Compound Structure IC50 ± SEM 
[µM] of 
aminated 
compound 
IC50 ± SEM 
[µM] of 
deaminated 
compound 
daYB039 
 
n. c.a (98 %) 3.62 ± 0.57 
daYB041 
 
> 10 (18 %) 10.0 ± 0.7 
a: n. c. no convergence 
 
3.4.2 Enhancement of ATP potency 
An increase of the maximum fluorescence increase of the agonist effect was noticed for several 
compounds during the initial screening experiments. This observation manifested itself in the 
form of negative inhibition values calculated after data analysis. The concerned compounds are 
visible as black dots located below the X-axis in Figure 3.5. Since for some compounds, a twofold 
fluorescence increase of the ATP control was observed, further tests were initiated to determine 
whether this phenomenon was actually caused by an interaction of the compound with the 
receptor or just an artefact of fluorescence measurement. 
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3.4.2.1 Anthraquinone derivatives 
All compounds which displayed an increase by more than 100 % at 10 µM in the initial screening 
experiment were further investigated. The first step was the determination whether the 
observed enhancement of maximal ATP effect was concentration-dependent. The ATP 
concentration injected in these experiments was lowered to the EC50 value (0.05 µM) to better 
characterize the magnitude of the enhanced maximal ATP effect. The results are presented in 
Table 3.10. The occurrence of enhancement could not clearly be linked to a common structural 
element. Nevertheless, some basic structural features could be identified who seem to facilitate 
the appearance of enhancement of maximal ATP effect at the P2X3 receptor. The most 
prominent residue was a phenylethylamino function added to the anthraquinone core in 
position 4 (YB094), defining scaffold F. 
 
Table 3.10: Enhancing potency of anthraquinone derivatives with scaffold F at the P2X3 receptor 
stimulated with ATP EC50 concentration 0.05 µM, and enhancement of maximal ATP effect. ATP 
control signal is based as 0 % for the calculation of the percental increase. Data is presented as 
mean ± SEM from 3-5 independent experiments. 
Scaffold 
 
  
Compound R1 R2 R3 EC50 Enhancement 
± SEM [µM] 
or ATP signal 
enhancement 
at 10 µM (%) 
Enhancement 
of maximal 
ATP 0.05 µM 
effect ± SEM 
[%] 
YB094 H H H 3.29 ± 0.83a 90 ± 21 
YB029 H OCH3 OCH3 > 10 (118 %) n. d.
b 
YB081 H H OH 2.28 ± 0.33a 41 ± 0 
YB087 H H Cl 2.59 ± 0.60a 111 ± 27 
YB093 H H F 4.21 ± 0.94a 87 ± 17 
YB080 H H OCH3 > 10 (51 %) n. d.
b 
YB147 H H Br > 10 (95 %) n. d.b 
YB112 Cl H H > 10 (44 %) n. d.b 
YB148 H F H > 10 (45 %) n. d.b 
YB149 H Cl H 2.17 ± 0.16 95 ± 21 
a: curve was extrapolated 
b: n. d. not determined 
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The introduction of various residues in different positions also led to compounds displaying 
enhancement of maximal ATP effect. A concentration-response relationship with EC50Enhancement 
values between 2 and 5 µM could be seen for compounds YB094, YB081, YB087, YB093 and 
YB149. The potency was similar to previously discussed compounds with inhibitory effect of the 
P2X3 receptor, respectively. Small residues like a hydroxyl function or halogen in the para-
position of the phenyl moiety were tolerated. A larger methoxy residue or bromine in the same 
position showed a much lesser enhancement of maximal ATP effect and were not further 
investigated. The combination of two methoxy groups in the para- and the meta-position did 
show a massive increase of ATP signal during the initial screening experiment, but a successful 
concentration-response relationship could not be generated. The magnitude of signal increase 
varied distinctively between the compounds. While fluorine in the para-position lead to the 
same and chlorine to the highest detected signal increase of all compounds (YB087 111 ± 27 %), 
the hydroxyl function reduced the enhancement by almost 50 % although no difference 
between the EC50Enhancement concentrations could be observed. The average dose-response curve 
for compound YB087 is shown in Figure 3.10. 
 
Table 3.11: Enhancing potency of anthraquinone derivatives with scaffold G at the P2X3 
receptor stimulated with ATP EC50 concentration 0.05 µM, and enhancement of maximal ATP 
effect. ATP control signal is based as 0 % for the calculation of the percental increase. Data is 
presented as mean ± SEM from three independent experiments. 
Scaffold 
 
  
Compound R1 R2 R3 EC50 Enhancement ± 
SEM [µM] or 
ATP signal 
enhancement 
at 10 µM (%) 
Enhancement 
of maximal 
ATP 0.05 µM 
effect ± SEM 
[%] 
YB032 H H H 2.43 ± 0.38 57 ± 13 
YB042 H H OH 2.56 ± 0.90a 33 ± 7 
a: curve was extrapolated 
 
A cyclohexylamino moiety in the same position (YB032) represents another scaffold of 
compounds with enhancing properties and was named scaffold G. Its derivatives increased the 
maximal ATP effect. The EC50Enhancement value obtained from concentration-response experiments 
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for YB032 and the derivative supplied with a hydroxyl function in position 4 of the cyclohexyl 
ring (YB042) lay in the same range as those of previously discussed compounds. However, the 
observed enhancement of ATP effect however was significantly reduced from 90 % to 57 % and 
33 %, respectively. 
 
Table 3.12: Enhancing potency of anthraquinone derivatives with scaffold C at the P2X3 receptor 
stimulated with ATP EC50 concentration 0.05 µM and enhancement of maximal ATP effect. ATP 
control signal is based as 0 % for the calculation of the percental increase. Data is presented as 
mean ± SEM from three independent experiments. 
Scaffold 
 
  
Compound R1 R2 R3 EC50 Enhancement ± 
SEM [µM] or 
ATP signal 
enhancement 
at 10 µM (%) 
Enhancement 
of maximal 
ATP 0.05 µM 
effect ± SEM 
[%] 
YB031 H H CH2PO(OCH2CH3)2 1.43 ± 0.49
a 44 ± 6 
YB038 H H CH2COOH 0.897 ± 0.296 24 ± 7 
YB047 H H NHCOCH3 1.50 ± 0.24
a 76 ± 16 
YB048 CH3 NH2 H 1.82 ± 0.40
a 66 ± 22 
YB085 H CH3 Cl 2.07 ± 0.34
a 48 ± 8 
YB095 F H H 1.22 ± 0.12a 68 ± 32 
YB159 H CHOHCH2CH3 H > 10 (77 %) n. d.
b 
YB160 H COCH2CH3 H 2.22 ± 0.45 83 ± 27 
a: curve was extrapolated 
b: n. d. not determined 
 
Derivatives obtained from scaffold C were already discussed as forwarding P2X3 receptor 
antagonists. Some compounds based on this scaffold showed enhancing properties instead. In 
particular, when bulky residues like diethoxyphosphorylmethyl (YB031), carboxymethyl (YB038) 
or acetamido (YB047) are introduced in para-position of the aniline moiety, enhancement 
instead of inhibition can be observed. The most potent enhancing compound of all proved to be 
YB038 with an EC50Enhancement value of 0.897 ± 0.296 µM. The respective concentration-response 
curve is presented in Figure 3.11. The magnitude of ATP 0.05 µM-induced enhancement though 
was much smaller than observed for other anthraquinone derivatives. A 1-hydroxypropyl 
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(YB159) or propranoyl residue (YB160) in the meta-position encouraged enhancement as well, 
but did improve neither affinity nor magnitude of fluorescence signal. 
Scaffold H was obtained by attaching a phenyl residue to carbon 3 of the 1-hydroxypropyl side 
chain of compound YB159. Neither the lead compounds (enantiomeric mixture YB088, 
(R)-enantiomer YB151 and (S)-enantiomer YB152) nor the introduction of various small residues 
in different positions of the newly introduced phenyl ring showed any ATP signal-enhancing 
properties. This modification apparently represents a possibility to repress any enhancement, 
but at the same time does not provide any inhibitory potency. 
Figure 3.10 and Figure 3.11 demonstrate the concentration-response relationship of four 
enhancement-showing compounds. Compounds YB087 and YB149 were selected for displaying 
enhancement-facilitating scaffold I, and YB038 and YB160 as variations of scaffold K. YB038 was 
selected because of its high affinity, the other three for the particularly strong enhancement of 
ATP 0.5 µM-induced fluorescence increase. 
 
Table 3.13: Enhancing potency of anthraquinone derivatives with scaffold H at the P2X3 
receptor stimulated with ATP EC50 concentration 0.05 µM and enhancement of maximal ATP 
effect. ATP control signal is based as 0 % for the calculation of the percental increase. Data is 
presented as mean ± SEM from three independent experiments. 
Scaffold 
 
  
Compound R1 R2 R3 EC50 Enhancement ± 
SEM [µM] or 
ATP signal 
enhancement at 
10 µM (%) 
Enhancement 
of maximal 
ATP 0.05 nM 
effect ± SEM 
[%] 
YB088 H H H < 10 (40 %) n. d.a 
YB151b H H H < 10 (-7 %) n. d.a 
YB152c H H H < 10 (-1 %) n. d.a 
YB150 H H F < 10 (-1 %) n. d.a 
YB153 H H Cl < 10 (48 %) n. d.a 
YB154 H H Br < 10 (43 %) n. d.a 
a: n. d. not determined 
b: (R)-enantiomer 
c: (S)-enantiomer 
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3.4.2.2 Further investigations of enhancement effect of anthraquinone derivatives 
The enhancement of ATP-induced effect seemed dependent on the compound concentration. 
Further experiments were conducted for compounds YB038, YB087, YB149 and YB160 in 
representation of the whole series. As the experiment is based on the detection of fluorescence, 
any interference of the colored test compound would distort the results, especially since the 
enhancement of fluorescence increased with enhanced compound concentration. As already 
described in chapter 2.2.2, each test plate was validated prior to agonist injection after the 
incubation time with test compound ended. Therefore, any increase of basic fluorescence due to 
the added test compound could be determined in situ by comparison to the control wells which 
did not contain any test compounds. As summarized in Table 2.1 and Table 2.2, the respective 
maxima for the fluorescent dyes are 494 nm and 516 nm for Fluo-4 and range between 470 and 
495 nm and 515 to 575 nm, respectively. Both fluorophores were excited at 485 nm, and the 
emission was measured at 520 nm. Wells with higher basic fluorescence than controls were 
marked for further investigation. An increase of basic fluorescence cannot only be caused by an 
interference of test compound and the dye, but also by cell toxicity, which causes leakage of dye 
from damaged cells into the calcium-containing buffer. A significant increase of basic 
fluorescence was observed using anthraquinone compound concentrations higher than 10 µM. 
All testing was therefore limited to a maximal concentration of 10 µM anthraquinone or 
desaminoanthraquinone derivative. 
In an attempt to finally exclude any distortion of the results, each anthraquinone derivative with 
enhancing properties was tested for agonistic activity by injecting various compound 
concentrations instead of ATP. No fluorescence signal increase for any compound was detected. 
Anthraquinone-based compounds therefore did not have any agonistic property at the P2X3 
receptor. All results described were conducted by stimulating the P2X3 receptor with the 
previously determined EC50 concentration of ATP. This concentration was selected in order to 
prove if the selected compounds were capable of increasing the activation state starting from 
the half maximal agonist concentration. The experiments were repeated using ATP 10 µM, a 
concentration causing maximal receptor stimulation, to determine whether these 
anthraquinone derivatives were capable of enhancing the maximal ATP effect past the maximal 
possible ATP response. The results are presented in Figure 3.10 and Figure 3.11 A2 to B2 for 
compounds YB038, YB087, YB149, and YB160. An increase of maximal ATP effect could be 
determined only for compound YB038, displaying scaffold C. This anthraquinone-based 
compound therefore is capable of enhancing the ATP effect at the P2X3 receptor even past the 
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physiologically possible level. The same effect is indicated for YB160, but a successful 
concentration-response relationship could not be obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Structures and mean dose-response curves (mean ± SEM, n = 3-4) of (A) YB087 and 
(B) YB149 stimulated with either (1) EC50 ( , 0.05 µM) or (2) maximal response concentration of 
ATP ( , 10 µM). 
 
Contrary to expectations and to the first experiments with ATP 0.05 µM, YB087 and YB149 
showed inhibition at concentrations higher than 5 µM at the P2X3 receptor when stimulated 
with 10 µM ATP. A similar effect can be seen for YB160 to a lesser extent. This indicates that the 
compound seemed to inhibit the P2X3 receptor when used in higher concentrations. It is 
possible that all three ATP binding pockets are occupied by test compound when high 
concentrations of YB087, YB149 and YB160 are used. This would prevent ATP from binding and 
subsequently activating the receptor. As the concentration and occupancy of binding pockets 
decreases, the remaining anthraquinone molecules bound to the receptor enhance the affinity 
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of ATP and therefore may cause the observed enhancement of maximal ATP effect. If the 
concentration is decreased further, it becomes too low to enhance the ATP-induced 
fluorescence, and the maximal ATP effect returns to the normal level. It is possible that the ATP 
concentration used for receptor stimulation somehow altered the receptor function, since this 
described phenomenon was not observed under receptor stimulation by the EC50 concentration 
of ATP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Structures and mean dose-response curves (mean ± SEM, n = 3-4) of (A) YB038 and 
(B) YB160 stimulated with either (1) EC50 ( , 0.05 µM) or (2) maximal response concentration of 
ATP ( , 10 µM) 
 
Compounds YB087, YB149 and YB160 were used in a patch clamp experiment in the group of PD 
Dr. med. Ralf Hausmann from the Institute of Toxicology and Pharmacology in Aachen in order 
to verify these observations. The results of these experiments are presented in Figure 3.12 and 
Table 3.14. 
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Figure 3.12: Mean dose response curves of YB087, YB149 and YB160 at the P2X3 receptor 
obtained by patch clamp experiments (MW ± SEM). The data was provided by PD Dr. Ralf 
Hausmann. Each concentration was measured at 4-6 times. 
 
The bell-shaped regression was selected for data analysis. The first EC50 value (EC50Enhancement) 
describes the first inflection point on the left side, the IC50 value represents the second inflection 
point on the right side of the bell curve. The effect of each concentration was measured 
between four to six times. The same observation can be seen as already described for 
Figure 3.10 and Figure 3.11 A1-B1, respectively. It also supports the theory that not only the 
compound concentration but also the ATP amount used for cell stimulation has influence on the 
conducted fluorescence signal. 
 
Table 3.14: Results of bell-shaped non-linear regression analysis and respective confidence 
intervals of concentration-response experiments using patch clamp experiments at the P2X3 
receptor. Each data point used in the analysis was measured 4-6 times. 
 EC50Enhancement 
[µM] 
IC50 [µM] Maximal current 
increase (%) 
Concentration of 
maximal current 
increase [µM] 
YB087 8.00 18.8 116 11.2 
YB149 6.12 12.7 123 8.07 
YB160 11.9 21.2 104 14.7 
 
An increase of maximal receptor stimulation possible under ATP influence could only be 
observed for YB038 (see Figure 3.11 A1 and A2). This indicates that YB038 somehow interacts 
differently with the P2X3 receptor than the other compounds YB087, YB149 and YB160. In an 
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attempt to get further insight in the mechanism of action, all four compounds were tested in 
another experiment analog to the determination of inhibition mechanism for antagonists, where 
cells were preincubated with certain concentrations of anthraquinone derivative selected based 
on their EC50Enhancement values, and subsequently stimulated with various concentrations of ATP 
(for experimental setup see chapter 2.2.2.1.3). The results are presented in Figure 3.13 and 
Figure 3.14. 
It was expected that under the influence of different concentrations of the respective 
anthraquinone compound, either the maximal level of fluorescence increase reached by full 
receptor stimulation would be enhanced or the EC50 value of ATP would be shifted to the left 
towards lower concentrations.  
As already observed in the previous experiments, the addition of high concentrations (10 µM 
and 5 µM) of YB087, YB149 and YB160 abolished any agonistic ATP activity (YB087) or visibly 
lowered it (YB149 and YB160, see Figure 3.13 and Figure 3.14). The decrease was statistical 
significant for YB087 and YB149. A slight enhancement of maximal ATP effect could be observed 
at concentrations lower than 5 µM, but it was nowhere nearly as high as detected in the initial 
concentration-response experiments (see Figure 3.10 A1 and B1 and Figure 3.11 B1). None of 
the slight increases were statistically significant, same as for the EC50 values of ATP. The results 
indicate that the enhancement of the ATP effect does not repose on an increase of ATP affinity 
to the P2X3 receptor, and seems to be dependent on the ATP concentration used for receptor 
stimulation, as observed previously (see again Figure 3.10 and Figure 3.11). Since high 
concentrations of anthraquinone enhancer lead to inhibition of the receptor, it is possible that 
this effect only occurs when not all binding pockets are occupied. 
A decrease of EC50 value could be observed for YB038, but the difference was not statistically 
significant from the EC50 value of the ATP control curve, and it could only be detected for the 
YB038 concentrations 5 µM and 1 µM (see higher pEC50 values in Figure 3.14 A2). Under the 
influence of YB038 0.5 µM, the EC50 value increased contrary to expectations, but the 
enhancement of fluorescence increase was the highest detected for all four compounds in this 
experiment. Due to the inconsistency of the results, a final conclusion about the mechanism how 
YB038 increases the ATP-induced fluorescence signal was still not possible, although all 
experiments indicate that the mechanism of action is different from the other three compounds 
used for further examination. A possible explanation would be the altercation of the ion pore by 
so that more calcium ions are capable of passing and therefore increasing the maximal ATP 
effect. This could also explain the further increase of maximum possible ATP-induced 
fluorescence signal demonstrated in Figure 3.10 and Figure 3.11. 
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Figure 3.13: (1) Mean ATP dose-response curves, (2) ATP pEC50 values and (3) enhancement of 
maximal ATP effect characterizing the influence scaffold G anthraquinone derivatives (A) YB038 
and (B) YB160. Cells were stimulated with ATP 0.0001-10 µM after preincubation with 0.1 µM     
( ), 0.5 µM ( ), 1 µM ( ), 5 µM ( ) or 10 µM (×) of test compound, respectively. Buffer 
containing 1 % DMSO without compound was used as control ( ). The unpaired Student’s t-test 
for determination of significant differences of means was conducted for pEC50 and enhanced 
maximal ATP effect. Statistical significance (p < 0.05) is marked with (*), highly statistical 
significant differences (p < 0.001) with (***).Data is presented as mean ± SEM from 3-8 
independent experiments. 
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Figure 3.14: (1) Mean ATP dose-response curves, (2) ATP pEC50 values and (3) enhancement of 
maximal ATP effect characterizing the influence scaffold G anthraquinone derivatives (C) YB038 
and (D) YB160. Cells were stimulated with ATP 0.0001-10 µM after preincubation with 0.1 µM     
( ), 0.5 µM ( ), 1 µM ( ), 5 µM ( ) or 10 µM (×), respectively. Buffer containing 1 % DMSO 
without compound was used as control ( ). The unpaired Student’s t-test for determination of 
significant differences of means was conducted for EC50 and enhanced maximal ATP effect (p< 
0.05). Statistical significance (p< 0.05) is marked with (*). Data is presented as mean ± SEM from 
3-8 independent experiments. 
 
3.4.2.3 Desaminoanthraquinone derivatives 
The initial screening experiments showed that the amino function in position 1 of the 
anthraquinone core is not essential for inhibitory activity (see chapter 3.4.1.4). Since certain 
structural elements of the anthraquinone series were identified to enhance the ATP-induced 
fluorescence signal increase (see chapters 3.4.2.1 and 3.4.2.2), special focus was laid on the 
deaminated versions of the most interesting compounds as far as they were available. The 
results are presented in Table 3.15. 
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Table 3.15: Enhancing potency of scaffold C desaminoanthraquinone derivatives at the P2X3 
receptor stimulated with ATP EC50 concentration 0.05 µM, and enhancement of maximal ATP 
effect. ATP control signal is based as 0 % for the calculation of the percental increase. Data is 
presented as mean ± SEM from 3-4 independent experiments. The data of the aminated 
derivatives is repeated for better comparison. 
Scaffold 
 
   
Compound R EC50 Enhancement ± 
SEM [µM] or 
ATP signal 
enhancement at 
10 µM (%) of 
aminated 
compound 
EC50 Enhancement ± 
SEM [µM] or 
ATP signal 
enhancement 
at 10 µM (%) of 
deaminated 
compound 
Enhancement 
of maximal 
ATP 0.05 µM 
effect ± SEM 
[%] of 
deaminated 
compound 
daYB047 NHCOCH3 1.50 ± 0.24 > 10 (29 %) n. d.
a 
daYB011 OH > 10 (21 %) n. c. (90 %)b n. da 
a: n. d. not determined 
b: n. c. no convergence 
 
None of the 26 desaminoanthraquinones showed any inhibition value below -100 % (see 
Figure 3.5). Since daYB011 came close, it was nonetheless tested in concentration-response 
experiments under stimulation with EC50 concentration of ATP. It was not possible to 
successfully create a dose-response relationship. The estimated EC50 value of three independent 
experiments exceeded 10 µM by far, so no further experiments were conducted. Any 
enhancement of compounds available as deaminated derivatives was abolished by removing the 
amino function. It seems that the residue is not important for inhibitory potency but plays an 
essential role for conducting enhancing properties. An interesting step would be the exchange to 
other polar or bulky residues in order to determine whether polarity or occupancy of the 
position are the important features for enhancement of the P2X3 receptor. 
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Table 3.16: Enhancing potency of scaffold F desaminoanthraquinone derivative daYB087 and 
scaffold G desaminoanthraquinone derivative daYB032 at the P2X3 receptor stimulated with ATP 
EC50 concentration 0.05 µM, and enhancement maximal ATP effect. ATP control signal is based 
as 0 % for the calculation of the percental increase. Data is presented as mean ± SEM from three 
independent experiments. The data of the aminated derivatives is repeated for better 
comparison. 
Compound Structure EC50 Enhancement 
± SEM [µM] or 
ATP signal 
enhancement 
at 10 µM (%) 
of aminated 
compound 
EC50 Enhancement 
± SEM [µM] 
or ATP signal 
enhancement 
at 10 µM (%) 
of 
deaminated 
compound 
Enhancement 
of maximal 
ATP 0.05 µM 
effect ± SEM 
[%] of 
deaminated 
compound 
daYB087 
 
2.28 ± 0.36a < 10 (28 %) n. d.b 
daYB032 
 
2.43 ± 0.38 < 10 (22 %) n. d.b 
a: curve was extrapolated 
b: n. d. not determined 
 
3.4.3 Cytotoxicity 
An increase of basic fluorescence could be observed for some compounds when used in higher 
concentrations over 6-8 µM. In order to eliminate any possibility that this could be caused by 
lysed cells leaking the loaded dye reacting with calcium ions in the buffer, five anthraquinone 
compounds, enhancers YB038, YB087, YB149 and YB160 and antagonist YB120 were tested for 
cytotoxicity by cell viability experiment using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT). The results are presented in Table 3.17. 
None of the tested anthraquinone derivatives caused any detectable cell toxicity when used in 
concentrations up to 100 µM. It was therefore estimated to be unlikely that any inhibitory action 
determined using calcium influx experiments is attributable to cytotoxicity of the anthraquinone 
test compounds. 
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Table 3.17: Cytotoxicity EC50 values of anthraquinone derivatives and positive control 5-FU at 
non-transfected 1321N1 astrocytoma cells (mean ± SEM, n = 4). 
 5-FU YB038 YB087 YB120 YB149 YB160 
Cytotoxicity 
EC50 [µM] 
1.29 ± 0.62 > 100 > 100 > 100 > 100 > 100 
 
3.4.4 Selectivity towards other P2X receptor subtypes 
Among other things, anthraquinone derivatives were reported to be potent inhibitors at least at 
the closely related P2X2 receptor, the P2Y12 receptor and the enzymes NTPDase and 
CD73.103, 206, 212, 213 The potency of the four enhancement showing anthraquinone compounds 
YB038, YB087, YB149 and YB160 and the antagonist YB120 were tested at the P2X receptor 
subtypes P2X1, P2X2, P2X4 and P2X7 in order to determine selectivity and whether the 
phenomenon of enhancement is only prominent at the P2X3 receptor. The results are shown in 
Figure 3.15. 
 
YB038 YB087 YB149 YB160
4.5
5.0
5.5
6.0
6.5 P2X1
P2X2
P2X3
P2X4
P2X7
p
IC
5
0
/p
EC
5
0
En
h
an
ce
m
e
n
t
 
Figure 3.15: pEC50Enhancement (YB038 at P2X1, all compounds at P2X3 receptor) and pIC50 values of 
anthraquinone derivatives at P2X receptors (mean ± SEM, n = 3-4). 
 
Enhancement of maximal ATP effect could only be detected for YB038 at the P2X1 receptor with 
an EC50Enhancement value of 9.09 ± 5.70 µM. That is tenfold less than for the P2X3 receptor 
(0.897 ± 0.296 µM).The graph for YB038 enhancement at the P2X1 receptor is presented in 
Figure 3.16. YB038 was not active at the other P2X receptor subtypes, neither as an enhancing 
agent nor as a receptor antagonist. The observed enhancement of maximal ATP effect was much 
higher than at the P2X3 receptor (108 ± 24 %), but occurred at much higher concentrations.  
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Figure 3.16: Mean dose-response curve of YB038 at the human P2X1 receptor (mean ± SEM, 
n = 5). 
 
Since the EC50Enhancement value at the P2X1 receptor is almost tenfold higher, YB038 can be viewed 
as a moderately selective positive enhancer of ATP potency at the P2X3 receptor, whereas the 
enhancing potency is much higher at the P2X1 receptor. YB038 acted as an antagonist at the 
other P2X receptor subtypes, with IC50 values in the micromolar range (see Table 3.18) and 
around three- to ninefold preference of the P2X3 receptor. The other three compounds YB087, 
YB149 and YB160, if active, all acted as antagonists at the other subtypes, with IC50 values 
comparable to the EC50Enhancement values seen at P2X3 receptor.  
 
Table 3.18: Enhancing potency (all compounds at the P2X3 and YB038 at the P2X1 receptor) and 
inhibitory potency of selected anthraquinone compounds at P2X receptors (mean ± 3, n = 3-4). 
 P2X1 P2X2 P2X3 P2X4 P2X7 
      
YB038 9.07 ± 5.70 
(EC50Enhancement) 
< 10 (20 %) 0.897 ± 0.296 
(EC50Enhancement) 
< 10 (23 %) < 10 (46 %) 
YB087 3.01 ± 1.42 4.48 ± 1.57 
(remaining 
receptor 
activity 21 %) 
2.59 ± 0.60 
(EC50Enhancement) 
1.51 ± 1.00 
(remaining 
receptor 
activity 13 %) 
4.98 ± 1.44 
YB149 3.26 ± 1.43 3.74 ± 0.82 
(remaining 
receptor 
activity 24 %) 
2.17 ± 0.16 
(EC50Enhancement) 
10.2 ± 6.9 
(remaining 
receptor 
activity 23 %) 
4.48 ± 1.10 
YB160 3.18 ± 1.43 3.32 ± 0.37 
(remaining 
receptor 
activity 64 %) 
2.22 ± 0.45 
(EC50Enhancement) 
< 10 (48 %) < 10 (30 %) 
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YB087 and YB149 were not able to completely inhibit the P2X2 and P2X4 receptor. Both 
receptors retained a residual activity of nearly 20 % at the highest concentration used in the 
experiment (10 µM). This effect was also observed for YB160 at the P2X2 receptor. Furthermore, 
YB160 did show no concentration-dependent activity at the P2X4 and P2X7 receptor.  
 
3.5 Discussion 
Anilinoanthraquinone derivatives were originally synthesized for pharmacological evaluation of 
P2 receptors. The lead structure RB-2 has previously been identified as a weak nonselective 
purinergic P2 and ectonucleotidase antagonist.66, 203 In order to study structure-activity 
relationships, the lead structure was truncated and various residues in different positions of the 
aniline moiety were introduced, as well as the replacement of the aniline ring itself against 
several aliphatic, polar or lipophilic structures. The pharmacological evaluation at mouse and 
human P2Y2 receptors showed inhibitory potency with IC50 values between 3 µM and 30 µM for 
several of the 4-phenylamino-substituted 1-amino-2-sulfoanthraquinone derivatives, which 
were also potent antagonists at the P2X3 receptor.205 The most potent compound at the P2Y2 
receptor was YB033 with an IC50 value of 3.04 ± 0.58 µM. The phenyl moiety was described to be 
essential for P2Y2 receptor activity.  
At ecto-5’-nucleotidase, YB052 and YB063 were the two most potent inhibitors with Ki 
concentrations of 0.260 ± 0.010 µM and 0.150 ± 0.020 µM, respectively. YB052 is based on 
scaffold C with a carboxyl group in position 2 and fluorine in position 4 of the aniline ring. In 
YB063, the aniline in position 4 of the 1-amino-2-sulfoanthraquinone core is exchanged to 2-
aminoanthracene. The naphthyl derivatives YB040 (α-naphthalene) and YB041 (β-naphthalene) 
were also potent ecto-5’-nucleotidase inhibitors with potency in the high nanomolar to low 
micromolar range (Ki 0.53 ± 0.03 µM and 1.47± 0.33 µM). The mechanism of inhibition was 
determined to be competitive. YB052 was further characterized as selective towards NTPDases, 
P2Y2, P2Y4, P2Y6 and P2Y12.
212 Both compounds were not active at the P2X3 receptor. Some 
anthraquinone derivatives were also identified as NTPDase inhibitors. YB022, also a scaffold C 
derivative with chlorine in position 4 of the aniline ring, was the most potent nonselective 
antagonist at NTPDase1, 2 and 3 with Ki values between 16 µM and 18 µM. The 2-naphthalene 
derivative YB041 also inhibited NTPDase1 (Ki 0.328 ± 0.110 µM) and 3 (Ki 2.22 ± 1.03 µM) with 
preference over NTPDase2.213 
As already discussed in chapter 1.2.7.1, the 1,3,5-triazine derivatives of scaffold C, PSB-10211 
and PSB-1011, were synthesized as potent antagonists of the P2X2 receptor with nanomolar 
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potency. The two compounds descend from the same library, but were not available for testing 
at the P2X3 receptor. Their selectivity towards P2X1 and P2X3 was described as moderate. The 
mechanism of action was again described as being competitive.103  
The anthraquinone library was extended and also evaluated for inhibitory potency at the human 
P2Y12 receptor. The aim was the development of a potent non-nucleotide antagonist with more 
drug-like properties like lower molecular weight and better subtype selectivity.206 The attached 
aniline ring in position 4 of the 1-amino-2-sulfoanthraquinone core was extended by a second 
phenyl ring via a one atom linker. The exchange of the linker to nitrogen, oxygen or sulfur did 
not decrease the potency as P2Y12 receptor antagonists, with IC50 values between 0.0249 (YB039, 
the most active inhibitor at P2Y12, also called PSB-0739) and 1.85 µM (YB026). For the most 
active compound YB039, the inhibition mechanism was determined as being competitive. The 
compounds were also expected to be selective towards other P2 receptors.  
The 4-phenylamino-3-carboxyphenylamino derivatives of PSB-0739 were the most active 
inhibitory compounds at the P2X3 receptor. An acidic function in position 3 of the aniline ring D 
is required for inhibitory activity, as well as an extension by a second aniline ring in position 4. 
Small residues like chlorine, fluorine, methyl, methoxy or ethoxy are tolerated in all positions of 
ring E, but without increasing the inhibitory potency of the compound. 
The enhancing properties of the anthraquinone derivatives is not surprising, since Cibacron 
Blue 3GA has previously been identified as a PAM of the P2X3 receptor (see chapter 1.2.8.2). The 
characterization of a scaffold causing enhancement of maximal ATP effect is much more 
complicated. The results at the P2X3 receptor indicate that the effect of respective substitution 
cannot be predicted. Scaffold F could be identified to facilitate enhancement, but it was not an 
essential structural feature. A lot of other compounds not based on scaffold F also showed 
enhancing properties. The structures were very heterogenic, and the structural differences 
between inhibiting and enhancing compounds were sometimes very small. The only structural 
feature that seemed to be necessary for enhancing properties is the amino residue in position 1 
of the 2-sulfoanthraquinone core. Its removal abolished any enhancing properties of the 
compound. Cibacron Blue 3GA is also described as a positive allosteric modulator of P2X4 (see 
chapter 1.2.9.2). So far, no data of the potency of anthraquinone derivatives at P2X4 receptor 
has been published, so structure-activity relationship at this P2X receptor subtype cannot be 
conducted. The results at the P2X3 receptor though indicate that allosteric modulation by 
anthraquinone derivatives could also be important at the P2X4 receptor.  
3 Results and Discussion 
-92- 
 
The mechanism of inhibition at the targets known so far has been described as competitive. The 
results conducted for YB120 at the P2X3 receptor indicate the same. Since negative charge is 
favorable for competitive binding due to the negative charge of ATP and its fixation by positively 
charged amino acids in the agonist binding pocket, the conclusion seems valid.  
The functional evaluation of the P2X3 receptor stably transfected in 1321N1 astrocytoma cells 
via fluorescent measurement of calcium influx was successful. The results demonstrate that the 
single point mutant of rat P2X3 receptor is suitable for high throughput screening, and new 
active compounds, lead structures and pharmacological effects could be demonstrated. 
In general, it can be said that 1-amino-2-sulfoanthraquinone derivatives are also potent 
inhibitors at the P2X3 receptor. The compound class does not solely contain antagonists, 
positive modulation leading to enhanced receptor activity was also observed and does not seem 
to follow any common structural feature.  
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4 Inhibitory potency of polyoxometalates at P2X receptors 
4.1 Introduction 
Polyoxometalates (POMs) are inorganic, negatively charged complexes consisting of metal ions 
in their highest oxidation state connected by oxygen atoms. The most frequently used ions are 
early transition metals such as tungsten (W), molybdenum (Mo), vanadium (V), niobium (Nb) 
and antimony (Sb), but many other elements, including noble metals, can be incorporated into 
the POM framework as heteroatoms. This enables a high variety of three-dimensional structures 
baring different polarity, redox potential, surface area properties and acidity.217-219 The most 
common basic three-dimensional structures are octahedra linked together through shared 
corner atoms and edges, but also square-planar and hexagonal-bipyramidal assemblies have 
been reported.220 For the present experimental series, 23 POMs were available, 17 with 
tungsten, four with rhenium and two with vanadium as the main metal ion. Most 
polyoxotungstates also contained further elements like titanium, cobalt or phosphorus. The 
compounds were provided by Dr. Holger Stephan from the Institute of Radiopharmaceutical 
Cancer Research of the Helmholtz Center, Dresden, Prof. Dr. Ulrich Kortz from the School of 
Engineering of the Jacobs University, Bremen and Prof. Dr. Wei Wang from the Center for 
Synthetic Soft Materials, Nankai University, China. Both vanadium salts were purchased from 
Sigma Aldrich Chemie GmbH. Basic information on all compounds including charge and stability 
are summarized in Table 4.1.  
PV2 and PW12 are basically the same compounds, though crystallized either as sodium salt 
(PW12) or as the free acid (PV2). Both compounds, as well as P6W18, show limited stability.
221, 222 
All results concerning those compounds therefore have to be interpreted with caution, since one 
experiment lasts nearly two hours, and it cannot be guaranteed that the compounds remain 
unaltered over that time period.  
The available compounds display variable three-dimensional shapes. The most common one is 
the Keggin structure of PV2 and PW12, PV3 and PV4 and the closely related Weakley and double-
Keggin shape. The complex consists of a central tetrahedron, circled by four trimetallic groups. 
The Weakley structure is also called a Keggin-derived sandwich. The higher the molecular 
weight, the more complicated the three-dimensional structure. These range from HPA-23, a 
cryptate encapsulating a sodium ion in its central cavity to the plate-like Pope-Jeannin-Preyssler, 
the wheel-shaped Contant-Tézé or the cylindrical Wells-Dawson structure. For better 
illustration, the different shapes of the compounds are demonstrated in Figure 4.1. 
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Table 4.1: General information of polyoxotungstates, rhenium and vanadate clusters available 
for calcium influx experiments at P2X receptors.221-242 
Name Formula Structure type Molecular 
weight 
[g/mol] 
Charge at 
pH 7.4 
Stability in 
aqueous 
solution 
PV1 Na6[H2W12O40] Metatungstate of 
corner- and edge-
sharing WO6-
octahedrons 
2986 -6 ++ 
PV2 H3[PW12O40] plenary Keggin 2862 -3 ± 
PV3 K7[Ti2W10PO40] disubstituted Keggin 2879 -7 ++ 
PV4 K6[H2TiW11CoO40] monosubstituted 
Keggin 
3006 -8 + 
PV5 K10[Co4(H2O)2(PW9O34)2] Weakley 5122 -10 ++ 
PV6 
(HPA-23) 
(NH4)18[NaSb9W21O86] Cryptate 
encapsulating a 
sodium ion in its 
central cavity 
6680 -18 ++ 
P5W30 Na15[P5W30O110] Pope-Jeannin-
Preyssler 
7780 -15 ++ 
P6W18 Na20[P6W18O79] Double Keggin 5222 -20 - 
P8W48 Na33[H7P8W48O184] Contant-Tézé 12790 -33 ++ 
PW12 Na3[PW12O40] Keggin 2948 -3 - 
OP8W12 Na16[(O3POPO3)4W12O36] Folded macrocyclic 
dodecatungstate 
with diphosphate 
complex 
3848 -16 ++ 
CP8W12 Na16[(O3PCH2PO3)4W12O36] Folded macrocyclic 
dodecatungstate 
with diphosphate 
complex 
3840 -16 ++ 
K-POM K8[H3P2W15V3O62] Wells-Dawson type 4278 -9 * 
(Bu4N)6-
POM 
(Bu4N)6[H3P2W15V3O62] Wells-Dawson 
encapsulated by 6 
tetrabutyl-
ammonium groups 
5422 -9 * 
(Bu4N)6-
PEG 
1000 
(Bu4N)6[H3P2W15V3O62]-
PEG 1000 
Added PEG chain 
with MW of 1000 
Da 
6672 -9 * 
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Continuation of Table 4.1 
(Bu4N)6-
PEG 
2000 
(Bu4N)6[H3P2W15V3O62]-
PEG 2000 
Added PEG chain 
with MW of 2000 Da 
7571 -9 * 
(Bu4N)6-
PEG 
5000 
(Bu4N)6[H3P2W15V3O62]-
PEG 5000 
Added PEG chain 
with MW of 5000 Da 
10568 -9 * 
KB1 K4[(Re6S8)(OH)6] Octahedral cluster 
chalcogenide anionic 
complex with 
terminal hydroxo 
ligands 
1632 0 to -2 due to 
formation of 
hydroxo 
complexes 
+ 
KB2 K4[(Re6Se8)(OH)6] Octahedral cluster 
chalcogenide anionic 
complex with 
terminal hydroxo 
ligands 
2007 0 to -2 due to 
formation of 
hydroxo 
complexes 
+ 
KB3 K4[Re6S8(CH3COO)6] 
 
Octahedral 
hexaacetate cluster 
complex 
1884 -4 + 
KB4 K4[(Re6S8)(HCOO)6] Octahedral cluster 
complex with 
monodentate 
coordinated formate 
ions 
1800 -4 ++ 
NaVO3 NaVO3 Metavanadate 122 -1 + 
Na3VO4 Na3VO4 Orthovanadate 184 -3 + 
++: very stable, +: stable, ±: stability not guaranteed during experiment, -: unstable, *: no 
information available about stability in aqueous solution, but thermostable up to 160°C. 
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Figure 4.1: Structures of investigated polyoxotungstates and rhenium cluster compounds. 
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The charge of the compound increases along with the complexity of the three-dimensional 
shape. All compounds are negatively charged in solution. The solubility of some compounds is 
low, namely PV5, KB1, KB2 and P8W48, despite their high charge, so that the concentration of the 
prepared stock solutions had to be reduced from 10 mM to 1 mM or 0.1 mM, respectively. 
The structural diversity of the available rhenium cluster compounds was lower than that of the 
available polyoxotungstates. All four compounds possess an octahedral shape with the basic 
formula [Re6Q8L6] containing sulfur, selenium or tellur in position of Q and OH, acetate or 
formate in position of L (see Figure 4.1). 
Several POMs were shown to have antitumoral, antibacterial, antiviral and antidiabetic 
properties.243-259 The anticancer effect is attributed to DNA ladder formation, induction of 
apoptosis and inhibition of histone deacetylase (HDAC).243, 246, 247 The effect was also proven in in 
vivo cancer models.244, 245 The antibacterial effect could be demonstrated particularly for 
polyoxotungstates with Keggin shape. The combination with β-lactam antibiotics oxacillin, 
piperacillin or cefazolin showed a synergistic effect in MRSA, which was attributed to a reduced 
formation of penicillin-binding protein 2’.248, 250 Antiviral properties were found against RNA-
viruses like influenza A, anti-respiratory syncytial virus (RSV), Dengue virus, Hepatitis B and 
SARS.251, 254 Particularly interesting is the activity against HIV-1, which was connected to 
inhibition of DNA polymerase activity.252, 253 Antidiabetic properties were proven for tungsten 
and vanadium-based Dawson structures in vivo in a mouse model.256 Vanadium-based 
compounds displayed insulin-mimetic features.257 The insulin-mimetic effect was associated with 
improvement of glucose homeostasis, reduction of insulin resistance and improvement of insulin 
sensitivity in liver and muscle.258  
Due to their high negative charge at physiological pH value, POMs were considered to not be 
able to cross cell membranes and enter intracellular compartments. It was therefore suggested 
that the pharmacological potency of POMs is conveyed through inhibition of structures 
presented on the extracellular site. Despite the fact that the high negative charge does hinder 
the entry of the compound into cells, measurable concentrations of various POMs inside cells 
were reported.217 An example is HPA-23, which is also part of this experimental setting (PV6). 
Intracellular crystals of HPA-23 were detected using Raman spectroscopy.260 Furthermore, the 
uptake of several polyoxotungstates in macrophages could be confirmed. Intracellular uptake 
and extracellular interaction were both assumed to be vital for antiviral activity.261  
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Recently, POMs were identified as potent inhibitors of nucleotide-degrading enzymes, especially 
NPPs and NTPDases, in rodents and humans. These results indicate that many of the described 
pharmacological properties of POMs can be associated with inhibition of this enzyme 
class.221, 262-265 Their potency was ascribed to their negative charge and their similarity to the 
physiological ectonucleotidase substrates ATP and ADP.221 Since nucleoside-degrading enzymes 
are not the only nucleotide-binding proteins expressed on the cell surface, polyoxometalates 
were tested at further structures activated by nucleotides. In 2011, Ramona Malek investigated 
POMs at G protein-coupled nucleotide-activated P2Y receptors.266 The aim of the present study 
was to determine whether POMs are also interacting with P2X receptor ion channels. The results 
are discussed in the following chapters.  
 
4.2 Z’-factor for determination of assay quality 
The Z’-factor was calculated for all experiments conducted with POMs tested at P2X receptor 
subtypes. The results are presented in Table 4.2. 
 
Table 4.2: Z‘-factors of experiments conducted for testing the inhibitory potency of 
polyoxometalates at P2X receptors. Data is presented as mean ± SEM. 
 P2X1 
(n = 28) 
P2X2 
(n = 27) 
P2X3 
(n = 28) 
P2X4 
(n = 28) 
P2X7 
(n = 15) 
Z’-factor ± SEM 0.61 ± 0.05 0.57 ± 0.05 0.62 ± 0.12 0.64 ± 0.04 0.68 ± 0.10 
 
All standard antagonists used as negative control for all P2X receptor subtypes are summarized 
in chapter 2.1.6.5. During the first experiments, the comparability of Z’-factors obtained using 
standard inhibitor and the derived Z’-factors using buffer as negative control were tested. Since 
no significant difference could be detected, buffer-derived Z’-factors were also included, when 
the use of standard antagonists was not possible due to space conflict on the measuring plate. 
All determined means of Z’-factors were higher than 0.50, therefore the assays for all receptor 
subtypes can be concluded to be useful for high-throughput screening. 
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4.3 Inhibitory potency of polyoxotungstates, vanadates and rhenium 
clusters at P2X receptors 
The inhibitory potency of 17 polyoxotungstates, two vanadates and four rhenium cluster 
compounds was determined at the human P2X receptor subtypes P2X1, P2X2, P2X4, P2X7 and 
the rat P2X3. All compounds were tested by measurement of calcium influx in stably transfected 
1321N1 astrocytoma cells. In order to exclude any interference by potential toxicity of the 
compounds cell viability experiments were performed. 
Prior to these experiments, the EC80 value of the physiological agonist ATP was determined for 
each receptor subtype. The corresponding concentration-response curves and EC50 
concentrations are shown in Figure 4.2. 
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Figure 4.2: Mean dose-response curves and EC50 values of ATP at P2X receptors, presented as 
mean ± SEM, n = 3-7. 
 
Based on these results, the ATP concentrations selected for testing for inhibitory potency of 
POMs were the EC80 concentrations (0.1 µM for P2X1 and P2X3, 1 µM for P2X2 and P2X4 and 
1 mM for P2X7 receptor) in all experiments described in the following chapters. 
 
4.3.1 Polyoxotungstates 
Polyoxotungstates of different shape, order and charge were available for testing. Four of those 
are based on the same polyoxotungstate core. Those are (Bu4N)6-POM, to which a PEG-chain of 
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different length, 1000 Dalton in (Bu4N)6-PEG 1000, 2000 Dalton in (Bu4N)6-PEG 2000 and 5000 
Dalton in (Bu4N)6-PEG 5000, was attached. The results of these PEGylated polyoxotungstates are 
presented in chapter 4.3.2. The results of the remaining polyoxotungstates are presented in 
Table 4.3. Four compounds, PV4, PV5, PV6 and P8W48 were active at all tested P2X receptor 
subtypes with different potencies. The corresponding concentration-response curves are shown 
in Figure 4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Mean dose response curves of polyoxotungstates (A) PV4, (B) PV5, (C) PV6 and (D) 
P8W48 at P2X receptors. Data is presented as mean ± SEM, n = 3-8. 
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Table 4.3: Inhibitory potency of polyoxotungstates and remaining receptor activity at human P2X 
receptors (mean ± SEM, n = 3-8). 
Name Formula IC50 ± SEM [µM] or inhibition (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
PV1 Na6[H2W12O40] 0.231 ± 
0.053 
0.246 ± 
0.074 
0.579 ± 0.218 0.542 
± 
0.258 
> 10 (2 %) 
PV2 H3[PW12O40] 0.260 ± 
0.072 
1.83 ± 
0.33 
0.862 ± 0.102 22.1 ± 
4.8 
> 10 
(14 %) 
PV3 K7[Ti2W10PO40] 0.0243 ± 
0.008 
0.0766 ± 
0.0245 
0.167 ± 0.025 > 10 
(-13 %) 
> 10  
(-10 %) 
PV4 K6[H2TiW11CoO40] 0.0126 ± 
0.0031 
0.0196 ± 
0.0033 
0.0724 ± 0.0111 0.108 
± 
0.028 
2.77 ± 
0.69 
PV5 K10[Co4(H2O)2(PW9O34)2] 0.0317 ± 
0.0119 
0.0382 ± 
0.0123 
0.0410 ± 0.0103 
(remaining receptor 
activity 13 %) 
1.61 ± 
0.42 
13.9 ± 1.9 
(remaining 
receptor 
activity 
27 %) 
PV6 (NH4)18[NaSb9W21O86] 0.0792 ± 
0.0031 
(remaining 
receptor 
activity 
18 %) 
0.0803 ± 
0.0316 
(remaining 
receptor 
activity 
23 %) 
0.757 ± 0.139 0.309 
± 
0.062 
0.572 ± 
0.143 
(remaining 
receptor 
activity 
65 %) 
       
P5W30 Na15[P5W30O110] 0.0173 ± 
0.0066 
(remaining 
receptor 
activity 
22 %) 
0.0716 ± 
0.0560 
0.806 ± 0.223 0.519 
± 
0.090 
> 10  
(4 % 
(100 nM)) 
P6W18 Na20[P6W18O79] 0.420 ± 
0.125 
0.186 ± 
0.076 
0.0941 ± 0.0138 
(remaining receptor 
activity 39 %) 
0.349 
± 0.04 
> 10 
(24 %) 
P8W48 Na33[H7P8W48O184] 0.0165 ± 
0.0062 
0.0144 ± 
0.0065 
0.0335 ± 0.0086 
(remaining receptor 
activity 33 %) 
0.723 
± 
0.571 
7.78 ± 
1.91 
PW12 Na3[PW12O40] 0.192 ± 
0.089 
1.16 ± 
0.361 
3.37 ± 2.03 15.6 ± 
7.1 
> 10 
(19 %) 
CP8W12 Na16[(O3PCH2PO3)4W12O36] > 10  
(49 %) 
4.51 ± 
1.38 
2.26 ± 0.64 
(remaining receptor 
activity 22 %) 
0.765 
± 
0.357 
> 10 (-5 %) 
OP8W12 Na16[(O3POPO3)4W12O36] 1.06 ± 
0.20 
0.727 ± 
0.270 
2.50 ± 0.41 96.1 ± 
3.0 
> 10 (-8 %) 
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The most active compound of this series was cobalt-and titanium-containing monosubstituted 
Keggin structure PV4. It completely inhibited all P2X receptor subtypes tested with IC50 values 
ranging from 0.0126 to 2.77 µM (see Table 4.3). It was the most active compound at P2X1 and 
P2X4 receptors, and showed almost the same inhibitory potency at P2X2 and P2X3 receptors as 
P8W48 (see Figure 4.3). PV1-3, P5W30, P6W18, PW12, CP8W12 and OP8W12 inhibited P2X1 to P2X4 
receptors, but showed no activity at the P2X7 receptor. PV2, provided by Prof. Dr. Ulrich Kortz, 
and PW12, provided by Dr. Holger Stephan, showed the same activity at all respective subtypes, 
due to being the same compound crystallized as different salts (see Table 4.1). All compounds of 
this POM series were shown to be potent antagonists of the P2X1, P2X2 and P2X3 receptor with 
IC50 values in the low nanomolar to low micromolar range. Only CP8W12 was not active at the 
P2X1 receptor, despite the fact that structurally it is almost identical to active compound 
OP8W12. Except for PV1, PV4, P5W30, P6W18 and CP8W12 at the P2X4 receptor, a significantly lower 
potency of the compounds towards P2X4 and P2X7 receptors than for the remaining P2X 
subtypes was observed, while their activity at the other subtypes tested was comparable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: pIC50 values of polyoxotungstates (A) PV1-6 and (B) P5W30, P6W18, P8W48, PW12, 
CP8W12 and OP8W12 at human P2X receptors. Data is presented as mean ± SEM (n = 3-8). 
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PV2 and PW12 have the same structure and charge, but were crystallized with different cations. 
Both compounds show at least tenfold less activity compared to the other polyoxotungstates at 
P2X1, P2X2 and P2X3, except for PV1. Since PV2 and PW12 bear the lowest negative charge in 
solution, closely followed by PV1, it is possible that the  negative charge could be a defining 
factor for potency of receptor inhibition at these three subtypes. The selectivity data presented 
in Figure 4.4 combined with the structural information in Table 4.1 suggest that a certain 
amount of negative charge has to be present in the respective polyoxotungstate compound in 
order to inhibit those receptor subtypes with nanomolar potency. However, the relationship 
does not appear to be linear. An increase in charge does not further enhance the inhibitory 
potency of the polyoxotungstate (see Table 4.3). No such relationship between charge and 
affinity could be observed for P2X4 and P2X7 receptors. The determined potencies of all 
polyoxotungstates were significantly lower at P2X4 and P2X7 receptors than at the other 
subtypes P2X1, P2X2 and P2X3. The only exception was CP8W12 at the P2X4 receptor. The 
dodecatungstate cluster compound was identified to be the most active one at the P2X4 
receptor with an almost three-fold selectivity versus the P2X3 receptor, where it showed its 
second highest affinity. The similar compound OP8W12 was considerably less potent, despite the 
high structural similarity and same charge. 
The activity profile of polyoxotungstates at the P2X7 receptor was different from the other 
subtypes. As already mentioned, most compounds showed no inhibitory activity at this subtype, 
and the potency of the active structures PV4, PV5 and P8W48 was moderate in comparison to the 
other P2X receptors. Although PV6 showed the lowest IC50 value and therefore seemed the most 
potent polyoxotungstate antagonist of P2X7 receptors, the inhibition was not complete and the 
receptor activity was only diminished by 35 % at the highest concentration tested. 
Next to the charge of the complex, the influence of the three-dimensional structure was 
considered for characterization of activity. PV2, PV3, PV4 and PW12 are all Keggin-derived 
structures, P6W18 displays the double-Keggin shape. All compounds were potent antagonists of 
P2X1, P2X2 and P2X3 receptors. A slight increase in potency can be observed for all compounds 
when charge and molecular weight increased from PV2 to PV4. The double-Keggin structure did 
not further enhance the respective potency. Since the other, more complicated and heavier 
structures like Weakley (PV5), Pope-Jeannin-Preyssler (P5W30), or Contant-Tézé (P8W48) were 
also effective antagonists of these P2X receptor subtypes, molecular weight and shape, like 
charge, cannot be the solely defining parameters for characterization of inhibitory potency of 
polyoxotungstates.  
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4.3.2 PEGylated polyoxotungstates 
Five polyoxotungstates displaying the Wells-Dawson structure with or without an attached linker 
connected to a polyethylene glycol chain of varying length were kindly provided by Prof. Dr. Wei 
Wang from the Nankai University in Tianjin, China. PEGylation of compounds is used as an 
attempt to prolong its biological half-life and to direct drug delivery.267, 268 The Wells-Dawson 
basic structure K-POM, its derivative attached to a linker (Bu4N)6-POM and the same structure 
with different PEG chains were available for testing. The results at human P2X receptors P2X1, 
P2X2, P2X4 and P2X3 receptor are presented in Figure 4.5 and Figure 4.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Mean dose-response curves of PEGylated and non-PEGylated Wells-Dawson 
polyoxotungstates at P2X receptors. Data is presented as mean ± SEM (n = 3-5). 
  
10-11 10-9 10-7 10-5 10-3
-50
-25
0
25
50
75
100
125
[compound], M
Fl
u
o
re
sc
e
n
ce
 in
cr
e
as
e
 (
%
)
10-11 10-9 10-7 10-5 10-3
-25
0
25
50
75
100
125
[compound], M
Fl
u
o
re
sc
en
ce
 in
cr
ea
se
 (
%
)
10-9 10-7 10-5 10-3
-25
0
25
50
75
100
125 K-POM
(Bu4N)6-POM
(Bu4N)6-PEG 1000
(Bu4N)6-PEG 2000
(Bu4N)6-PEG 5000
[compound], M
Fl
u
o
re
sc
e
n
ce
 in
cr
e
a
se
 (
%
)
10-11 10-9 10-7 10-5 10-3
-25
0
25
50
75
100
125
[compound], M
Fl
u
o
re
sc
e
n
ce
 in
cr
e
as
e
 (
%
)
(B)                     P2X2 
(C)                   P2X3 (D)                       P2X4 
(A)                  P2X1 
4 Results and Discussion 
-105- 
 
Table 4.4: Inhibitory potency of PEGylated and non-PEGylated Wells-Dawson polyoxotungstates 
at P2X receptors. (mean ± SEM, n = 3-6) 
Name Formula IC50 ± SEM [µM] or inhibition (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
K-POM K8[HP2W15V3O62] 
0.0216 ± 
0.0097 
0.00660 ± 
0.00117 
0.0106 ± 
0.0042 
9.65 ± 
0.59 
see 
chapter 4.3.3 
(Bu4N)6-
POM 
(Bu4N)6[H3P2W15V3O62] 
0.0104 ± 
0.0074 
0.0170 ± 
0.0095 
0.0128 ± 
0.0043 
35.6 ± 
11.8 
(Bu4N)6-
PEG 1000 
(Bu4N)6[H3P2W15V3O62]-
PEG 1000 
0.0731 ± 
0.0413 
0.0148 ± 
0.0034 
0.0288 ± 
0.0063 
23.4 ± 
5.8 
(Bu4N)6-
PEG 2000 
(Bu4N)6[H3P2W15V3O62]-
PEG 2000 
0.0892 ± 
0.0374 
0.0257 ± 
0.0052 
0.0846 ± 
0.0195 
> 100 
(-36 %) 
(Bu4N)6-
PEG 5000 
(Bu4N)6[H3P2W15V3O62]-
PEG 5000 
0.168 ± 
0.072 
0.0213 ± 
0.00562 
0.0840 ± 
0.0231 
> 100 
(-47 %) 
 
K-POM was proven to be the most active POM of all at the P2X2 receptor with an IC50 value of 
6.60 ± 1.17 nM. The inhibitory potency at P2X1 and P2X3 receptors was comparable to the other 
very potent polyoxotungstates with IC50 values in the low nanomolar range as well. All 
derivatives were again significantly less active at the P2X4 receptor than at the before 
mentioned receptor which is further demonstrated in Figure 4.6. 
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Figure 4.6: The pIC50 values of polyoxotungstates at P2X receptors subtypes P2X1-4. Data is 
presented as mean ± SEM (n = 3-5). 
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All five compounds showed comparable potency at P2X1, P2X2 and P2X3 receptors, as was 
already seen with the previous series of polyoxotungstates. A very small decrease in IC50 values 
could be observed upon PEGylation and with increase in the PEG chain length. Thus, PEGylation 
of the compound did not seem to have much effect on the potency of the Wells-Dawson 
compound. It can be concluded that PEGylation is well tolerated and may therefore be a means 
to increase the half-life of POMs used as P2X receptor antagonists for in vivo studies. 
At the P2X4 receptor however, PEGylation resulted in a decrease of inhibitory potency, which 
was already low for the parent POM. 
 
4.3.3 PEGylated POMs at P2X7 
The results at the P2X7 subtype were proven to be more complex than at the other P2X 
receptors, as can be seen in Figure 4.7 and Table 4.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Mean dose response data of PEGylated Wells-Dawson POMs and the non-PEGylated 
versions at the human P2X7 receptor. The concentrations of respective antagonist [M] on the X-
axis are plotted against the fluorescence increase (%) on the Y-axis. (MW ± SEM, n = 3-5). 
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At first, it was considered that the enhancement of ATP-induced fluorescence increase might 
have been due to a pipetting error during the experiment, but the phenomenon occurred at the 
same concentrations in all experiments conducted for all five compounds. The inhibitory 
potency is expressed in IC50, while the enhancing concentration is described in the concentration 
at which the maximal enhancement of ATP-induced fluorescence increase is observed. The PEG 
chain seemed to slightly decrease the inhibitory potency, although the effect was not 
proportional to the chain length. The same can be observed for the concentration of 
fluorescence signal enhancement. Due to a lack in sufficient amount of compound, it was not 
possible to conduct further experiments. The data available for the non-PEGylated derivatives 
K-POM and (Bu4N)6-POM indicated that the concentration window in which enhancement of 
ATP-induced signal occurred was small and peaked in a sharply defined maximum, while the 
addition of a PEG chain seemed to broaden the concentration range for enhancement and 
decrease the maximum of enhancement. The length of the chain did not appear to have any 
influence; the inhibitory IC50 value shifted with elongation from 1000 to 2000 Dalton, but then 
reduced again when extending to 5000 Dalton. The same was observed for the EC50Enhancement and 
the maximal ATP effect.  
 
Table 4.5: Inhibitory and enhancing potency of PEGylated POMs and the non-PEGylated 
derivatives at human P2X7 receptor, calculated by bell-shaped non-linear regression analysis of 
concentration-response experiments. Data is presented as mean ± SEM from 3-5 independent 
experiments. 
 K-POM (Bu4N)6-POM (Bu4N)6-PEG 
1000 
(Bu4N)6-PEG 
2000 
(Bu4N)6-PEG 
5000 
EC50Enhancement 
[µM] 
0.0241 ± 
0.0087 
0.0362 ± 
0.0090 
0.0251 ± 
0.0143 
0.167 ± 
0.148 
0.113 ± 
0.045 
IC50 [µM] 0.230 ± 
0.059 
0.714 ± 0.463 8.84 ± 1.05 21.5 ± 5.9 6.58 ± 1.80 
Enhancement of 
fluorescence 
signal (%) 
271 ± 27 261 ± 48 164 ± 34 191 ± 68 181 ± 38 
Concentration of 
peak 
enhancement 
[µM] 
0.0333 ± 
0.0112 
0.0738 ± 
0.0367 
1.32 ± 0.62 3.61 ± 1.39 1.25 ± 0.45 
 
No fluorescence enhancement could be detected at any concentration for any of the remaining 
POMs at any target. Since those five compounds are the only ones displaying the Wells-Dawson 
structure, but contain the same elements as the remaining polyoxotungstates, it is possible that 
4 Results and Discussion 
-108- 
 
enhancement at the P2X7 receptor is associated with the three-dimensional shape of the 
compound.  
 
4.3.4 Rhenium cluster compounds 
Four rhenium cluster polyoxometalates were available for testing next to the polyoxotungstates. 
In contrast to the tungstate-based compounds, the rhenium cations are not connected by 
oxygen, but by other chalcogenide elements such as tellurium, selenium (KB2) or sulfur (KB1, 
KB3 and KB4). The results of calcium influx experiments are presented in Figure 4.8 and 
Table 4.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Mean dose response curves of rhenium clusters at P2X receptors. Data is presented 
as mean ± SEM, n = 3-5. 
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In general, the inhibitory potency of rhenium cluster compounds at different P2X receptors is 
less than that of polyoxotungstates. None of the compounds available was capable of inhibiting 
the P2X7 receptor, but all of them were active at the P2X2 subtype. The most active compound 
was KB3 with an IC50 value of 843 ± 138 nM (see also Figure 4.8), closely followed by KB1 with 
1.11 ± 0.58 µM. Neither KB1 nor KB2 were active at P2X1 or P2X4 receptors. KB2 inhibited the 
P2X4 receptor only when used in high micromolar concentrations. KB3 and KB4 inhibited both 
subtypes at low micromolar concentrations, but not even upon increase of test compound 
concentration, the ATP-induced P2X4 receptor activity was reduced completely to 0 %.  
 
Table 4.6: Inhibitory potency of rhenium cluster compounds at P2X receptors (mean ± SEM, 
n = 3-5). 
Compound Formula IC50 ± SEM [µM] or inhibition ± SEM (%) at 10 µM 
  P2X1 P2X2 P2X3 P2X4 P2X7 
       
KB1 K4[Re6S8(OH)6] > 10 
(32 %) 
1.11 ± 
0.58 
4.28 ± 1.49 > 10 
(-7 %) 
> 10 
(14 %) 
KB2 K4[(Re6Se8)(OH)6] > 10 
(14 %) 
4.09 ± 
1.97 
> 10 
(35 %) 
48.8 ± 16.4 > 10 
(13 %) 
KB3 K4[Re6 S8(CH3COO)6] 0.933 ± 
0.177 
0.843 ± 
0.138 
39.5 ± 30.3 6.21 ± 2.73 
(remaining 
receptor 
activity 
12 %) 
>10 
(8 %) 
KB4 K4[(Re6S8)(HCOO)6] 4.33 ± 3.78 4.52 ± 
1.27 
17.8 ± 3.51 1.80 ±0.50 
(remaining 
receptor 
activity 
21 %) 
> 10 
(24 %) 
 
All of the compounds showed weak potency in comparison to polyoxotungstates at the P2X3 
receptor. Despite the high structural similarity to KB1, the most active compound, KB2 was not 
capable of inhibiting the P2X3 receptor. The addition of acetate (KB3) or formate residues (KB4) 
to the KB1 basic structure reduced its inhibitory potency.  
Although the potency of rhenium cluster compounds is lower, they appear to be more P2X 
subtype selective. For a better overview, the results are highlighted in Figure 4.9. KB2 was active 
at the P2X2 receptor with a tenfold higher potency in comparison to the P2X4 receptor and no 
activity at the other receptor subtypes. KB1 was inactive at P2X1, P2X4 and P2X7 receptors, but 
inhibited P2X2 and P2X3 receptors with similar potency. KB3 and KB4 were sparsely to 
moderately active at all subtypes except P2X7. Although the compounds appear to show a 
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preference for certain receptor subtypes, they are not likely to play an important role as P2X 
antagonists due to low potency. 
KB 1 KB 2 KB 3 KB 4
4.0
4.5
5.0
5.5
6.0
6.5
P2X1
P2X2
P2X3
P2X4
P2X7p
IC
5
0
 
Figure 4.9: pIC50 values of rhenium clusters at P2X receptors. Data is presented as mean ± SEM 
(n = 3-4). 
 
4.3.5 Vanadium-based polyoxometalates 
Two vanadium salts were purchased and tested at human P2X subtypes P2X1, P2X2, P2X4, P2X7 
and P2X3 to determine the activity of vanadium-based metal clusters. The results are presented 
in Table 4.7. 
 
Table 4.7: Inhibitory potency of vanadium-based complexes at P2X receptors (mean ± SEM, 
n = 3). 
Name IC50 ± SEM [µM] or inhibition at 10 µM or 1 µM (%) 
 P2X1 P2X2 P2X3 P2X4 P2X7 
NaVO3 > 10 (-30 %) 3.15 ± 0.56 > 10 (43 %) > 10 (23 %) < 10 (12 %) 
Na3VO4 > 10 (-3 %) > 10 (1 %) > 1 (30 %) > 10 (25 %) > 10 (17 %) 
 
Compared to the remaining polyoxometalates, both vanadium salts had little to no inhibitory 
potency at most of the P2X receptor subtypes. The most potent compound was metavanadate 
sodium salt NaVO3 at the human P2X2 receptor with an IC50 value of 3.15 ± 0.56 µM. Since both 
compounds are significantly smaller than the other POMs, it is possible that a certain three-
dimensional size is needed for successful inhibition of P2X receptors. 
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4.3.6 Determination of inhibition mechanism of selected polyoxometalates 
Single concentrations of selected compounds were tested by determining their effect on the 
EC50 value of ATP in order to understand how POMs inhibit P2X receptors. The human P2X1 
receptor was initially selected for this experiment. It was incubated with four of the most active 
compounds at concentrations that were based on the determined IC50 values. The selected 
compounds showed different three-dimensional structures: Keggin structures PV3 and PV4, 
cryptate PV6 and Contant-Tézé P8W48. The selected compounds were also tested at the P2X3 
receptor to determine whether the species has an influence on the inhibition mechanism. The 
results determined at both receptors are presented in Figure 4.10 to Figure 4.13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: (1) pEC50 concentrations, (2) maximal ATP effect with or without addition of a 
defined concentration of polyoxotungstates (A) PV3 and (B) PV4, and (3) the respective Schild 
plots at the human P2X1 receptor. Buffer containing 1 % DMSO without compound was used as 
control. Data is presented as mean ± SEM from 3-10 independent experiments. The Schild plots 
are presented as mean ± 95 % confidence interval. 
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Figure 4.11: (1) pEC50 concentrations, (2) maximal ATP effect with or without addition of a 
defined concentration of polyoxotungstates (A) PV6 and (B) P8W48, and (3) the respective Schild 
plots at the human P2X1 receptor. Buffer containing 1 % DMSO without compound was used as 
control. Data is presented as mean ± SEM from 3-10 independent experiments. The Schild plots 
are presented as mean ± 95 % confidence interval. 
 
PV6 at the human P2X1 receptor was the first compound to be tested. Only three different 
concentrations were selected for the experiment. Five to six concentrations of the remaining 
compounds were tested in all following experiments, since three concentrations were 
insufficient for a valid analysis. Every compound caused the ATP curve to shift to the right. 
Higher ATP concentrations have to be used to reach the full level of receptor activity. This 
indicates a competitive inhibition mechanism for PV6, where the antagonist competes with the 
agonist for the binding cavity. An increase in agonist concentration prevents the antagonist from 
binding to the receptor. If an antagonist does not inhibit by binding to the agonist binding site, 
but to another binding site, it is called an allosteric antagonist. The inhibition mechanism of an 
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allosteric antagonist is an altercation of receptor conformation induced by the allosteric 
modulator which reduces the efficacy of the agonist. In that case, the EC50 value of the agonist is 
not affected by the antagonist independent of its concentration. Upon an increase in agonist 
concentration, it is no longer capable of activating the receptor to full level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: (1) pEC50 concentrations, (2) maximal ATP effect with or without addition of a 
defined concentration of polyoxotungstates (A) PV3 and (B) PV4, and (3) the respective Schild 
plots at the P2X3 receptor (mean ± SEM, n = 3-6). Buffer containing 1 % DMSO without 
compound was used as control. Data is presented as mean ± SEM from 3 to 6 independent 
experiments. The Schild plots are presented as mean ± 95 % confidence interval. 
 
A shift of the agonist curve to the right side can be observed for all four compounds at both 
receptors. This indicates that these compounds are orthosteric antagonists. However, the 
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shifted curves for PV4 and to some extent for P8W48 also show a decrease in maximal 
fluorescence, which cannot be restored upon increase in ATP concentration. For PV3 and PV6, 
the shift of the ATP dose-response curves indicates a competitive mechanism of inhibition at 
both receptor subtypes. The results were further examined using the Gaddum/Schild analysis. 
The results are summarized in Table 4.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: (1) pEC50 concentrations, (2) maximal ATP effect with or without addition of a 
defined concentration of polyoxotungstates (A) PV6 and (B) P8W48, and (3) the respective Schild 
plots at the rat P2X3 receptor. Buffer containing 1 % DMSO without compound was used as 
control. Data is presented as mean ± SEM from 3 to 6 independent experiments. The Schild plots 
are presented as mean ± 95 % confidence interval. 
 
PA2 represents the negative logarithm of antagonist needed to shift the dose response curve to 
the right by a factor of 2. The higher the pA2 value the lower the respective concentration 
needed to shift the curve and the more effective the antagonist is. The highest pA2 value of the 
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series was featured by P8W48 at the P2X1 receptor. Generally, the pA2 values were higher at 
P2X1 than at P2X3 receptors. These results correspond with the previously determined IC50 
concentrations of the compounds, which were all more potent at P2X1 than at P2X3 receptors 
(see Table 4.3). 
 
Table 4.8: pA2, Schild slope and Hill slope of Gaddum/Schild EC50 shift analysis for determination 
of competitive mechanism of inhibition of selected POMs at P2X1 and P2X3 receptors. 
 pA2 Hill slope Schild slope 
P2X1    
PV3 8.65 0.775 1.27 
PV4 8.37 0.472 3.12 
PV6 7.73 1.00 2.18 
P8W48 10.3 0.533 1.06 
    
P2X3    
PV3 7.42 2.85 0.929 
PV4 7.77 1.62 2.51 
PV6 6.58 2.01 0.972 
P8W48 7.81 2.07 0.920 
 
The Schild slope represents the slope of the linear regression of the log (DR-1) versus the 
logarithm of tested antagonist concentration. The mechanism of inhibition is deemed 
competitive when the Schild slope matches unity. The slopes of linear regression of PV3 and PV6 
at P2X3 receptors and P8W48 at both receptor subtypes lied closely to unity and can be 
considered as orthosteric antagonists at the respective receptors. The data of PV3 and PV6 at 
the P2X1 receptor is inconclusive, since the Schild slopes did not exactly match unity. For PV6, it 
can probably be attributed to the fact that only three antagonist concentrations were tested. 
Since the decrease of ATP EC50 concentrations is clearly visible (see Figure 4.13), a competitive 
mechanism of inhibition is assumed. The slope of linear regression of PV4 at both receptor 
subtypes definitely differed from unity. A competitive mode of inhibition cannot not be 
confirmed for PV4, even though its three-dimensional structure is the same as PV3. Additionally, 
a concentration-dependent decrease of maximal ATP effect was observed, which is a sign for 
allosteric interaction of PV4 with both P2X receptors. It is possible that PV4 can interact with P2X 
receptors by two different binding sites.  
In conclusion, it can be said that POMs inhibit P2X receptors predominantly by competitive 
interaction. Since other influences on the receptors were observed for PV4, the determined 
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mode of inhibition cannot be transferred to the whole group of POMs and seemed to be 
influenced even by small structural changes. 
 
4.3.7 Cytotoxicity of polyoxometalates 
Since all compounds mainly consist of heavy metal ions, cytotoxicity was a possible factor not to 
be underestimated. Cytotoxicity can be mistaken for inhibition in a functional experiment like 
measurement of calcium influx. Cell viability assays using MTT were conducted. 1321N1 
astrocytoma cells were incubated with various concentrations of polyoxometalates starting from 
300 µM or 100 µM, respectively, and incubated for 72 hours. One hour before reading point, 
MTT was added. Only still live cells were capable of converting yellow MTT to purple formazan. 
Cells were lysed with DMSO to dissolve produced formazan, and UV absorbance was measured. 
The results are presented in Table 4.9. 
Most of the polyoxotungstates and all of the rhenium cluster where slightly cytotoxic when used 
in high concentrations above 50 µM, respectively. Since all of them had inhibitory activity at low 
nanomolar to low micromolar concentrations, it is unlikely that the results are biased by 
cytotoxicity. The same can be said for PV1, PV4, and PV6, for whom dose-response relations for 
cytotoxicity could be detected. The EC50 values of P8W48, K-POM, (Bu4N)6-POM and the 
PEGylated versions (Bu4N)6-PEG 1000 and (Bu4N)6-PEG 2000 were shown to be cytotoxic in 
concentrations close to the detected IC50 values at human P2X4 or P2X7 receptor, respectively 
(see Table 4.3 and Table 4.4). Based on the results for both PEGylated POMs, it is possible that 
(Bu4N)6-PEG 5000 is also cytotoxic. Due to lack of compound, it was not possible to test it in a 
cell viability assay.  
The most cytotoxic compound was P5W30, which was already toxic when used in concentrations 
in the nanomolar range (cytotoxicity EC50 0.283 ± 0.055 µM). The respective concentration-
response curve can be seen in Figure 4.14 along with the positive control 5-FU and P8W48.The 
detected cytotoxic concentrations are higher than the IC50 values determined for human P2X1, 
P2X2 and rat P2X3 receptors. Therefore, the detected receptor inhibition is unlikely to be 
affected by compound toxicity. It is unlikely that the observed reduced calcium influx at the 
human P2X4 receptor can be attributed to actual receptor inhibition, because the IC50 values 
determined to characterized the inhibitory potency and the cytotoxicity values are almost the 
same.  
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Table 4.9: Cytotoxicity EC50 values of polyoxotungstates, rhenium cluster compounds and 
positive control 5-FU at non-transfected 1321N1 astrocytoma cells (mean ± SEM, n = 4). 
Name Formula Cytotoxicity 
EC50 ± SEM 
[µM] 
 non-transfected1321N1 
astrocytoma cells 
5-FU 
 
1.29 ± 0.62 
PV1 Na6[H2W12O40] 170 ± 35 
PV2 H3[PW12O40] > 300 
PV3 K7[Ti2W10PO40] > 50 
PV4 K6[H2TiW11CoO40] 125 ± 9 
PV5 K10[Co4(H2O)2(PW9O34)2] > 50 
PV6 (NH4)18[NaSb9W21O86] 9.50 ± 0.64 
P5W30 Na15[P5W30O110] 0.283 ± 0.055 
P6W18 Na20[P6W18O79] > 100 
P8W48 Na33[H7P8W48O184] 3.48 ± 0.56 
PW12 Na3[PW12O40] > 100 
OP8W12 Na16[(O3PCH2PO3)4W12O36] > 200 
CP8W12 Na16[(O3POPO3)4W12O36] > 100 
K-POM K8[HP2W15V3O62] 10.4 ± 1.4 
(Bu4N)6-POM (Bu4N)6[H3P2W15V3O62] 6.46 ± 0.39 
(Bu4N)6-PEG 1000 (Bu4N)6[H3P2W15V3O62]-PEG 1000 5.79 ± 1.10 
(Bu4N)6-PEG 2000 (Bu4N)6[H3P2W15V3O62]-PEG 2000 6.42 ± 0.68 
(Bu4N)6-PEG 5000 (Bu4N)6[H3P2W15V3O62]-PEG 5000 n. d.
a 
KB1 K4[Re6S8(OH)6] > 100 
KB2 K4[(Re6Se8)(OH)6] > 60 
KB3 K4[Re6 S8(CH3COO)6] > 70 
KB4 K4[(Re6S8)(HCOO)6] > 70 
a: n. d. not determined, due to lack of compound 
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Figure 4.14: Mean dose-response cytotoxicity curves of polyoxotungstates P5W30, P8W48 and 
known cytotoxic agent 5-FU at non-transfected 1321N1 astrocytoma cells determined via MTT 
cell viability experiment (mean ± SEM, n = 3-4). 
 
4.4 Discussion 
POMs were identified previously as potent modulators of various targets. The antitumoral effect 
was of particular interest. Keggin and Dawson-derived polyoxotungstates and 
germanotungstates were identified as potent inhibitors of HDAC, a protein closely connected to 
cell cycle progression. The loss of functionality of these enzymes is associated with several 
cancers.243 Furthermore, polyoxotungstates were found to generally inhibit the growth of rats 
infected with cancer cell lines including cervical HeLa, liver SSMC-7721, leukemia HL-60 and 
colon HLC cancer cells.244, 245 The detailed mechanisms of cytotoxicity by POMs in these cancer 
cells were not described. Antitumoral activity in osteosarcoma cell lines was determined for 
copper-containing K7Na3[Cu4(H2O)2(PW9O34)2]20H2O. The cytotoxic effect was higher in tumorous 
than in normal cells, and was associated with an increase of reactive oxygen species, a decrease 
of the glutathione/glutathione disulfide (GSH/GSSG) ration and cell cycle arrest in the G2/M 
phase, which progressively lead to apoptosis.269 Furthermore, three Keggin-shaped POMs 
containing cobalt and titanium were identified as cytotoxic agents in breast and kidney cancer 
cell lines. The binding to ctDNA and the penetration of the compound into the cell were named 
as contributing factors of antitumoral activity of POMs.270 In all these cases, the cytotoxicity was 
determined by MTT cell viability assay. The respective values ranged from low to high 
micromolar concentrations and are comparable to the cytotoxic concentrations determined for 
POMs in this experimental setting. Only the most toxic POM P5W30 showed higher toxicity. The 
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inhibitory activity at P2X1, P2X2 and P2X3 receptors of almost all compounds was proven to be 
10-100fold higher than their cytotoxic activity.  
POMs were previously identified to be potent inhibitors especially of ATP/ADP-degrading 
enzymes: rat ecto-5’-nucleotidases, human and rat NTPDase subtypes 1, 2, 3 and human 
NTPDase8, human NPP subtypes 1, 2 and 3 and human TNAP.221, 271 These enzymes were found 
to play an important role in cancer growth and progression.272 In 2011, Ramona Malek 
determined the inhibitory potency of polyoxotungstates and rhenium cluster compounds at 
purinergic P2Y receptor subtypes P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 receptor.
266 
PW12 and PV2 showed little to no activity at the P2Y receptors tested; only at the human P2Y2 
receptor, an IC50 value could be determined for PW12. At human NTPDases and NPPs, both 
compounds showed comparable activity to P2X receptors. Most polyoxotungstate compounds 
were as potent at human P2X receptor subtypes P2X1, P2X2 and rat P2X3 as determined at 
NPP1, with the exception of CP8W12 and OP8W12. Both were more than 20 or 30-fold selective for 
NPP1 (Ki 0.02 or 0.041 µM, respectively), and PV4 and PV5 displayed a tenfold preference for 
NPP1 (Ki 0.00146 and 0.00498 µM). The potency of polyoxotungstates at all NTPDases was either 
comparable or lower than at P2X receptors. The only exception was PV5, which was around ten 
times more potent at NTPDase1 (Ki 0.00388 ± 0.00140 µM) than at all P2X receptor subtypes. All 
compounds were only moderately active at the P2Y receptors, in most cases in the same range 
of potencies shown at P2X4 and P2X7 receptors.266, 271 P5W30 can only be assessed as an 
antagonist when used in concentrations below 0.2 µM due to its toxicity (see chapter 4.3.7). 
Since all IC50 values of POMs determined for the P2Y receptors were either equal or higher than 
that, the observed decrease of calcium influx-induced fluorescence is more likely ascribed to 
toxicity than receptor inhibition, as was already discussed for P2X4 and P2X7 receptors. At 
NTPDases and NPPs, P5W30 acted as a very potent inhibitor with Ki values between 0.0218 
(NTPDase2) and 0.0777 µM (NTPDase3), which was comparable to its activities at the P2X 
receptor subtypes P2X1 and P2X3. 
All rhenium cluster compounds did not show any inhibitory potency at the P2Y receptors tested, 
with the exception of KB1 at the rat P2Y6 receptor, for which an IC50 value of 21.0 ± 10.9 µM was 
determined.266 At the human NTPDase subtypes 1, 2 and 3, only KB4 was active. It was almost 
tenfold more potent at the latter two subtypes than at all P2X receptors (Ki 0.680 ± 0.151 µM for 
NTPDase2 and 0.582 ± 0.050 µM for NTPDase3, respectively). All four rhenium cluster 
compounds were even more potent at the human nucleotide pyrophosphatase NPP1 with Ki 
values between 0.100 and 0.537 µM.271  
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The PEGylated compounds and corresponding non-PEGylated forms K-POM and (Bu4N)6-POM 
were not tested previously, so no comparison of activity is possible. Since all compounds were 
proven to be exceedingly active at all P2X receptor subtypes except for P2X7, it would be of 
interest to test their inhibitory potency at NTPDases and NPPs as well. Further experiments are 
planned.  
In conclusion, it can be said that POMs are potent inhibitors at P2X1, P2X2 and P2X3 receptors, 
and fairly selective towards P2X4 and P2X7. The potency of most compounds is comparable or 
lower than at most of the ATP- and ADP-degrading enzymes. The most notable exception was 
NPP1, at which several POMs showed around ten-fold higher potency than at P2X receptors. It 
could be demonstrated that high inhibitory potency is not limited to nucleotide-degrading 
enzymes, but can also be found at other nucleotide-binding receptors.  
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5 Interaction of approved drugs with P2X receptors 
5.1 Introduction 
The rediscovery of already approved drugs for new pharmacological targets and medical 
indications is referred to as drug repurposing, repositioning, reprofiling or redirecting.273 It was 
proven to be a powerful and effective tool for the development of new cures for complicated 
and tricky diseases. The procedure is used especially by pharmaceutical companies to reduce the 
existing gap between the economical investments in research and development, including 
structure-based drug design, combinatorial chemistry, genomics and high-throughput screening, 
and the number of newly approved drugs.274 There are several benefits to the repurpose 
approach: 
1) known pharmacological safety profiles and pharmacokinetics in humans 
2) reduction of time between discovery and approval of the drug  
3) cost effectiveness due to no longer required early drug development 
4) easier attracted investments due to close proximity to market authorization.274, 275 
One of the most important aspects for the rediscovery of known drugs is cost effectiveness, 
which can be attributed to a shortcut of several important steps during drug development. The 
initial years required for drug development are not needed. This advances the process directly to 
preclinical testing or even clinical trials, reducing the developmental process from 10 to 17 years 
to 3 to 12 years next to risk and cost reduction (see Figure 5.1).  
 
 
Figure 5.1: Comparison of de novo drug discovery and drug repositioning (modified from 
Ashburn et al.)274  
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The successful repositioning of drugs needs careful considerations in order to enhance the 
probability of matching for various medical problems. The process can be facilitated 
considerably by application of computational methods e.g. biology, chemo- and bioinformatics 
in order to combine the information about known targets, drugs, disease biomarkers and 
pathways (see Figure 5.2). The starting point for a drug repositioning study can be a drug itself, a 
certain target or a specific disease. The method of choice depends on the starting point and the 
available information. 
 
 
Figure 5.2: Flowchart demonstrating existing drug repositioning methods.276 
 
In a target-based drug repositioning approach, the affinity and/or activity of drug library 
compounds at a known target structure like a protein (e.g. receptor or enzyme) or a biomarker is 
determined via actual screening (HTS) or virtual docking experiments. A successfully validated 
assay system or a good virtual target fit allows fast screening of large compound libraries. 
Depending on the selected method, valuable hits with minimal effort and low cost can be 
identified. A disadvantage is that high potency at the target structure may not automatically be 
relevant for disease pathogenesis. It may also not be sufficient enough to be applied as therapy. 
Since the target-based drug repositioning approach does not render much information about 
new mechanisms beyond the known target, a method using knowledge is much more useful for 
predicting e. g. unknown drug targets, drug-drug similarities, interactions or new disease 
biomarkers. Specific genetic signatures are further aspects considered in computational 
methods for drug repurposing. These signatures include any genetic altering responsible for 
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complicated metabolic or signaling pathways. The inclusion of genetic signatures enables the 
connection of different disease alterations and known protein interactions for better 
characterization of the mechanism of action of drugs.276-278  
It is reported that out of the 75 first-in-class drugs approved between 1999 and 2008, containing 
50 small molecules (67 %) and 25 biologics (33 %), 28 of the small molecule drugs were 
discovered by phenotypic drug screening and 17 by target-based methods. Both methods do not 
require pharmaceutical or biological information, and can easily be applied to a large number of 
drugs and diseases.279 Phenotypic screening is the oldest and most important method applied 
for the search of new and rediscovering drugs. It often starts with clinical observations rendering 
a certain hitherto unknown pharmacological effect. The general alteration of an entire 
phenotype to a desired state and knowledge about the mechanistic insight of a specific drug are 
very useful tools in the discovery of first-in-class drugs for unknown disease patterns and orphan 
diseases.280-283  
The use of large publically accessible drug libraries like the National Center for Advancing 
Translational Sciences (NCATS) or the Open Innovation Drug Discovery program (OIDD) at Lilly is 
a useful tool for strategical organization of drug repurposing.273, 283-286 NCATS contains the largest 
public repository of approved drugs including those in clinical trials. Both allow access to large 
small molecule libraries directly applicable to in vitro screening assays for fast and effective 
determination of potency. A library of 600 compounds from NCATS was recently used in a study 
to identify potential drugs capable of inhibiting the entry of Ebola virus-like particles in HeLa 
cells. The screening identified 53 hits.287 Another screening experiment of 2600 FDA-approved 
drugs to find anti-Ebola-active compounds rendered 80 Ebola inhibitors, with matching hits like 
selective estrogen receptor modulator toremifene, antihistamines bentropine and clemastine, 
tricyclic and tetracyclic antidepressants clomipramine and maprotiline and microtubule inhibitor 
vinorelbine.287, 288  
Drug repurposing is preferably used for discovery of new agents for orphan, particularly 
dangerous and acute diseases lacking proper and effective drugs. Efforts to discover new cancer 
therapies are also exceptionally strong. For example, next to their capability of blocking Ebola 
virus entry into cells, tricyclic antidepressants like imipramine and promethazine were identified 
to be potent growth inhibitors of small cell lung cancer and other neuroendocrine tumors via 
inhibition of caspase 3, among other targets.289 Ion channels proven to be involved in 
oncogenesis, like potassium and voltage-gated calcium channels, were recently the focus of a 
study investigating the anticancer effect of approved drugs on these targets.275  
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Another very prominent example of successful drug repurposing is sildenafil, a PDE-5 inhibitor. 
Originally designed as an antihypertensive drug, the blood pressure-lowering effect in early 
studies was proven to be only moderate. Simultaneously, the positive effect on penile erectile 
dysfunction due to the involvement of PDE-5 in the incurrence of an erection was discovered, 
and clinical studies with a new outcome were designed, leading to the approvement of sildenafil 
(Viagra®) as the first orally available drug to treat penile erectile dysfunction in 1998 by Pfizer 
Inc., New York, NY, USA. Since then, due to the strong and selective inhibition of PDE-5, sildenafil 
has been approved for the treatment of pulmonary hypertension (Revatio®) by the FDA.290 The 
drug is not recommended for children in this indication.291 
Another very prominent example for successful drug repositioning is thalidomide. It was 
originally approved as a sedative in 1957 under the tradename Contergan® by German company 
Grünenthal, with recommended use particularly for pregnant women.292 This indication was 
based on the lack of toxicity in rodents when used in high doses.293 The discovery of the direct 
association between the intake of thalidomide during early pregnancy and infantile congenital 
abnormalities led to the retraction of the drug from the market and to a complete change of 
procedure of therapeutic drug approval.294, 295 However, in the past years, thalidomide was 
rediscovered as an active and potent agent against multiple myeloma in combination with 
dexamethasone296 and against erythema nodosum leprosum. The latter was already discovered 
in 1965.297 In Germany it has been available since 2009 only by submission of the so-called T-
prescription. It is part of the T register, which supervises the prescription and emission of 
thalidomide and its derivatives lenalidomide and pomalidomide.298, 299 Both derivatives are also 
approved for the treatment of multiple myeloma. The strict control of prescription serves the 
prevention of deformities in newborn children. Strict safety measures were demanded from all 
EU member states by the European Commission. 
Since the rediscovering of approved drugs for new indications, diseases and targets can be a 
successful strategy, we tested a small library of 440 drugs for inhibitory potency at purinergic 
P2X receptors. The aim of this study was the discovery of new potent and selective ligands for 
various P2X subtypes. The library was screened at each receptor subtype expressed in 1321N1 
astrocytoma cells in a final concentration of 20 µM via measurement of calcium influx. 
Subsequently, concentration-response curves were generated for active compounds. The results 
are discussed in the following chapter. 
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5.2 Determination of Z’-factor 
As already discussed in the previous chapter, the Z’-factor was calculated for every experiment 
and each receptor subtype. The Z’-factor is described as a suitable statistical parameter to asses 
assay quality. When it was not possible to use the standard antagonist as negative control due to 
space conflict, the buffer data was taken instead. The results are presented in Table 5.1. 
 
Table 5.1: Z‘-factors of all experiments conducted for testing the inhibitory potency of approved 
drugs and structurally related derivatives at P2X receptors. Data is presented as mean ± SEM. 
 P2X1 
(n = 52) 
P2X2 
(n = 35) 
P2X3 
(n = 100) 
P2X4 
(n = 7) 
P2X7 
(n = 100) 
Z’-factor ± SEM 0.58 ± 0.06 0.77 ± 0.03 0.61 ± 0.06 0.63 ± 0.07 0.53 ± 0.02 
 
When the Z’-factor is higher than 0.5, the assay is considered as suitable for high-throughput 
screening. Since all Z’-factors determined were higher than 0.5, the experiments are suitable for 
high-throughput screening and the determined results can be considered as valid. 
 
5.3 Inhibitory potency of approved drugs at P2X receptors 
5.3.1 Screening  
A library of 440 already approved drugs was tested at the human P2X receptor subtypes P2X1, 
P2X2, P2X7 and the rat P2X3 in order to identify new lead structures for the synthesis of 
selective agonists and antagonists. Dr. Aliaa Abdelrahman and Stefanie Weyer generated the 
data at the human P2X4 receptor using the same experimental setup. The results are presented 
in Figure 5.3. 
All compounds were screened once at a final concentration of 20 µM. It was planned to further 
investigate all drugs showing an inhibition of the respective receptor higher than 50 %. Since a 
lot of compounds exceeded this limit, especially at the P2X1 and the P2X3 receptor, it was 
decided to test those hits at the receptors P2X1, P2X3 and P2X7 once again at lower final 
concentration of 1 µM. When the detected inhibition was again higher than 50 %, dose-response 
experiments were conducted. Only a small amount of drugs were identified to inhibit the P2X2 
receptor by more than 50 % at 20 µM final concentration. All hits were tested in concentration-
response experiments. The potency and importance of the detected hits are discussed in detail 
in the following chapters, categorized in different subgroups based on their structure, with 
special focus on the human P2X1, P2X7 and the rat P2X3 receptor. 
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Figure 5.3: Receptor inhibition (%) of approved 
drug library containing 440 compounds 
determined by screening experiments with 
20 µM final concentration via measurement of 
calcium influx at human (A) P2X1 ( ), (B) P2X2  
( ), (C) rat P2X3 ( ), (D) P2X4 ( ) and (E) P2X7 
receptor ( ). Compounds with inhibition 
higher than 50 % are marked blue and declared 
as hits. Compounds with inhibition lower 
than -100 % are marked red and declared 
enhancing hits. (mean, n = 1-3) 
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5.3.1.1 Steroids 
Several compounds bearing a steroidal basic structure were among the hits detected in the 
initial screenings. The results of the subsequently determined concentration-response 
experiments are presented in Table 5.2. 
Next to female sexual hormones like estrogen derivatives estradiol valerate and ethinyl 
estradiol, the 4-azasteroid finasteride, the 19-nortestosteron-derived norgestrel, the class III 
glucocorticoid mometasone furoate and natural steroids including glycosides digitonin, 
lanatoside C, saponine β-escin and pentacyclic triterpene 18β-glycyrrhetinic acid were able to 
diminish calcium influx in P2X receptor-transfected cells.  
Estradiol is the primary female sex hormone belonging to the estrogens. It plays an important 
role in reaching sexual maturity and the induction of the female cycle proliferation phase. Signal 
transduction follows a translocation of the hormone receptor into the nucleus, where the 
transcription of respective genes is regulated upon binding of the hormone-receptor-complex to 
DNA segments. The initially detected inhibitory potency could not be confirmed for all 
compounds. Estradiol valerate was identified as a potential antagonist at the P2X1 receptor. 
However, it did not show any dose-response relation at this P2X receptor subtype. Ethinyl 
estradiol, the metabolically stable 17α-ethinyl-derivative of estradiol, was found to be capable of 
inhibiting the P2X2 receptor at micromolar concentrations. High inhibitory potency was also 
detected at the P2X1 receptor at 20 µM, but since this could not be observed any longer upon 
reduction of the concentration to 1 µM, no concentration-response experiments were 
conducted. As estradiol valerate did not show any dose-response relation at this receptor, it was 
to be expected that the inhibitory potency of ethinyl estradiol at P2X1 receptors would be 
comparable to the one detected for the P2X2 receptor or weaker. 
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Table 5.2: Inhibitory potency of steroids and steroid-derived drugs at P2X receptors (mean ± SEM, n = 3-4). 
IC50 ± SEM [µM] or inhibition at 20 µM or 1 µM (%) 
P2X7 
> 20 (-76 %) 
> 20 (-10 %) 
> 20 (-36 %) 
> 20 (-78 %) 
P2X4 
> 1 (12 %) 
> 1 (2 %) 
> 20 (17 %) 
> 20 (17 %) 
P2X3 
> 20 (-1 %) 
> 20 (41 %) 
> 1 (-28 %) 
> 20 (-32 %) 
P2X2 
> 20 (1 %) 
15.0 ± 3.0 
> 100 (n. c.)a 
> 20 (-18 %) 
P2X1 
> 100 (n. c.)a 
> 1 (-36 %) 
> 1 (-12 %) 
> 100 (n. c.)a 
Structure 
 
 
 
 
 
Compound 
Estradiol valerate 
Ethinyl estradiol 
Norgestrel 
Finasteride 
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Continuation of Table 5.2 
1.27 ± 0.41 
> 1 (13 %) 
> 1 (37 %) 
 
> 1 (-11 %) 
> 1 (-21 %) 
0.643 ± 0.094 
> 1 (-48 %) 
> 1 (24 %) 
> 1 (29 %) 
7.16 ± 1.37 
remaining 
receptor activity 
30 %  
10.2 ± 0.1 
Remaining 
receptor activity 
40 % 
0.700 ± 0.176 
Remaining 
receptor activity 
26  % 
> 1 (8 %) 
> 1 (4 %) 
> 100 (n. c.)a 
 
 
 
Mometasone 
furoate 
18β-Glycyrrhetinic 
acid 
β-Escin 
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Continuation of Table 5.2 
> 1 (-34 %) 
> 20 (21 %) 
a: n. c. no convergence of sigmoidal dose-response analysis in three independent experiments 
0.540 ± 0.013 
> 20 (20 %) 
0.483 ± 0.092 
0.282 ± 0.139 
0.380 ± 0.021 
Remaining 
receptor activity 
54 % 
> 20 (24 %) 
0.133 ± 0.005 
Remaining 
receptor activity 
23 % 
0.355 ± 0.109 
Remaining 
receptor activity 
43 % 
 
 
Digitonine 
Lanatoside C 
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Finasteride is a 5α-reductase inhibitor which blocks the conversion of testosterone to 
dihydrotestosterone and is approved for the treatment of benign prostatic hypertrophy and 
androgenetic alopecia. It was active at the P2X1 receptor, but like for estradiol valerate, no IC50 
value could be determined. The same was observed for norgestrel, whose (S)-enantiomer is used 
in the morning after pill and the so-called mini pill, at the P2X2 receptor. It could be assumed 
that sexual hormones and closely related derivatives are capable of inhibiting P2X1 and P2X2 
receptors at high concentrations. However, for other derivatives (5α-androstan-17β-ol-3-one, 
medroxyprogesterone acetate, testosterone, methyltestosterone, norethindrone acetate and 
estradiol), which are closely related to the detected hits, no such observation could be made. 
Since a successful dose-response relationship could only be detected for ethinyl estradiol at the 
P2X2 receptor, it is possible that the observed reduction of calcium influx by the other hits was 
not related to P2X receptor inhibition, but other effects due to poor solubility or cell toxicity. 
Closely related glycosylated steroids digitonin, lanatoside C and β-escin were also capable of 
inhibiting P2X receptors at both concentrations tested, respectively. The detected IC50 values for 
digitonin at the P2X1, P2X4 and P2X3 receptor were comparable in the high nanomolar range. 
The same was observed for lanatoside C at P2X1 and P2X3. Both drugs are cardiac glycosides, 
lanatoside C of the group of cardenolides, a steroid associated to a five-membered unsaturated 
lactone ring, and digitonin, a triterpene saponine detergent from foxglove. Although the two 
compounds appeared to be potent antagonists of P2X receptors, there were doubts whether the 
observed reduced calcium influx was due to a receptor inhibition. High basic fluorescence values 
were detected for digitonin during the assay validation previous to ATP injection. This indicates 
either strong autofluorescence of the compound or cytotoxic effects. Since both compounds 
were described as being cytotoxic before, with IC50 values comparable to the ones determined in 
these experiments, it is more likely that the supposed inhibitory potency detected via 
measurement of calcium influx was caused by cytotoxicity.300 
18β-Glycyrrhetinic acid is a triterpenoid derivative of the β-amyrin type and one of the main 
ingredients of liquorice. It is used in traditional Chinese medicine and as a herbal remedy against 
respiratory diseases. Furthermore, 18β-glycyrrhetinic acid was identified to have anti-
mycobacterial, anti-rotaviral and anti-inflammatory effects against Mycobacterium bovis 
infections and rheumatoid arthritis, respectively.301-303 The compound was capable of inhibiting 
the P2X2 receptor subtype with an IC50 value of 10.2 ± 0.1 µM. At 20 µM, the compound also 
showed affinity to the remaining P2X receptor subtypes tested. Since no subtype was blocked 
more than 50 % in the second screening at 1 µM final concentration, no concentration-response 
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experiments were conducted. Due to the decrease of inhibitory potency, the IC50 values at the 
remaining receptors were estimated between 20 µM and 1 µM.  
Despite the primarily observed activity of several steroid-based drugs, the suitability of steroids 
as potential lead structures for new P2X receptor ligands does not appear to be promising. The 
glucocorticoid compounds are approved for their immunosuppressive and anti-inflammatory 
properties. Only mometasone furoate, a class III glucocorticoid agent, was identified as a hit at 
the P2X2 and P2X7 receptor. The subsequent dose-response experiments yielded IC50 values in 
the low micromolar range (7.16 ± 1.37 µM and 1.27 ± 0.41 µM, respectively). Since none of the 
other corticosteroids showed any inhibitory activity at any P2X receptor subtype, the steroid 
moiety did not seem to be a suitable starting point for the development of new P2X receptor 
ligands. 
 
5.3.1.2 Tricyclic antidepressants and phenothiazines 
Several tricyclic compounds including phenothiazine derivatives were identified as potential 
ligands especially at the human P2X2 and P2X4 receptor. Phenothiazines are one of the oldest 
classes of antipsychotic drugs whose basic structure was not obtained from natural products.304 
Furthermore, they also have antimicrobial and antihelmintic properties.305 Their antipsychotic 
effects can mainly be attributed to their affinity for dopamine receptors, but phenothiazines are 
also known to bind to a variety of other targets, e.g. histamine, muscarinic, adrenergic, 
serotoninergic and cholinergic receptors. This widespread binding behavior is regarded as the 
reason for their broad efficacy for different medical indications. The phenothiazine derivatives 
prochlorperazine and trifluoperazine were previously identified to be potent modulators of P2X7 
receptor.193 Both compounds were not part of the compound library used in the present 
experiments. However, the related piperazine-containing derivatives fluphenazine and 
perphenazine were found to have affinity to all P2X receptors tested when used in high 
concentrations (see Table 5.3). The results are summarized in Table 5.3. An IC50 value of 
7.84 ± 2.32 µM was determined at the P2X4 receptor for fluphenazine. Perphenazine was 
initially active at P2X1, P2X4 and P2X3 receptors at 20 µM. The subsequently measured IC50 
value at the P2X4 receptor was in the same range as the one for fluphenazine (5.88 ± 1.43 µM). 
Levomepromazine and promazine were also identified as hits with inhibitory potency at the 
P2X2 receptor. The respective IC50 values were comparable to those of phenothiazines at the 
P2X4 receptor (5.63 ± 2.19 and 4.61 ± 1.70 µM, respectively). 
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Table 5.3: Inhibitory potency of phenothiazine drugs at P2X receptors (mean ± SEM, n = 3-4). 
Compound Structure IC50 ± SEM [µM] or inhibition at 20 µM or 1 µM (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
Promazine-
HCl 
 
> 1  
(18 %) 
4.61 ± 1.70 
Remaining 
receptor 
activity 
37 % 
> 1  
(49 %) 
5.91 ± 1.74 
Remaining 
receptor 
activity  
26 % 
> 20  
(27 %) 
Levome-
promazine-
HCl 
 
> 1  
(29 %) 
5.63 ± 2.19 
remaining 
receptor 
activity 
36 % 
> 20 
(33 %) 
3.77 ± 0.32 
Remaining 
receptor 
activity 
26 % 
> 20  
(1 %) 
Fluphenazine 
 
> 1  
(-21 %) 
> 1 (19 %) > 1  
(-26 %) 
7.84 ± 2.32 > 1  
(9 %) 
Perphenazine 
 
> 1  
(-10 %) 
> 20 (10 %) > 1  
(-44 %) 
5.88 ± 1.43 > 20  
(-49 %) 
 
Some of the structurally related tricyclic antidepressants (TCA), amitriptyline and dosulepin, 
were also identified as P2X receptor antagonists (see Table 5.4). Same as phenothiazines and 
other antipsychotics, tricyclic antidepressants also show inhibitory potency at a broad variety of 
targets, including α-adrenergic and muscarinic acetylcholine receptors. Both TCA were identified 
as antagonists at the P2X2 receptor with IC50 values comparable to levomepromazine and 
promazine. Amitriptyline additionally inhibited the P2X1 receptor in the same concentration 
range, and was slightly more potent at the P2X4 receptor. The results at the P2X4 receptor are in 
contrast to previously published data, where amitriptyline was found to have no effect on 
P2X4.136 The inhibitory potency of dosulepin at P2X4 receptors was in the low micromolar range, 
as was determined for levomepromazine, fluphenazine and perphenazine. The results indicate 
that purinergic ion channels, particularly P2X2 and P2X4, also belong to the broad target 
spectrum of tricyclic CNS-drugs.  
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Table 5.4: Inhibitory potency of tricyclic antidepressants at P2X receptors (mean ± SEM, n = 3-4). 
Compound Structure IC50 ± SEM [µM] or inhibition at 20 µM or 1 µM (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
Amitriptyline 
 
17.8 ± 6.6 30.8 ± 7.9 > 20 
(1 %) 
6.87 ± 
1.41 
> 20 
(-5 %) 
Dosulepin 
 
> 1 (-53 %) 11.3 ± 1.0 > 20 
(-66 %) 
7.21 ± 
0.70 
> 20 
(19 %) 
 
5.3.1.3 Imidazole-containing antifungal drugs 
Imidazole-based antifungal drugs are broad spectrum fungistatic agents. The antifungal effect is 
achieved by their binding to the heme iron cation of 14-α-demethylase and thereby preventing 
the conversion of lanosterol to ergosterol. This causes a lack of ergosterol, which is equivalent to 
cholesterol in fungal membranes, and inhibits the fungal growth due to membrane instability. 
The essential structure for this mechanism is the imidazole function of the compounds.  
During the initial screening, several of the imidazole antifungals diminished the calcium influx in 
P2X receptor-transfected 1321N1 astrocytoma cells. The results and respective IC50 values are 
summarized in Table 5.5. Inhibitory activity could be detected especially at the P2X1 and the 
P2X3 receptor, respectively, with comparable IC50 values in the low micromolar range between 
2.05 and 3.00 µM. The same was seen for econazole at P2X1 and P2X4 receptors. None of the 
compounds were active at a final concentration of 1 µM at P2X2 and P2X7 receptors, so no 
dose-response experiments were conducted. All hits led to full inhibition, no remaining receptor 
activity could be detected. Not all of the imidazole drugs in the library showed affinity for P2X 
receptors. Ketoconazole, oxiconazole and sertaconazole did not show a decrease in ATP-induced 
calcium influx. An elongation of the side chain next to the imidazole ring therefore had no 
positive effect on the affinity towards P2X receptors.  
Of the triazole antifungals, only fluconazole was available for testing. No activity at any P2X 
receptor subtype could be detected.  
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Table 5.5: Inhibitory potency of imidazole antifungal drugs at P2X receptors (mean ± SEM, 
n = 3-4). 
Compound Structure IC50 ± SEM [µM] or inhibition at 20 µM or 1 µM (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
Bifonazole 
 
> 1 (-9 %) > 20 
(27 %) 
2.78 ± 1.21 > 20 
(47 %) 
> 1 (9 
%) 
Clotrimazole 
 
2.09 ± 0.04 > 20 
(-19 %) 
2.09 ± 0.99 > 20 
(40 %) 
> 1 
(-8 %) 
Econazole 
 
3.00 ± 1.21 > 1 (9 %) > 1 (32 %) 7.60 ± 
1.77 
> 1 
(-8 %) 
Isoconazole 
nitrate 
 
1.65 ± 0.55 > 1 
(10 %) 
> 1 (7 %) 6.10 ± 
1.62 
> 20 
(25 %) 
Miconazole 
nitrate 
 
> 1 (3 %) > 1 
(15 %) 
> 1 (-7 %) 6.36 ± 
1.69 
> 1 
(-42 %) 
Tioconazole 
 
> 1 (-7 %) > 1 
(15 %) 
4.32 ± 1.01 3.12 ± 
0.51 
> 1 
(19 %) 
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5.3.1.4 Butyrophenones 
Butyrophenone-based drugs also play an important role in the treatment of schizophrenia next 
to phenothiazines. Their antipsychotic activity was identified after structural modification of 
phenylpiperidine-based analgesics with a butyrophenone core structure. Haloperidol is the most 
commonly used butyrophenone antipsychotic in Germany, with high affinity for the dopamine 
receptor subtype D2, next to D1, D3, D4 and the α-adrenergic receptor.
306 Dopamine receptor 
subtypes D2, D3 and D4 are members of the so-called D2-like family. All members are GPCR 
coupled to Gi/α, which inhibits the adenylyl cyclase and reduces the intracellular cAMP 
concentration upon activation. This leads to opening of potassium channels, stabilizing the 
resting potential and reducing the excitability of the cell. The antipsychotic effect though cannot 
be attributed to the drug’s affinity at one specific receptor subtype. In fact, the inhibitory 
potency at various targets like 5-HT, acetylcholine, norepinephrine or histamine receptors was 
demonstrated to promote the antipsychotic efficacy of a drug against positive and negative 
symptoms of schizophrenia. The D2 and 5-HT3 receptor subtypes are also prominent in the area 
postrema, a circumventricular organ in the brain that represents the chemoreceptor trigger zone 
for emesis. Inhibition of the D2 receptor is associated with relief of nausea and emesis. 
Haloperidol was part of the drug library tested, but did not show any inhibitory activity at any 
P2X receptor subtype in the initial screening at 20 µM final concentration. The same was 
observed for azaperone, a pyridinylpiperazine derivative of haloperidol and mainly used as a 
sedative in veterinary medicine. 
The closely related derivative bromperidol was identified as a hit with low micromolar IC50 value 
(3.46 ± 0.33 µM) at the P2X1 receptor. It showed no activity any of the other subtypes tested 
(see Table 5.6). The structurally related benzimidazolone containing derivatives pimozide and 
the antiemetics domperidone and droperidol were all identified as hits at the P2X2 receptor, but 
had no longer any inhibitory potency at the P2X1 receptor when tested at 1 µM. At P2X4, only 
pimozide was active, with potency comparable to the results at the P2X2 subtype. 
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Table 5.6: Inhibitory potency of butyrophenone-derived drugs at P2X receptors (mean ± SEM, 
n = 3-4). 
Compound Structure IC50 ± SEM [µM] or inhibition at 20 µM 1 µM (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
Bromperidol 
 
3.46 ± 
0.33 
> 20 (15 %) > 20 
(-33 %) 
> 20 
(46 %) 
> 20 (15 %) 
Droperidol 
 
> 1  
(-15 %) 
104 ± 60 > 20 
(-28 %) 
> 20 
(4 %) 
> 20 (43 %) 
Domperidone 
 
> 1 
(-10 %) 
14.4 ± 3.0 > 1 
(-31 %) 
> 20 
(38 %) 
> 1 (-11 %) 
Pimozide 
 
> 1 (24 %) 3.57 ± 1.45 
Remaining 
receptor 
activity 
27 % 
 
> 1 
(-48 %) 
2.10 ± 
0.30 
> 20 
(-34 %) 
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5.3.1.5 Thyroid hormones and related drugs 
Levothyroxine and liothyronine are two homologous iodinated thyronine hormones produced in 
the thyroid gland which are indispensable for normal metabolism, growth and development.307 
Both are synthesized starting from L-tyrosine, which is posttranslationally modified after 
stimulation by thyrotropin, the thyroid regulating hormone secreted from the anterior pituitary 
gland. Therapeutically, both are indicated for substitution in case of hypothyroidism. Both 
compounds are distinguished structurally by the number of iodine bound to the thyronine core, 
which is reflected in the abbreviated term T3 (liothyronine, L-3,5,3’-triiodothyronine) and T4 
(levothyroxine, L-3,5,3’,5’-tetraiodothyronine). While levothyroxine was identified as an 
antagonist of P2X1 and P2X3 receptor with IC50 values in the low micromolar range (see 
Table 5.7), liothyronine reduced the activity of P2X2 receptors with slightly lesser potency 
(15.0 ± 1.9 µM). No or weaker inhibitory activity was detected at the other subtypes. 
Liothyronine appeared to be selective for the P2X2 receptor, but inhibition was seen only when 
the drug was used in concentrations way above those used normally in a therapeutic context. 
Amiodarone is an antiarrhythmic drug with high affinity to potassium ion channels. Due to 
structural similarity and molecular interference when used in combination with thyroid 
hormones, it was included into the discussion of inhibitory potency of thyroid hormones at P2X 
receptors.308 It blocks the potassium outflow in phase III of the action potential in 
cardiomyocytes by inhibiting potassium ion channels and selectively prolongs their refractory 
period and reduces cardiac arrhythmia.309 The initial screening showed inhibition higher than 
50 % of all P2X receptor subtypes except the P2X7 subtype. Concentration-response 
experiments were conducted at P2X2 and P2X4 receptors, demonstrating IC50 values in the low 
micromolar range (10.2 ± 0.5 µM and 4.01 ± 1.02 µM, respectively). The affinity at the P2X2 
receptor is comparable to liothyronine. At P2X7 receptors, it was initially demonstrated to be a 
potential enhancer of ATP potency, which is further discussed in chapter 5.4.3. 
  
5 Results and Discussion 
-139- 
 
Table 5.7: Inhibitory potency of thyroid hormones at P2X receptors (mean ± SEM, n = 3-4). 
Compound Structure IC50 ± SEM [µM] or inhibition at 20 µM or 1 µM (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
Levo-
thyroxine-Na 
 
5.30 ± 4.08 
Remaining 
receptor 
activity 
11 % 
> 20 (46 %) 3.52 ± 0.44 > 20 
(38 %) 
> 20 
(-10 %) 
Liothyronine-
Na 
 
> 1 (-55 %) 15.0 ± 1.9 > 1 (10 %) > 20 
(21 %) 
> 20 
(34 %) 
Amiodarone 
 
> 1 (-29 %) 10.2 ± 0.5 
Remaining 
receptor 
activity 
23 % 
> 1 (7 %) 4.01 ± 
1.02 
> 20 
(-39 %) 
 
5.3.1.6 Bisphosphonates 
Since polyoxometalates have been identified as potent inhibitors of all P2X receptors (see 
chapter 4.3), similar negatively charged drugs were of peculiar interest. Bisphosphonates are 
small negatively charged inorganic diphosphate analogues approved for the treatment of 
osteoporosis. Bisphosphonates accumulate in the bone, which is attributed to their high affinity 
to hydroxyapatite. They inhibit the activity of osteoclasts, which leads to a reduction of bone 
resorption. None of the compounds tested showed any inhibitory activity at P2X receptors (see 
Table 5.8). Since the molecular weight is much lower in comparison to POMs, it is possible that 
the compounds are too small for potent inhibition. 
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Table 5.8: Inhibitory potency of bisphosphonate derivatives at P2X receptors (mean ± SEM, 
n = 3-4). 
Compound Structure Inhibition ±SEM at 10 µM (%) 
  P2X1 P2X2 P2X3 P2X4 P2X7 
Alendronate 
 
> 10 
(2 %) 
> 10 
(1 %) 
> 10  
(-3 %) 
> 10 
(14 %) 
> 10  
(-9 %) 
Clodronate 
 
> 10 
(13 %) 
> 10 
(1 %) 
> 10 
(10 %) 
> 10 
(10 %) 
> 10 
(7 %) 
Difluoromethylene-
diphosphonate 
 
> 10  
(-3 %) 
> 10  
(-2 %) 
> 10 
(16 %) 
> 10 
(11 %) 
> 10 
(2 %) 
Etidronate 
 
> 10 
(15 %) 
> 10  
(-8 %) 
> 10  
(-9 %) 
> 10 
(27 %) 
> 10 
(4 %) 
Ibadronate 
 
> 10 
(1 %) 
> 10 
(1 %) 
> 10  
(-12 %) 
> 10 
(20 %) 
> 10 
(6 %) 
Methylene-
diphosphonate  
> 10 
(1 %) 
> 10  
(-1 %) 
> 10 
(7 %) 
> 10 
(10 %) 
> 10  
(-14 %) 
Zoledronate 
 
> 10  
(-2 %) 
> 10 
(2 %) 
> 10  
(-6 %) 
> 10 
(16 %) 
> 10  
(-20 %) 
 
5.3.1.7 Various screening hits without structural relation 
Not all detected hits could be subdivided into groups with similar structural properties. All 
compounds with inhibitory potency that were singletons are summarized in Table 5.9. 
All hits presented in this chapter are structurally non-related drugs with potency ranging from 
low nanomolar (e.g. 0.0324 ± 0.0288 µM for amphotericin B at the P2X3 receptor) to micromolar 
concentrations (e. g. 48.9 ± 19.6 µM for meclizine at the P2X1 receptor). Most compounds were 
active at particular P2X subtypes, with low inhibitory potency at the remaining receptors tested 
when used in high concentrations.  
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Table 5.9: Inhibitory potency of structurally non-related hits at P2X receptors (mean ± SEM, n = 3-4). 
IC50 ± SEM [µM] or inhibition at 20 µM or 1 µM (%) 
P2X7 
> 20 (10 %) 
> 20 (-63 %) 
0.0962 ± 
0.0324 
> 1 (-4 %) 
P2X4 
> 20 (45 %) 
> 20 (22 %) 
0.711 ± 0.297 
Remaining 
receptor activity 
16 % 
14.7 ± 3.4 
Remaining 
receptor activity 
10 % 
P2X3 
> 20 (-29 %) 
0.0324 ± 0.0288 
Remaining 
receptor activity 49 
% 
> 100 (n. c.)a 
> 1 (-17 %) 
P2X2 
5.69 ± 1.06 
> 20 (-27 %) 
> 20 (21 %) 
16.3 ± 2.70 
Remaining 
receptor activity 32 
% 
P2X1 
> 20 (38 %) 
> 1 (25 %) 
> 100 (n. c.)a 
> 1 (21 %) 
Structure 
 
 
 
 
 
Compound 
Ambroxol 
Amphotericin B 
Bisacodyl 
Celecoxib 
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Continuation of Table 5.9 
> 20 (12 %) 
> 20 (3  %) 
> 20 (-46 %) 
> 20 (-21 %) 
> 20 (9 %) 
> 20 (36 %) 
> 1 (1 %) 
> 1 (14 %) 
> 20 (32 %) 
> 20 (37 %) 
> 1 (6 %) 
> 20 (-15 %) 
> 20 (-32 %) 
> 1 (9 %) 
> 20 (-10 %) 
> 1 (11 %) 
> 20 (1 %) 
> 20 (-28 %) 
> 20 (17 %) 
> 20 (25 %) 
0.302 ± 0.088 
Remaining 
receptor activity 
26 % 
> 100 (n. c.)a 
> 100 (n. c.)a 
5.02 ± 2.46 
Remaining 
receptor activity 
27 % 
35.9 ± 12.2 
 
 
 
 
 
Chlorhexidine 
Epicatechin 
Ergocalciferol 
Fenofibrate 
Flavoxate 
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Continuation of Table 5.9 
> 20 (-8 %) 
> 20 (-32 %) 
> 20 (-12 %) 
0.322 ± 0.129 
> 20 (49 %) 
> 20 (-63 %) 
> 20 (35 %) 
> 20 (-14 %) 
> 100 (n. c.)a 
> 20 (48 %) 
2.73 ± 1.16 
> 1 (-21 %) 
> 20 (-33 %) 
0.0134 ± 0.0029 
> 1 (-34 %) 
> 20 (19 %) 
12.6 ± 2.2 
Remaining 
receptor activity 
18 % 
> 20 (-15 %) 
> 20 (-17 %) 
> 20 (13 %) 
1.72 ± 0.23 
Remaining 
receptor activity 33 
% 
48.9 ± 19.6 
> 10 (n. c.)a 
> 1 (-6 %) 
50.8 ± 19.6 
 
 
 
 
 
Ivermectin 
Meclizine 
Mepivacaine 
Niclosamide 
Oxybutynin 
5
 R
esu
lts an
d
 D
iscu
ssio
n
 
-1
4
4
- 
  
Continuation of Table 5.9 
> 1 (14 %) 
> 20 (-12 %) 
> 1 (10 %) 
a: n. c. no convergence in 3 independent experiments 
> 1 (5 %) 
> 20 (-21 %) 
10.4 ± 3.4 
> 1 (-51 %) 
14.6 ± 3.3 
> 20 (38 %) 
27.1 ± 12.0 
Remaining 
receptor activity 17 
% 
> 20 (30%) 
8.47± 1.21 
Remaining 
receptor activity 
18 % 
> 1 (-9 %) 
> 1 (20 %) 
> 1 (9 %) 
 
 
 
Quinidine sulfate 
Sennoside A 
Tetrandrine 
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Ambroxol was identified as a selective antagonist of the P2X2 receptor with an IC50 value in the 
low micromolar range (5.69 ± 1.06 µM). No significant inhibition of the other P2X receptors 
could be detected at 20 µM, which makes ambroxol selective at the P2X2 subtype towards other 
P2X receptors. It is approved as an expectorant for children and adults. Expectorants generally 
increase mucin secretion or mucus hydration. Additionally, ambroxol increases the production of 
surfactant by type II pneumocytes of the alveoli and stimulates the activity of the ciliated 
epithelium.310 A local anesthetic effect by inhibition of both tetrodotoxin-sensitive and 
tetrodotoxin-resistant neuronal voltage-gated sodium channels in rat dorsal root ganglia, as well 
as inhibition of closely related voltage-gated calcium channels and glutamate receptors also 
have been reported.311 Suppression of chronic, inflammatory and neuropathic pain could be 
confirmed in in vivo animal models.312 Ambroxol itself is an active N-desmethyl metabolite of 
bromhexine, which is also approved as an expectorant drug in respiratory diseases. The 
bioavailability of a single oral dose of ambroxol 30 mg amounts to 72.9 % and leads to plasma 
concentrations between 0.148 µM and 0.257 µM (1.007-1.142 ng/ml).313, 314 These 
concentrations are much lower than necessary for antagonistic activity at the P2X2 receptor. 
Since a lot of the experiments in the literature were conducted at rat dorsal root ganglia, the 
efficacy of ambroxol at the heteromeric P2X2/3 receptors would be interesting. Nevertheless, it 
could be a promising leading structure for the development of selective P2X2 receptor ligands 
due to its P2X receptor selectivity. 
Other hits at the P2X2 receptor with comparable IC50 values were COX-2-selective NSAID 
celecoxib (IC50 16.3 ± 2.70 µM), antiarrhythmic agent quinidine sulfate (IC50 27.1 ± 12.0 µM) and 
calcium channel blocker tetrandrine (IC50 8.47 ± 1.21 µM). Amiodarone and meclizine were also 
potent inhibitors of the P2X2 receptor, but were also active at P2X1 or P2X4 receptors with 
comparable potency, respectively.  
Tetrandrine and quinidine share remote resemblance due to the bis-benzylisoquinoline 
(tetrandrine) and quinoline (quinidine) structures. Tetrandrine is an active ingredient in Chinese 
medicinal herb Radix Stephanae tetrandrae, and possesses antiarrhythmic and antihypertensive 
properties by inhibition of cardiac voltage-dependent calcium- and calcium-activated potassium 
channels.315, 316 Calcium influx is also reduced in cells lacking voltage-gated calcium channels. 
This observation was attributed to a potential inhibition of either the α-adrenergic receptor or 
the intracellular pathway of IP3-induced calcium release from sarcoplasmic reticulum.
317 Since 
the P2X2 and P2X4 receptors are also expressed in cardiomyocytes, it is possible that at least 
part of reduced calcium influx may be attributed to antagonism of both P2X receptor 
subtypes.318  
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Quinidine is a class Ia antiarrhythmic drug used for the treatment of supraventricular and 
ventricular arrhythmia. It mainly inhibits the inward sodium current as well as cardiac potassium 
channels and downregulates the activity of the Na+/Ca2+-exchanger.319 In this experimental 
series, it was moderately potent at the P2X2 receptor, but also showed comparable potency at 
P2X1 and P2X7 receptors. Since the receptor inhibition at 1 µM final concentration was lower 
than 50 %, no IC50 value was determined at those subtypes. 
Celecoxib is a COX-2-selective inhibitor and member of the classical NSAID approved for the 
treatment of rheumatoid arthritis. Inhibitory potency was detected at all P2X receptor subtype 
at 20 µM. Only the P2X2 receptor was inhibited more than 50 % when the concentration was 
reduced to 1 µM. The subsequently determined IC50 concentration was in the moderate 
micromolar range. The drug was not capable to block the receptor activity completely. A 
remaining P2X2 receptor activity of 32 % was detected, as was also seen for amiodarone (23 %). 
Amphotericin B has strong antifungal properties, like the imidazole derivatives. It belongs to the 
polyene derivatives and is related to the antibiotic class of macrolides. The mechanism of action 
though is different; amphotericin B and its closely related derivatives nystatin and natamycin 
bind to ergosterol. This complex leads to a pore-like formation through the cell membrane with 
the hydrophobic surface localized on the outer side towards the lipid bilayer and the hydrophilic 
parts of both structures oriented towards the inside. Due to the high stability of these 
complexes, the integrity of the cell membrane is compromised leading to an outflow of ions and 
the destruction of the fungi cells.320 Amphotericin B has been gold standard in the treatment of 
systemic fungal infections. The therapeutic use is limited by its poor water solubility at 
physiological pH and the dose-related nephrotoxicity. In order to improve its pharmacology, 
amphotericin B is administered mainly as a colloidal solution with sodium desoxycholate, as a 
lipid formulation (Abelcet®) or encapsulated in liposomes (AmBisome®). The amphotericin B in 
our compound library was available without any complex or lipid supplement. While the stock 
solutions and the dilutions were prepared in DMSO and therefore perfectly soluble, this cannot 
be guaranteed for the assay system, where the compound dilutions are added to an aqueous 
buffer system. Although a visual control did not yield any anomalies, it is most likely that 
amphotericin B precipitated onto the cell monolayer on the bottom of the assay plate during the 
experiment. At the P2X3 receptor, antagonism at nanomolar concentrations 
(IC50 0.0324 ± 0.0288 µM) was observed. The initial screening data at 20 µM at P2X7 receptors 
implied enhancement of maximal ATP effect, which will be discussed in chapter  5.4.3 . No effect 
was detected at P2X1, P2X2 and P2X4 receptors. Since complete solubility of amphotericin B 
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during the experiment cannot be guaranteed, it cannot be considered as a P2X receptor ligand 
based solely on these results. 
Fenofibrate, the first member of the fibric acid derivatives, was identified as a selective P2X1 
receptor antagonist. It is approved for the treatment of hypertriglyceridemia. The modulation of 
lipid metabolism is evoked by activation of peroxisome proliferator-activated receptor alpha 
(PPARα). The potency at PPARα is relatively weak. The receptor is activated by fenofibrate with 
an EC50 value of 22.4 µM.
321 The inhibitory potency at P2X1 receptors is four times higher 
(5.02 ± 2.46 µM). At the P2X3 receptor, inhibition higher than 50 % at 20 µM final concentration 
was detected, which was reduced to 9 % at 1 µM. The closely related bezafibrate was not active 
at any P2X subtype. 
Ivermectin, flavoxate and meclizine were identified as further hits at the P2X1 receptor. 
Meclizine is a piperazine-based antihistamine drug of the first generation and inhibits the 
histamine H1 receptor. Like many other first generation antihistamines, it also binds to 
muscarinic acetylcholine receptors, constitutive androstane receptors and pregnane X 
receptors.322-324 It is mainly used for the prophylactic treatment and management of motion 
sickness due to its strong antiemetic effects, which exceeds the abilities of other antihistamines 
such as cetirizine and hydroxyzine. The inhibitory effect of meclizine at the P2X1 receptor was 
weak. The compound also showed inhibition of the P2X2 receptor with slightly higher potency 
(IC50 12.6 ± 2.2 µM vs. 48.9 ± 19.6 µM, respectively).  
Ivermectin was identified as an inhibitory agent at P2X1 and P2X3 receptors. This was surprising, 
since ivermectin has previously been described as a PAM of P2X4 and P2X7 receptors.147, 156 The 
ATP-enhancing effect at the P2X4 receptor was postulated to be caused by insertion of 
ivermectin between the transmembrane helices of the receptor trimer, potentially leading to 
pore-dilation that also diminished receptor desensitization.149 Ivermectin inhibited P2X1 and 
P2X3 receptors at micromolar concentrations (IC50 1.72 ± 0.23 µM and 2.73 ± 1.16 µM, 
respectively), without showing any signs of positive allosteric modulation. 
In comparison to ivermectin, flavoxate and oxybutynin were weaker antagonists of the P2X1 
receptor with similar activity as meclizine. Both are approved for the treatment of overactive 
bladder syndrome. Additionally, oxybutynin is used in the treatment of hyperhidrosis. The effect 
of flavoxate is carried out by inhibition of phosphodiesterases and calcium influx. A local 
anesthetic effect comparable to lidocaine is known as well.325 After oral administration, 
flavoxate is rapidly absorbed and metabolized to 3-methyl-flavone-8-carboxylic acid (MFCA). 
Only traces of flavoxate are detectable in the blood.326 Since the activity of flavoxate at the P2X1 
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receptor is relatively low, the potency of the metabolite MFCA should be determined. 
Oxybutynin is applied orally, in intravesical or transdermal therapeutic system. The systemic 
bioavailability of oral formulations is less than 10 % due to high first-pass metabolism in the 
liver. The primary metabolite is N-desethyloxybutynin.327 The concentration of the metabolite is 
significantly higher than of the drug itself upon oral administration of 5 mg (0.0375 – 0.0895 µM 
for oxybutynin vs. 0.162 – 0.193 µM for N-desoxybutynin).328 The bioavailable concentrations 
are too low to activate the P2X1 receptor, and the inhibitory potency of the metabolite could 
not be determined, since it was not part of the compound library. The application of higher 
oxybutynin doses is most likely not possible due to higher incidence of anticholinergic adverse 
events. 
Sennoside A is an O-glycoside anthranoid derivatives isolated from Senna plants and widely used 
for its laxative effect. It was identified as an antagonist with a micromolar IC50 value at the P2X3 
receptor. During the initial screening at 20 µM, high inhibition was also detected at P2X1, P2X4 
and P2X7 receptor subtypes, which was, however, less than 50 % at 1 µM concentration. 
Therefore, no dose-response experiments were conducted. The Senna anthraquinones were the 
lead structures for the development of the anthraquinone library tested at the P2X3 receptor 
(see chapter 3), so the inhibitory potency of one of the original structures is not surprising. 
Epicatechin, ergocalciferol and mepivacaine were initially tested as potential hits at the P2X1 
receptor, but concentration-dependent effects could not be observed, so inhibitory potency of 
those drugs could not be proven. None were active at other P2X receptor subtypes tested.  
The two most interesting hits detected in the initial screening were bisacodyl and niclosamide. 
Both were identified to be potent antagonists of both P2X3 and P2X7 receptors. Bisacodyl 
additionally inhibited the P2X4 receptor. The respective dose-response curves are presented in 
Figure 5.4. 
Bisacodyl was identified as a potent hit at P2X1, P2X3, P2X4 and P2X7 receptors in the initial 
screening at 20 µM. Concentration-response curves could be generated successfully for the P2X4 
and P2X7 receptors. The compound is almost eightfold less potent at the P2X4 than at the P2X7 
receptor. Both screening concentrations 20 µM and 1 µM were identified to potently inhibit also 
the P2X3 receptor, but the subsequent dose-response experiments were not successful. 
However, niclosamide was potent at both P2X3 and P2X7 receptors in the low (P2X3) and high 
nanomolar range (P2X7). The drug also blocked the activity of P2X1 and P2X4 receptors at 
20 µM, but no inhibitory activity was detected during the repeat at 1 µM final concentration at 
the P2X1 receptor and no dose-response relation could be generated at the P2X4 receptor. 
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Weak inhibitory potency at both subtypes therefore has to be taken into account for evaluation 
of its selectivity.  
 
 
 
 
 
 
 
 
Figure 5.4: Mean dose-response curves of (A) bisacodyl and (B) niclosamide at P2X3, P2X4 and 
P2X7 receptors. Data is presented as mean ± SEM from 3-5 independent experiments. 
 
Both compounds were very interesting hits, since they are not toxic when used in therapeutic 
concentrations in an animal model, and the potency at the respective targets was very high in 
comparison to other drugs.329, 330 Therefore, further investigations were conducted to 
additionally characterize their activity and their potential as lead structures for drug 
development. 
 
5.3.2 Structure-activity-relationships of bisacodyl and niclosamide derivatives 
Bisacodyl and niclosamide were identified as potent antagonists at P2X3 and P2X7 receptors, 
respectively. Both compounds are reported to be non-toxic and have been used as drugs in high 
concentrations for a long time. Both were selected for further characterization based on their 
high potency. A small library of nine compounds derived from the bisacodyl structure with 
aliphatic side chains of varying length were synthesized by M. Sc. The-Hung Vu. Niclosamide 
bears high structural similarity to N-(3,5-bis-trifluoromethylphenyl)-5-chloro-2-
hydroxybenzamide, also known as IMD-0354, here MT164, a selective NFκB inhibitor, which has 
been identified as a potent P2X1 receptor antagonist by M. Sc. Sabrina Densborn and Dr. Aliaa 
Abdelrahman.331-334 A series of structural derivatives has been synthesized by Dr. Maoqun Tian. 
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The whole library was tested at P2X3 and P2X7 receptors. The results of both experiment series 
are discussed in the following chapters. 
 
5.3.2.1 Bisacodyl derivatives 
Bisacodyl is a triarylmethane-based drug approved for the treatment of chronic obstipation. It 
was identified as a potent and moderately selective antagonist of human P2X7 receptor with an 
IC50 value of 0.0962 ± 0.0324 µM. A small library of compounds bearing aliphatic residues of 
varying length instead of the ester moieties was synthesized by The-Hung Vu. The structures of 
the derivatives and the corresponding experimental results are presented in Table 5.10.  
 
Table 5.10: Inhibitory potency of bisacodyl derivatives at P2X receptors (mean ± SEM, n = 3-4). 
Name Residues IC50 ± SEM [µM] or inhibition at 10 µM (%) 
 
 
     
 R1 R2 P2X1 P2X2 P2X3 P2X4 P2X7 
THV-B01 H H > 10 
(35 %) 
> 10 
(41 %) 
0.0194 
± 0.0036 
> 10 
(25 %) 
> 10 
(46 %) 
THV -B02-1 CH3 CH3 > 10 
(1 %) 
> 10 
(28 %) 
7.55 ± 
1.72 
> 10 
(16 %) 
> 10  
(-29 %) 
THV -B02-2 H CH3 > 10 
(1 %) 
> 10 (7 %) 6.43 ± 
3.98 
> 10 
(6 %) 
> 10  
(-13 %) 
THV -B03-1 CH2CH3 CH2CH3 > 100 
(n. c.)a 
> 10 
(48 %) 
1.19 ± 
0.29 
> 10 
(16 %) 
> 10  
(-17 %) 
THV -B03-2 H CH2CH3 > 10 
(22 %) 
> 10 (9 %) 5.97 ± 
2.06 
> 10 
(10 %) 
> 10  
(-23 %) 
THV -B04-1 CH2CH2CH3 CH2CH2CH3 > 10 
(41 %) 
1.55 ± 
0.60 
remaining 
receptor 
activity 
46 % 
0.452 ± 
0.053 
> 10 
(33 %) 
> 10 
(10 %) 
THV -B04-2 H CH2CH2CH3 > 10 
(42 %) 
> 10 
(36 %) 
4.14 ± 
0.23 
> 10 
(25 %) 
> 10  
(-19 %) 
THV -B05-1 
  
> 10 
(17 %) 
> 10 
(23 %) 
> 10 
(28 %) 
> 10 
(18 %) 
> 10 
(7 %) 
THV -B05-2 H 
 
> 100 
(n. c.)a 
> 10 
(38 %) 
1.86 ± 
0.12 
> 10 
(32 %) 
> 10  
(-25 %) 
a: n. c. no convergence seen in three independent experiments 
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Figure 5.5: Mean dose-response curves of bisacodyl derivatives (A) THV-B01, (B) THV-B02-1 ( ) 
and THV-B02-2 ( ), (C) THV-B03-1 ( ) and THV-B03-2 ( ), (D) THV-B04-1 ( ) and THV-B04-2 ( ) 
and (E) THV-B05-1( ) and THB-B05-2 ( ) at the rat P2X3 receptor. (mean ± SEM, n = 3-4) 
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The cleavage of the acetate residues and subsequent etherification of the phenolic hydroxyl 
residues led to new derivatives and allowed the observation of structure-activity relationships. 
While bisacodyl was a potent P2X7 antagonist with no concentration-dependent inhibition 
detectable at the other P2X receptor subtypes except P2X4, the newly synthesized derivatives 
showed no inhibitory potency higher than 50 % at P2X7, but at the P2X3 receptors. THV-B05-1 
was the only compound from this series with less than 50 % inhibitory potency at this target. The 
symmetrical propyl derivative THV-B04-1 was additionally active at the P2X2 receptor, but only 
reduced the receptor activity to about 50 %. The symmetric ethyl-substituted THV-B03-1 and the 
asymmetrical benzyl-substituted compound THV-B05-2 showed P2X1 receptor inhibition higher 
than 50 % when screened at 10 µM final concentration, but no concentration-dependent 
inhibition was observed. No other derivative was active at any other subtype. 
The most active compound of this series at the P2X3 receptor was the hydrolyzed diphenol, 
which is the active metabolite of bisacodyl and responsible for the intestinal stimulating effect. 
Elongation of the attached aliphatic side chains did not seem to have any effect on the affinity 
towards the P2X3 receptor (see also Figure 5.5). The asymmetric propyl compound THV-B04-2 
was found to be almost tenfold less active than its symmetric variant THV-B04-1. This was also 
seen to a lesser extend for the ethyl derivatives THV-B03-1 and THV-B03-1. The observation 
supports the theory that symmetric substitution of the diphenol is necessary for higher 
inhibitory potency at the P2X3 receptor, but the effect was not observed for the methyl-
substituted derivatives THV-B02-1 and THV-B02-2. Furthermore, the asymmetric benzyl 
derivative THV-B05-2 was demonstrated as a potent P2X3 antagonist with a low micromolar IC50 
value, while symmetric THV-B05-1 did not show any inhibitory potency when screened at 10 µM. 
 
5.3.2.2 Niclosamide derivatives 
Niclosamide was identified as a potent antagonist of both P2X3 and P2X7 receptors. The 
compound bears high structural similarity to N-(3,5-bis-trifluoromethylphenyl)-5-chloro-2-
hydroxybenzamide (IMD-0354, also named MT164, see Figure 5.6 B). It is one of 1140 
compounds of a commercial TOCRIS library, which has been identified as a lead structure for the 
development of P2X1 receptor ligands (data not yet published). The whole library of IMD-0354 
derivatives, synthesized by Dr. Maoqun Tian, has now been tested at the P2X3 and the P2X7 
receptor.  
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Figure 5.6: Structures of (A) niclosamide and (B) N-(3,5-bis-trifluoromethylphenyl)-5-chloro-2-
hydroxybenzamide (IMD-0354, MT164). 
 
All compounds were initially screened at a final concentration of 10 µM. Every compound except 
MT205, MT239, MT267, MT273 and MT316 was capable of inhibiting both P2X3 and P2X7 
receptors by more than 80 %. The same was seen for MT279 at the P2X3, and for MT232 and 
MT234 at the P2X7 receptor. The screenings of all compounds were repeated at both receptors 
at final concentrations of 1 µM and 0.1 µM for further characterization. When the inhibitory 
potency at 0.1 µM still remained higher than 50 %, concentration-response experiments were 
conducted. The results are summarized in Table 5.11. The substitution of both phenyl rings 
named A and B (see structure in Table 5.11) was considered separately to facilitate the 
discussion of structure-activity relationships, starting with ring A. The lead structure MT164 
(IMD-0354) was proven to be a potent antagonist at both receptor subtypes with a slight 
preference for the P2X3 receptor (IC50 0.0147 ± 0.0103 µM and 0.128 ± 0.019 µM, respectively, 
see also Figure 5.7). The compound was almost tenfold more potent at P2X3 than at P2X7 
receptors. 
 
 
 
 
 
 
 
 
Figure 5.7: Mean dose-response curves and structure of MT164 at the P2X3 and the P2X7 
receptor. Data is presented as mean ± SEM from 3-4 independent experiments. 
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Table 5.11: Inhibitory potency of niclosamide-related N-(3,5-bis-trifluoromethylphenyl)-5-
chloro-2-hydroxybenzamide derivatives at P2X3 and P2X7 receptors (mean ± SEM, n = 3-4).  
Name Residues IC50 ±SEM [µM] or 
inhibition at 10 µM, 1 
µM or 0.1 µM (%) 
 R1 R2 R3 R4 R5 R6 R7 R8 R9 P2X3 P2X7 
Niclosamide          0.0134 ± 
0.0029 
0.322 ± 
0.129 
 
 
  
MT263 H CF3 H CF3 H Cl H H OH >0.1 > 1 
            
MT165 H H H Cl H CF3 H CF3 H >0.1 (15 %) > 1 (30 %) 
MT166 OH H H H H CF3 H CF3 H >0.1 (38 %) > 0.1 
(17 %) 
MT169 OH H H CH3 H CF3 H CF3 H 0.124 ± 
0.039 
> 0.1 
(13 %) 
MT173 OH Cl H H H CF3 H CF3 H 0.0158 ± 
0.0040 
Remaining 
receptor 
activity  
24 % 
> 0.1 
(28 %) 
MT175 OH H Cl H H CF3 H CF3 H 0.0109 ± 
0.0052 
0.0513 ± 
0.0025 
MT205 OCH3 H H Cl H CF3 H CF3 H > 10 (10 %) > 10 
(41 %) 
MT232 Cl H H H H CF3 H CF3 H > 0.1 (42 %) > 10 (6 %) 
MT234 CH2OH H H H H CF3 H CF3 H > 1 (15 %) > 1 (8 %) 
MT235 H OH H H H CF3 H CF3 H > 1 (39 %) > 1 (17 %) 
MT240 OH F H H H CF3 H CF3 H 0.113 ± 
0.024 
> 1 (36 %) 
MT244 OH CH3 H H H CF3 H CF3 H 0.169 ± 
0.035 
> 0.1 
(15 %) 
MT246 OH NO2 H H H CF3 H CF3 H > 0.1 (37 %) > 0.1 
(26 %) 
MT259 H H H H H CF3 H CF3 H > 1 (46 %) > 1 (39 %) 
MT264 OH H H NO2 H CF3 H CF3 H 0.0922 ± 
0.0054 
0.739 ± 
0.163 
MT265 OH H H OH H CF3 H CF3 H > 1 (43 %) > 1 (2 %) 
MT266 H CF3 H H H CF3 H CF3 H > 1 (48 %) > 1 (29 %) 
MT279 NO2 H H H H CF3 H CF3 H > 1 (3 %) > 1 (24 %) 
MT281 NH2 H H H H CF3 H CF3 H > 1 (16 %) > 1 (46 %) 
MT283 OH H H H OH CF3 H CF3 H 0.0174 ± 
0.0040 
0.593 ± 
0.141 
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Continuation of Table 5.11 
 R1 R2 R3 R4 R5 R6 R7 R8 R9   
MT303 OH H H F H CF3 H CF3 H 0.0370 ± 
0.0171 
0.144 ± 
0.022 
MT305 OH H H OCH3 H CF3 H CF3 H 0.127 ± 
0.0083 
0.572 ± 
0.170 
            
MT164 OH H H Cl H CF3 H CF3 H 0.0147 ± 
0.0103 
0.128 ± 
0.019 
MT170 OH H H Cl H H CF3 H H 0.0140 ± 
0.0041 
Remaining 
receptor 
activity 
17 % 
> 0.1 
(32 %) 
MT301 OH H H Cl H H Cl H H 0.0823 ± 
0.0318 
1.79 ± 
0.043 
MT304 OH H H Cl H H NO2 H H 0.0563 ± 
0.0098 
Remaining 
receptor 
activity  
18 % 
1.07 ± 
0.306 
MT310 OH H H Cl H H F H H > 1 (33 %) 6.38 ± 0.48 
MT341 OH H H Cl H H CN H H > 0.1 (-6 %) > 1 (n c.)a 
MT182 OH H H Cl H NO2 H H H 0.104 ± 
0.010 
> 1 (35 %) 
MT184 OH H H Cl H CN H H H >0.1 (26 %) > 1 (9 %) 
MT167 OH H H Cl H H H CF3 H > 10 (n. c.)
a > 1 (41 %) 
MT188 OH H H Cl H H H Cl H > 0.1 (40 
%) 
> 0.1 
(40 %) 
MT221 OH H H Cl H H H SO2CF3 H > 0.1 (29 
%) 
1.47 ± 
0.340 
MT227 OH H H Cl H H H C(CH3)3 H > 0.1 (-10 
%) 
0.661 ± 
0.274 
MT274 OH H H Cl H H H 
 
H > 0.1 (2 %) > 1 (2 %) 
MT309 OH H H Cl H H H OCF3 H 0.0511 ± 
0.0148 
Remaining 
receptor 
activity  
16 % 
0.504 ± 
0.175 
MT171 OH H H Cl H H H H CF3 > 0.1 (-36 
%) 
> 1 (17 %) 
MT177 OH H H Cl H CH3 H CH3 H > 0.1 (19 
%) 
> 0.1 (-6 %) 
MT179 OH H H Cl H Cl H Cl H 0.0155 ± 
0.0030 
0.408 ± 
0.022 
MT186 OH H H Cl H OCH3 H OCH3 H > 1 (46 %) > 1 (1 %) 
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Continuation of Table 5.11. 
 R1 R2 R3 R4 R5 R6 R7 R8 R9   
MT215 OH H H Cl H F H F H > 0.1  
(44 %) 
> 10 (n. c.) 
MT267 OH H H Cl H OH H OH H > 10 (37 %) > 1 (30 %) 
MT275 OH H H Cl H NO2 H NO2 H > 1 (44 %) >0.1 (38 %) 
MT230 OH H H Cl H NO2 H CF3 H 0.0690 ± 
0.0337 
0.340 ± 
0.088 
MT282 OH H H Cl H H Cl NO2 H 0.0140 ± 
0.0023 
0.540 ± 
0.024 
            
MT177 OH H H Cl H CH3 H CH3 H > 0.1 (19 %) > 0.1 (-6 %) 
MT179 OH H H Cl H Cl H Cl H 0.0155 ± 
0.0030 
0.408 ± 
0.022 
MT186 OH H H Cl H OCH3 H OCH3 H > 1 (46 %) > 1 (1 %) 
MT215 OH H H Cl H F H F H > 0.1 (44 %) > 10 (n. c.) 
MT267 OH H H Cl H OH H OH H > 10 (37 %) > 1 (30 %) 
MT275 OH H H Cl H NO2 H NO2 H > 1 (44 %) > 0.1 
(38 %) 
MT230 OH H H Cl H NO2 H CF3 H 0.0690 ± 
0.0337 
0.340 ± 
0.088 
MT282 OH H H Cl H H Cl NO2 H 0.0140 ± 
0.0023 
0.540 ± 
0.024 
            
MT162 OH H H H H CF3 H H H > 0.1 (27 %) > 1 (6 %) 
MT239 OH H H H H H H SO2NH2 H > 10 (29 %) > 10  
(-52 %) 
MT241 OH H H H H H H Br H > 1 (34 %) > 1 (21 %) 
MT258 OH Cl H H H NO2 H CF3 H > 0.1 (8 %) > 1 (39 %) 
            
MT273 OH H H H H 
 
> 10 (42 %) > 10 (25 %) 
MT316 OH H H H H 
 
> 1 (42 %) > 0.1 
(46 %) 
MT207 
 
CF3 H CF3 H > 0.1 (14 %) 0.896 ± 
0.122 
a: n. c. calculation of IC50 not successful in three independent experiments 
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MT164 was around three times more potent than niclosamide at the P2X7 receptor, whereas 
the activity at the P2X3 receptor remained unchanged. By eliminating the hydroxyl substituent in 
the ortho-position of ring A (MT165), the inhibitory activity at both receptor subtypes was 
diminished to lower than 20 % at 0.1 µM concentration. A similar effect was observed when the 
chlorine in position 5 was removed (MT166), when the hydroxyl function was methylated 
(MT205), and when both substituents were replaced with hydrogen (MT 259).  
When chlorine in position 5 of the 2-hydroxybenzamide is exchanged for a methyl (MT169), a 
nitro (MT264), a second hydroxyl (MT265), a methoxy group (MT305) or to fluorine (MT303), the 
inhibitory potency at the P2X3 receptor is reduced in comparison to niclosamide. Only the 
fluorine-substituted compound MT303 has comparable activity to MT164 at the P2X7 receptor, 
the methoxy- and nitro derivative’s potency were significantly lower (IC50 0.572 ± 0.170 µM and 
0.739 ± 0.163 µM, respectively). The compounds with methyl or hydroxyl substituents in the 
same position already showed inhibitory activity lower than 20 % when screened at a final 
concentration of 0.1 µM. 
When chlorine is moved from position 5 to 4 (MT175), the inhibitory potency at both receptor 
subtypes was markedly increased (IC50 0.0109 ± 0.0052 µM and 0.0513 ± 0.0025 µM, 
respectively, see also Figure 5.8). MT175 was the most active compound of this series at both 
receptors, and therefore selected for further experiments along with MT164 discussed in later 
chapters. Its activity at the P2X3 receptor was comparable to MT164 and niclosamide. MT175 
was about six times more potent at the P2X7 receptor when compared to niclosamide. 
 
 
 
 
 
 
 
 
 
Figure 5.8: Mean dose-response curves and structure of MT175 at the P2X3 and the P2X7 
receptor. Data is presented as mean ± SEM from 3-6 independent experiments. 
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When chlorine is moved from position 4 to 3 (MT173), the inhibitory potency at the P2X7 
receptor was reduced. The activity of MT173 at the P2X3 receptor is comparable to MT175, but 
even at higher concentrations, it was not possible to inhibit the receptor completely. An 
exchange of chlorine for fluorine (MT240), a methyl (MT244) or a nitro residue (MT246) reduced 
the activity at both receptor subtypes.  
The elimination of chlorine in position 5 followed by the introduction of a second hydroxyl group 
in position 6 (MT283) shows inhibitory potency at P2X3 and P2X7 receptors comparable to 
niclosamide. However, the potency at the P2X7 receptor is almost ten times less than MT175, 
the most potent antagonist of this series. 
The substitution pattern was also varied at the second phenyl ring B. When one trifluoromethyl 
residue is removed (MT167), the inhibitory potency at the P2X7 receptor is reduced to less than 
20 % at 0.1 µM final concentration, but not at the P2X3 receptor. However, it was not possible to 
conduct successful concentration-response experiments. When the one remaining 
trifluoromethyl residue was moved to position 2, the activity at the P2X3 receptor was 
comparable to niclosamide, but the calcium influx could not be completely blocked. The transfer 
to position 4 diminished the inhibitory potency in comparison to both niclosamide and the 
leading structure MT164. Both substitution patterns lead to less potency at the P2X7 receptor. 
When the one trifluoromethyl residue in position 2 was exchanged to a nitrile (MT184), SO2CF3 
(MT221), ethinyl (MT274) or isobutyl group (MT227), the affinity at the P2X3 receptor at a final 
concentration of 0.1 µM was reduced to less than 40 %, respectively. A nitro substituent in this 
position (MT182) was potent during the first screening experiments, but almost eight times less 
active than niclosamide. Less activity was also observed for the exchange against a 
trifluormethoxy group (MT309). The substitution against a SO2CF3 (MT221), trifluoromethoxy or 
isobutyl residue led to inhibitory potency at the P2X7 receptor, but was demonstrated to be less 
potent in comparison to the lead structure MT164 and the most active compound MT175. 
Moving the one remaining trifluoromethyl residue to position 4 (MT170) led to a potent 
compound. The activity of MT170 at the P2X3 receptor was comparable to niclosamide. The 
exchange to nitrile (MT304) was tolerated, but did not improve potency. Fluorine in the para-
position diminished the inhibitory activity. Neither MT170 nor the fluorine- or nitrile derivative 
showed higher potency than niclosamide or MT164 at the P2X7 receptor.  
The complete exchange of both trifluoromethyl residues for two methyl residues (MT177), two 
methoxy (MT186), two hydroxyl (MT267) or two nitro substituents (MT275) reduced the 
inhibition of both targets to less than 20 % at a concentration of 0.1 µM. MT215 at the P2X3 
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receptor was the only exception; here the receptor activity was reduced to 44 %. When 
exchanged for two chlorine substituents, the compound MT179 showed inhibitory potency 
comparable to MT164 at the P2X3, but was slightly less potent at the P2X7 receptor. 
In conclusion, it can be stated that the hydroxyl function in position 2 of ring A plays an 
important role for high inhibitory potency with nanomolar IC50 values at both receptors. A small 
elongation or replacement by other polar residues reduced the activity. Chlorine in position 4 or 
5 did not have the same importance for high affinity of the compound. In ring B, various 
substituents were tolerated; the most common substitution pattern with high inhibitory activity 
was two substituents in the meta-positions 3 and 5, both polar and nonpolar. All hits were 
comparable or at least three to four times more potent at the P2X3 receptor than at P2X7, 
except MT227, the only compound with a bulky isobutyl residue in position 5 of ring B. Since no 
further elongations of side chains on both phenyl rings were available, no clear estimation can 
be made about the tolerance of bulky residues at the pharmacophore. This could be a possibility 
for the future development of a selective P2X7 ligand. 
 
5.3.2.3 Selectivity of niclosamide derivatives 
Nearly all niclosamide derivatives were proven to be very potent antagonists of both P2X3 and 
P2X7 receptors. Screening experiments at human P2X1, P2X2 and P2X4 receptor were 
conducted for the two most interesting compounds MT164 and MT175 in order to determine 
whether the compounds are selective towards other P2X receptor subtypes. The results are 
presented in Table 5.12. 
 
Table 5.12: Inhibitory potency of niclosamide derivatives MT164 and MT175 at human P2X 
receptors (mean ± SEM, n = 3-4). 
 IC50 ± SEM [µM] or inhibition (%) at 10 µM 
 P2X1 P2X2 P2X3 P2X4 P2X7 
MT164 0.0192 ± 0.0041a > 10 (34 %) 0.0147 ± 0.0103 6.14 ± 2.44 0.128 ± 0.019 
MT175 0.0231 ± 0.0036a > 10 (48 %) 0.0109 ± 0.0052 6.34 ± 1.56 0.0513 ± 0.0025 
a: Data determined by Dr. Aliaa Abdelrahman by measurement of calcium influx in 1321N1 
astrocytoma cells stably transfected with human P2X1 receptor. Data not yet published. 
 
Both compounds were proven to be selective towards the human P2X2 and P2X4 receptor. 
However, Dr. Aliaa Abdelrahman previously identified the compounds to be potent antagonists 
of the human P2X1 receptor (data not yet published). The activity at this subtype was 
comparable to the affinity determined for the P2X3 receptor. Due to the high structural 
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similarity and generally high potency, it is likely that niclosamide derivatives are selective 
towards P2X2 and P2X4 receptors, but not among the remaining subtypes.  
 
5.3.3 Determination of inhibition mechanism at P2X3 and P2X7 receptors 
Several drugs of the compound library were proven to be potent ligands at P2X receptors. In 
order to better characterize their mode of action, the most interesting hits were selected for 
ATP curve shift experiments determining their effect on the ATP potency at the respective 
receptor. Bisacodyl and niclosamide were already discussed as interesting agents at the P2X3 
and the P2X7 receptor, respectively. Additionally, the niclosamide-like derivatives MT164 and 
MT175 were tested. The resulting ATP curves in the presence and absence of antagonist are 
presented in Figure 5.9 A1-C1 for the P2X3 and in Figure 5.11 A1-D1 for the human P2X7 
receptor. 
For several of the higher concentrations tested, the calculation of EC50 concentrations was either 
not successful (MT164 0.5 µM at P2X3, niclosamide 10 µM, MT164 0.25 µM and 0.5 µM, and 
MT175 1 µM and 10 µM at the P2X7 receptor), or only one of three to four experiments gave a 
interpretable result (niclosamide 0.5 µM, MT164 0.1 µM, and MT175 1 µM and 10 µM at the 
P2X3, bisacodyl 15 µM, niclosamide 0.5 µM and 1 µM, and MT175 0.5 µM at the P2X7 receptor). 
MT175 10 µM was only tested twice at the P2X7 receptor. The decrease of maximal 
fluorescence signal was visualized by plotting the fluorescence increase caused by the highest 
ATP concentrations used in the experiments, 10 µM for the P2X3 and 5 mM for the rP2X7 
receptor against the respective concentration of test compound.  
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Figure 5.9: (A1-C1) Mean ATP dose response curves, (A2-C2) ATP pEC50 values and (3) maximal 
ATP effect (A) niclosamide, (B) MT164 and (C) MT175 at the rat P2X3 receptor. Cells were 
incubated with compounds concentrations 0.001 µM ( ), 0.01 µM ( ), 0.05 µM ( ), 0.1 µM ( ) 
and 0.5 µM (×) prior to stimulation with ATP 0.0001 to 10 µM, respectively. Buffer containing 
1 % DMSO without compound was used as control ( ). The unpaired Student’s t-test for 
significant differences of means was conducted for pEC50 values and maximal fluorescence 
increase. Significant differences (p < 0.05) are marked with (*), very significant differences 
(p < 0.01) with (**) and highly significant differences (p < 0.001) with (***). Data is presented as 
mean ± SEM from 2 to 4 independent experiments. 
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Figure 5.10: (A1-C1) Mean ATP dose response curves, (2) ATP pEC50 values and (3) ATP 5 mM-
induced fluorescence signal characterizing the influence of (A) bisacodyl 0.05 µM-15 µM and (B) 
niclosamide 0.01 µM-10 µM at the rat P2X3 receptor. Cells were incubated with respective 
compound concentration prior to stimulation with ATP 0.0001 to 10 µM. Buffer containing 1 % 
DMSO without compound was used as control ( ). The unpaired Student’s t-test for significant 
differences of means was conducted for pEC50 values and maximal fluorescence increase. 
Significant differences (p < 0.05) are marked with (*), very significant differences (p < 0.01) with 
(**) and highly significant differences (p < 0.001) with (***). Data is presented as mean ± SEM 
from 2 to 4 independent experiments. 
 
No EC50 concentrations for bisacodyl at the P2X3 receptor could be calculated, so the compound 
was not tested at the P2X3 receptor in this experimental setting. All compounds diminished the 
maximal ATP effect at both receptors, while the EC50 concentration was barely affected. 
Therefore, a Schild plot analysis for determination of orthosteric receptor antagonism, where 
the receptor can always be activated to the full level upon agonist concentration increase, was 
not possible. The pEC50 values of ATP in presence and absence of various antagonist 
concentrations are presented in Figure 5.9 to Figure 5.11 A2-B2. They visualize the minor change 
10-4.5 10-4.0 10-3.5 10-3.0 10-2.5 10-2.0
-20
-10
0
10
20
30
40
50
60
70
80
90
100
110
[ATP], M
Fl
u
o
re
sc
e
n
ce
 in
cr
e
a
se
 (
%
)
co
nt
ro
l
+ 
0.
05
 µ
M
+ 
0.
1 
µM
+ 
1 
µM
+ 
10
 µ
M
+ 
15
 µ
M
2.5
2.6
2.7
2.8
2.9
3.0
p
EC
5
0
co
nt
ro
l
+ 
0.
05
 µ
M
+ 
0.
1 
µM
+ 
1 
µM
+ 
10
 µ
M
+ 
15
 µ
M
0
10
20
30
40
50
60
70
80
90
100
110
***
*** **
***
**
m
a
xi
m
a
l A
T
P
 e
ff
e
ct
 (
%
)
10-4.5 10-4.0 10-3.5 10-3.0 10-2.5 10-2.0
-30
-20
-10
0
10
20
30
40
50
60
70
80
90
100
110
[ATP], M
Fl
u
o
re
sc
e
n
ce
 in
cr
e
a
se
 (
%
)
co
nt
ro
l
+ 
0.
01
 µ
M
+ 
0.
02
5 
µM
+ 
0.
05
 µ
M
+ 
0.
07
5 
µM
+ 
0.
1 
µM
+ 
0.
25
 µ
M
+ 
0.
5 
µM
+ 
1 
µM
+ 
10
 µ
M
2.5
2.6
2.7
2.8
2.9
3.0
* *
p
EC
5
0
co
nt
ro
l
+ 
0.
01
 µ
M
+ 
0.
02
5 
µM
+ 
0.
05
 µ
M
+ 
0.
07
5 
µM
+ 
0.
1 
µM
+ 
0.
25
 µ
M
+ 
0.
5 
µM
+ 
1 
µM
+ 
10
 µ
M
-50
-30
-10
10
30
50
70
90
110
*
***
*
**
**
*****
m
a
xi
m
a
l A
T
P
 e
ff
e
ct
 (
%
)
(A) Bisacodyl at human P2X7 
(A1) (A2) (A3) 
(B) Niclosamide at human P2X7 
(B1) (B2) (B3) 
5 Results and Discussion 
-163- 
 
in ATP potency at the respective receptor subtype. MT164 and MT175 both reversed the 
fluorescence increase to a decrease when used at high concentrations above 0.5 µM. The 
inversely proportional correlation between the maximal ATP effect and the concentration of 
antagonist with which cells were incubated prior to ATP injection is shown in Figure 5.9 to 
Figure 5.11 A3-D3, respectively. The higher the antagonist concentration, the lower was the 
maximal receptor activation level. Both observations indicate that bisacodyl, niclosamide, 
MT164 and MT175 are likely to be allosteric antagonists of P2X3 and human P2X7 receptors, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: (A1-C1) Mean ATP dose response curves, (2) ATP pEC50 values and (3) maximal ATP 
effect characterizing the influence of (A) MT164 0.01 µM-10 µM and (B) MT175 0.001 µM-10 µM 
at the rat P2X3 receptor. Cells were incubated with respective compound concentration prior to 
stimulation with ATP 0.0001 to 10 µM, respectively. Buffer containing 1 % DMSO without 
compound was used as control ( ). The unpaired Student’s t-test for significant differences of 
means was conducted for pEC50 values and maximal fluorescence increase. Significant 
differences (p < 0.05) are marked with (*), very significant differences (p < 0.01) with (**) and 
highly significant differences (p < 0.001) with (***) Data is presented as mean ± SEM from 2 to 4 
independent experiments. 
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5.4 Enhancement of maximal ATP effect 
An apparent increase of the maximal ATP effect was observed during the initial screening 
experiments of the drug library for some compounds, similar to the observation already 
discussed for the anthraquinone derivatives at the P2X3 receptor in chapter 3.4.2. The affected 
P2X receptor subtypes were rat P2X3 (14 enhancing hits) and human P2X7 (11 enhancing hits). 
Additional experiments were conducted to determine whether this observation could be 
attributed to a true binding effect or if it was a measuring error. Furthermore, it was tested 
whether the effect was concentration-dependent, and if the enhancement was due to agonistic 
effects.  
 
5.4.1 ATP concentrations used for receptor stimulation 
Prior to this experimental series, new cells carrying the P2X3 and P2X7 receptor had to be 
defrosted from liquid nitrogen and cultured. In order to characterize receptor expression, ATP 
curves of both cell lines were conducted at the beginning and for the P2X7 receptor also in 
between the respective experiments for investigation of enhancement. The EC50 concentrations 
determined were 0.0760 ± 0.0032 µM for r P2X3 and 2.70 ± 1.8 mM for P2X7 receptors. Based 
on these results, the ATP concentration used in the enhancement experiments was adjusted to 
2.5 mM for P2X7, in order to ensure 50% receptor stimulation. The concentration used for the 
P2X3 receptor remained unchanged at 0.05 µM ATP.  
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Figure 5.12: Mean dose-response curves of ATP at P2X3 and P2X7 receptors. Data is presented 
as mean ± SEM from 2-6 independent experiments. 
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5.4.2 Enhancing hits at the rat P2X3 receptor 
All enhancing hits detected during the initial screening experiments using 20 µM final 
concentration were first tested in dose-response experiments using the 0.05 µM ATP for 
receptor stimulation. The results are presented in Table 5.13. 
Most drugs which enhanced the ATP-induced fluorescence signal during the initial screening did 
not show any concentration-dependent potentiation of ATP effect upon further 
characterization. Only one compound, emetine, a natural drug from ipecac root and clinically 
used as an anti-amoebic and antiemetic, did further increase the maximal ATP effect in a 
concentration-dependent manner by 132 ± 36 % in cells stimulated with EC50 concentration of 
ATP (0.05 µM). 
 
Table 5.13: Potency of enhancing hits of enhancing hits at the rat P2X3 receptor identified 
during initial screening experiments at 20 µM final concentration. Data is presented as 
mean ± SEM from 2-3 independent experiments 
Name Structure EC50Enhancement ± SEM [µM] or 
inhibition (%) at 20 µM 
   
Emetine-HCl 
 
9.75 ± 3.82  
(stimulation with ATP 0.05 µM) 
 
n. c.a 
(stimulation with ATP 10 µM) 
Aciclovir 
 
n. c.b (-192 %) 
Atropine sulfate 
 
n. c.b (-163 %) 
Bacampicillin HCl 
 
n. c.b (-112 %) 
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Continuation of Table 5.13 
Benzathine-
Benzylpenicillin 
 
n. c.b (-107 %) 
Barbaloin 
 
n. c.b (-168 %) 
Benserazide HCl 
 
n. c.b (-143 -%) 
Betamethasone 
dipropionate 
 
n. c.b (-109 %) 
Bezafibrate 
 
n. c.b (-188 %) 
Bromperidol 
 
n. c.b (-102 %) 
Brompheniramine 
maleate 
 
n. c.b (-287 %) 
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Continuation of Table 5.13 
Dimetindene 
maleate 
 
n. c.b (-104 %) 
Diphenhydramine 
HCl 
 
n. c.b (-108 %) 
Doxapram HCl 
 
n. c.b (-124 %) 
a: n. c. no convergence in 4 independent experiments 
b: n. c. no convergence in 2 independent experiments 
 
When tested in cells stimulated with 10 µM ATP, an increase of maximal receptor activation 
could be observed, but the concentration-response relation was inconclusive. This indicates that 
the magnitude of receptor enhancement is dependent on the agonist concentration. The 
concentration-response curve for the experiments with ATP 0.05 µM is presented in Figure 5.13. 
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Figure 5.13: Mean dose-response curves of emetine at the P2X3 receptor, stimulated with ATP 
0.05 µM. Data is presented as mean ± SEM from 3 to 4 independent experiments. 
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The enhancing effect may also be attributed to agonistic properties of the compound. An 
experiment was conducted in order to determine any agonism of emetine at the P2X3 receptor 
by injection of various compound concentrations between 0.0001 and 100 µM instead of ATP. 
No fluorescence signal increase was detected. This excludes any agonistic activity of the 
compound. 
The influence of a single concentration of enhancer on the EC50 concentration of ATP was 
determined for further characterization. The experiment is related to the determination of 
inhibition mechanism, which was discussed for various antagonists in chapters 3.4.1.3, 4.3.6, and 
5.3.3. Cells were incubated with one single concentration of emetine (1 µM, 10 µM and 100 µM, 
respectively), and then stimulated with various concentrations of ATP ranging from 10 to 
5000 µM. Although the ATP control experiment worked, the generation of dose-response curves 
under influence of any emetine concentration was not successful. The final mechanism how 
emetine is capable of enhancing the maximal ATP effect could not be further cleared through 
these experiments.  
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5.4.3 Enhancing hits at the human P2X7 receptor 
Not all of the initially identified potential enhancers of P2X7 receptor could be confirmed. 
Table 5.14 gives an overview over all initially identified enhancing compounds and their 
enhancing potency at the P2X7 receptor.  
 
Table 5.14: Potency of enhancing hits at the human P2X7 receptor identified during initial 
screening experiments at 20 µM final concentration. Data is presented as mean ± SEM from 2-4 
independent experiments. 
Name Structure EC50Enhancement ± SEM 
[µM] and 
inhibition ± SEM (%) 
at 20 µM final 
concentration 
Enhancement 
of maximal 
ATP effect ± 
SEM [%] 
  P2X7  
Amphotericin B 
 
3.90 ± 3.39 56 ± 24 
Benzathine-
benzylpenicillin 
 
12.5 ± 5.4 82 ± 57 
Cefaclor 
 
> 100 19 ± 6 
(at 100 µM 
carvedilol) 
Cefatrizine 
 
> 100 54 ± 10 
(at 100 µM 
cefatrizine) 
Cephaloridine 
 
15.2 ± 7.9 105 ± 56 
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Continuation of Table 5.14. 
Cephradine 
 
n. c.a (-142 %) - 
Medroxy-
progesterone 
acetate 
 
1.06 ± 0.56 39 ± 1 
Methyl-
testosterone 
 
n. c.a (-92 %) - 
Amiodarone-HCl 
 
n. c.a (-183 %) - 
Carvedilol 
 
n. c.a (-102 %) - 
a: no convergence in 2 independent experiments 
 
Cefaclor and cefatrizin showed a concentration-dependent enhancement of maximal ATP effect, 
but the EC50Enhancement concentration was calculated to be higher than 100 µM, which was the 
highest concentration used. The experiment was successful for amphotericin B, benzathine-
benzylpenicillin, cephaloridine and medroxyprogesterone acetate. The respective concentration-
response curves are presented in Figure 5.14. When compared to the enhancing hits at the other 
receptor subtypes, a common structural feature could be detected. Cefaclor, cephaloridine, 
cephradine and cefatrizine are broad-spectrum antibiotics of the cephalosporin class. 
Benzylpenicillin, also known as penicillin G, the first known antibiotic, bears close structural 
relation to cephalosporins. Both classes belong to the so-called β-lactam antibiotics. Cephradine, 
cefatrizine and cephaloridine are part of the first generation cephalosporines. Cephradine is 
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orally available, same as the second generation drug cefaclor. Cephaloridine is unique among 
the cephalosporin antibiotics due to its zwitterionic nature. Like the penicillin drugs, 
cephalosporines act bactericidal by inhibition of penicillin-binding transpeptidases. This disrupts 
the bacterial cell wall synthesis, which leads to cell lysis. The diverging antibacterial activity of 
cephalosporins is attributed to side chain substitutions at position C7 in the lactam-ring. The 
bioavailability of oral cephalosporins is higher than 95 %. The drugs are eliminated rapidly from 
the blood in the space of two hours by renal excretion in their unchanged form.335 Penicillin G 
was available in combination with benzathine, building a water soluble depot complex that is 
administered intramuscularly. A single dose of 1.2 million units leads to a maximal plasma 
concentration of 0.154 µM in adults (0.14 mg/l).336 Since the available stock solution contained 
the water-soluble depot complex, any effect could not be clearly attributed to benzathine or 
benzylpenicillin, respectively. The common structural feature indicated that the cephalosporin 
core could be a possible scaffold for positive modulators for purinergic P2X7 receptors. Since 
cephalosporins and penicillin are present in the blood, interaction with P2X7 receptors 
expressed in macrophages is possible, but the low plasma concentrations reached by 
intramuscular depot injection would not be high enough to cause any effect. 
The EC50Enhancement concentrations of cephalosporins were comparable, but the magnitude of 
enhancement showed considerable standard error for depot penicillin combination benzathine-
benzylpenicillin and cephaloridine, and also varied between compounds. The highest 
enhancement of maximal ATP effect was determined for cephaloridine (105 ±56 %), while the 
concentration-dependent enhancement measured for cefaclor was barely above the normal 
ATP-induced fluorescence signal (19 ± 6 %). Medroxyprogesterone acetate showed the best 
reproducibility, the lowest EC50Enhancement concentration and the least standard error of all hits. 
None of the other steroidal drugs showed enhancement of maximal ATP effect to this extent. 
They are prone to show inhibition of calcium influx in stably transfected cells (see 
chapter 5.3.1.1).   
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Figure 5.14: Mean dose-response curves for determination of enhancement of maximal ATP 
effect of (A) amphotericin B, (B) benzathine-benzylpenicillin, (C) cefaclor, (D) cefatrizine, (E) 
cephaloridine and (F) medroxyprogesterone acetate at the P2X7 receptor. Data is presented as 
mean ± SEM from 3 to 4 independent experiments. 
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Medroxyprogesterone acetate is a synthetic derivative of the female sexual hormone 
progesterone. It structurally differs from progesterone by introduction of a methyl residue at 
carbon 6 and an acetate group at carbon 17, which enhances oral bioavailability and 
progestational potency. It is approved as a contraceptive and for postmenopausal hormone 
replacement therapy. In the Women’s Health Initiative trial, the use of postmenopausal 
medroxyprogesterone acetate was associated with increased risk for the development of breast 
cancer and cardiovascular diseases. This led to a downturn of its use in postmenopausal 
osteoporosis prevention therapy. Medroxyprogesterone acetate is potent at both the androgen 
and the glucocorticoid receptor. The application of a 10 mg oral dose leads to peak serum 
concentrations between 0.0088 µM and 0.011 µM (3.4-4.4 ng/ml).337, 338 These serum 
concentrations would be insufficient for any enhancing effect on the P2X7 receptor in vivo. 
Despite the high structural similarity to medroxyprogesterone acetate, the enhancing effect of 
methyltestosterone was not quantifiable. This indicates that the acetyl residue in position 17 
plays an important role for the positive modulating effect.  
An experiment for testing whether the observed enhancement is due to agonistic activity of the 
drug itself was conducted for amphotericin B, benzathine-benzylpenicillin, cephaloridine and 
medroxyprogesterone acetate by injecting various concentrations of the respective drugs 
instead of ATP. No fluorescence signal increase for any compound was observed. The enhancing 
effect therefore cannot be attributed to any agonistic activity at the P2X7 receptor. 
The influence of several single concentrations of the most active enhancers amphotericin B, 
benzathine-benzylpenicillin, cephaloridine and medroxyprogesterone acetate (1 µM, 10 µM and 
100 µM of all compounds, respectively, medroxyprogesterone acetate was additionally tested in 
a final concentration of 50 µM), on the EC50 concentration of ATP at the P2X7 receptor were 
tested. The respective ATP dose-response curves are presented in Figure 5.15 and Figure 5.16. 
Amphotericin B, benzathine-benzylpenicillin and cephaloridine caused a shift of the ATP EC50 
values to the left. The shift was prominent upon incubation with the highest concentration 
(100 µM). This indicates an increase of ATP affinity as a possible cause for the observed 
enhancement of receptor activity. The conclusion was supported by the marginal and non-
significant effect of the different compound concentration on the maximal ATP effect, 
determined from the highest ATP concentration used in the experiment (5 mM).  
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Figure 5.15: (1) Mean ATP dose response curves, (2) ATP pEC50 values and (3) enhancement of 
maximal ATP effect characterizing the influence of (A) amphotericin B and (B) benzathine-
benzylpenicillin at the human P2X7 receptor. Cells were stimulated with ATP 10 µM-5000 µM 
after preincubation with 1 µM ( ), 10 µM ( ), 50 µM ( ) or 100 µM ( ), respectively. 
Enhancement of fluorescence increase was calculated of cells stimulated with the highest ATP 
concentration (5 mM), with ATP control ( ) based as 0 %. The unpaired Student’s t-test for 
determination of significant differences of means was conducted for pEC50 and enhanced 
fluorescence increase. Significant differences (p < 0.05) are marked with (*) and very significant 
differences (p < 0.01) are marked with (**). Data is presented as mean ± SEM from 3-4 
independent experiments. 
 
A slight shift of the EC50 value to the left could be observed upon incubation with increasing 
concentrations of medroxyprogesterone acetate. The maximal ATP effect also increased. No ATP 
EC50 value and no fluorescence signal increase could be determined upon incubation with 
100 µM medroxyprogesterone acetate. The mismatch to the other three compounds tested 
indicates a different mechanism of enhancement that increases both the affinity of the 
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physiological ligand ATP and its effect. A different binding site or a variable conformational 
change upon the binding of the ligand could be the reason for this effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: (1) Mean ATP dose response curves, (2) ATP pEC50 values and (3) enhancement of 
maximal ATP effect characterizing the influence of (A) cephaloridine and (B) 
medroxyprogesterone acetate at the human P2X7 receptor. Cells were stimulated with ATP 
10 µM-5000 µM after preincubation with 1 µM ( ), 10 µM ( ), 50 µM ( ) or 100 µM ( ), 
respectively. Enhancement of fluorescence increase was calculated of cells stimulated with the 
highest ATP concentration (5 mM), with ATP control ( ) based as 0 %. The unpaired Student’s t-
test for determination of significant differences of means was conducted for pEC50 and 
enhanced fluorescence increase. Significant differences (p < 0.05) are marked with (*), very 
significant differences (p < 0.01) are marked with (**) and highly significant differences 
(p < 0.001) are marked with (***). Data is presented as mean ± SEM from 3-4 independent 
experiments. 
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5.5 Discussion 
A library containing 440 approved drugs was tested at human P2X receptor subtypes P2X1, 
P2X2, P2X4, P2X7 and rat receptor mutant P2X3. Several hits were detected. Three compounds, 
bromperidol, ambroxol and flavoxate were identified as selective antagonists at the P2X1 
receptor with micromolar potency. No inhibitory or enhancing potency at the other P2X 
receptor subtypes was detected for both drugs when tested at 20 µM final concentration. 
Furthermore, bisacodyl and niclosamide were determined as potent antagonists at the P2X3 and 
the P2X7 receptor, respectively. A library of derivatives closely related to niclosamide was 
already available. A small sublibrary with structurally similar compounds was newly synthesized 
based on bisacodyl, and SARs were analyzed.  
Niclosamide is approved as an antihelmintic agent against infections with Taenia saginata, 
Taenia solium, diphyllobothrium latum and hymenolepis nana (beef, pork, fish and dwarf 
tapeworm) under the tradename Yomesan®. The treatment lasts for one day, consisting of four 
single doses of 500 mg. In case of an infection with Hymenolepis nana, another two chewable 
tablets have to be taken until day 7.339 The antihelmintic effect is attributed to inhibition of 
oxidative phosphorylation and a stimulation of adenosine triphosphatase activity in 
mitochondria of the cestodes, leading to cell damage and its promoting digestion by the infected 
host. It is well tolerated in humans.340, 341 The absorption of the drug from the gastrointestinal 
system is relatively low, which is attributed to the poor water solubility of the drug.342 
Pharmacokinetic studies in mice reveal maximal plasma concentrations of 893.7 ng/ml 
(2.73 µM), that decreases to 40-50 ng/ml (0.122-0.153 µM) within 30-45 minutes and rebounds 
to 78 ng/ml (0.238 µM) at 1.5 hours after oral application of 200 mg/kg niclosamide.343 Another 
pharmacokinetic study in rats describes a maximal plasma concentration of 354 ± 152 ng/ml 
(1.08 ± 0.46 µM) at 30 minutes that decrease to 83.6 ± 31.7 ng/ml (0.256 ± 0.097 µM) after 
1 hour and to 37.5 ± 10.6 ng/ml (0.115 ± 0.032 µM) at 2 hours after an oral dose of 5 mg/kg. 
After 24 hours, the plasma concentration was lower than 0.5 ng/ml, the limit of quantitation. 
The bioavailability was 10 % of the oral dose.344 These plasma concentrations are high enough to 
inhibit P2X3 and P2X7 receptors in vivo when compared to our results. Niclosamide is 
physiologically metabolized in the liver via CYP1A2 by hydroxylation to 3-hydroxy-niclosamide 
and glucuronidated by UGT1A1 in position 2.345 Besides its long known antihelmintic properties, 
niclosamide was recently discovered as a potent agent in a broad variety of diseases and targets. 
It is reported to inhibit the Wnt/β-catenin pathway in ovarian cancer stem cells, downregulating 
cell proliferation and increasing cell death.346 The Wnt/β-catenin pathway is an important part in 
organ and tissue development and homeostasis. More than 80 % of hereditary cancers of the 
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gastrointestinal system have been associated with hyperactivity of the Wnt/β-catenin pathway 
due to mutations mainly in the APC, but also in β-catenin or axin 2 genes.347 There are several 
hints that the mechanism of niclosamide-induced inhibition of Wnt/β-catenin pathway depends 
on the cancer cell line used in the respective experiments.348, 349 Other targets affected by 
niclosamide are the mammalian target of rapamycin complex 1 (mTORC1), which plays an 
important role in the expression of mRNAs essential for cell growth and metabolism, the STAT3 
pathway and NFκB signaling.341, 350-352 The inhibition of cell growth and promotion of cell death 
make niclosamide a suitable candidate for clinical development as a new and potent anticancer 
agent for the treatment of aggressive tumors like glioblastoma, prostate cancer to diminish 
resistance to antiandrogen enzalutamide or lung cancer to reduce radioresistance.351, 353, 354 
Haygood et al. describe the in vitro anticancer activity of two niclosamide derivatives. One of the 
two was identical to MT170, which was part of the hydroxybenzamide library. The compounds 
were tested on cells harvested from ascites and tumor samples of patients suffering from 
ovarian cancer. Cells were incubated with the test compound for 48 hours. Cell viability was 
determined by the ATPlite luminescence-based assay, yielding IC50 values of 0.1-5 µM for 
niclosamide and 0.15-5 µM for MT170.355 These values are comparable to the inhibitory potency 
determined at the P2X7 receptor in this experimental setting, and lower than its potency at the 
P2X3 receptor. The P2X7 subtype was associated to play an important role in solid tumor 
progression, although it cannot be determined clearly whether the inhibition or enhancement of 
receptor activity reduces cancer progression.178 It is possible that the inhibition of the P2X7 
receptor by niclosamide and its derivatives contributes to the anticancer effect of the drugs. 
Furthermore, the P2X7 receptor is involved in inflammatory processes due to its widespread 
expression in immune cells.178 It is also associated with chronic pain, which often occurs in 
tandem with cancer in late stages, as is the P2X3 receptor.356 No evidence could be found that 
niclosamide was ever tested in a pain model, but one study demonstrates its ability to modulate 
the function of dendritic cells and reduce the production of inflammatory cytokines and the 
antigen specific T-cell responses. Niclosamide dose-dependently reduced the release of pro-
inflammatory cytokines and chemokines in lipopolysaccharide-stimulated mature mouse bone 
marrow-derived dendritic cells. The concentrations used were between 0.3125 µM and 
1.25 µM.357 Since P2X7 receptors are also expressed in these cells and have previously been 
associated to have a proinflammatory effect by influencing the activity of IL-1β, it is possible that 
they could be the mediating factor of niclosamide effect. Currently, the theory cannot be 
proven, since the exact mechanism of niclosamide action in dendritic cells is not yet determined.  
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The role of niclosamide in inhibition of Wnt/β-catenin pathway and internalization of Frizzled 
receptor was recently further investigated. The Frizzled receptor consists of seven 
transmembrane regions. It is activated by secreted Wnt glycoproteins together with the single 
transmembrane receptor LRP5/6. The binding of Wnt leads to activation of the cytosolic protein 
Dishevelled, which forces internalization of the Frizzled receptor. Niclosamide has previously 
been associated with downregulation of Dishevelled, β-catenin and Wnt-signaling in general. In 
order to improve its pharmacokinetic properties without loss of inhibitory potency on the 
Wnt/β-catenin pathway, several derivatives of niclosamide were synthesized and evaluated. 
Some of these derivatives are identical to members of the library tested in our experiments. The 
concerned compounds are MT170, MT301, MT304 and MT310 the derivatives with a single 
residue (NO2, CF3 or Cl) introduced in position 4, MT167 and MT188 with a single residue (CF3 or 
Cl) introduced in position 3 and MT179 with two chlorine residues introduced in position 3 and 5 
of ring B of the niclosamide scaffold respectively. Internalization of Frizzled 1 receptor was 
determined via confocal microscopy in cells stably transfected with the receptor linked to YFP. 
Furthermore, the inhibition of Wnt/β-catenin was measured via TOPflash reporter assay. The 
observed IC50 values of the respective compounds were in the high nanomolar to low 
micromolar range. High nanomolar inhibitory potency was always connected to high 
internalization of the Frizzled 1 receptor. The highest potency was detected for the compound 
MT170 with an IC50 value of 0.29 ± 0.06 µM.
358 The potency determined in our experiments at 
the P2X3 receptor was either comparable or at least tenfold higher than described for the 
inhibition of the Wnt/β-catenin pathway, including the lead compound niclosamide. The 
inhibitory potency at the P2X7 receptor was comparable to the values described in the Wnt/β-
catenin study.  
Guo et al. describe a direct connection between the P2X7 receptor and the Wnt/β-catenin 
pathway. In E10 cells stably transfected with P2X7, a downregulation of Wnt/β-catenin signaling 
was observed upon P2X7 receptor stimulation with BzATP. The activation of the P2X7 receptor is 
associated with an increase in apoptosis and cell death in HEK293, A549, H441 RLE-6TN and RFL-
6 cancer cell lines.359 However, the activation of the P2X7 receptor in several melanoma cell lines 
was associated with reduced apoptosis and cell death.360, 361 Inhibition of both Wnt/β-catenin 
and P2X7 receptor signaling could mean a beneficial effect in both enhancing apoptosis and 
reduction of inflammation. 
P2X3 receptors are mainly found in the central nervous system. So far, the receptor was not 
associated with immune response or management. Niclosamide therefore could be a potential 
candidate for chronic pain treatment, since P2X3 receptors were identified to be a particular 
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part of this. An experiment to determine antinociceptive effects of niclosamide in a chronic pain 
or cancer pain model could help determining its benefit on this matter further. 
The high inhibitory potency of the niclosamide derivatives at P2X3 and P2X7 receptors suggests 
that various patterns of small hydrophilic and lipophilic substituents introduced at rings A and B 
are well tolerated by both receptor subtypes. Although the sublibrary contained compounds 
with various substitution patterns, P2X receptor selectivity could not be obtained. Furthermore, 
the compounds were first developed as potent antagonists of the human P2X1 receptor, and the 
preliminary data indicates that nearly all compounds have comparable or less potency at both 
P2X3 and P2X7 receptors than this intended target (data not yet published). For compounds 
MT303, MT283, MT304, MT282 and MT309, a considerable selectivity at the P2X3 receptor 
could be observed, with almost 100-fold selectivity towards the human P2X1 receptor 
(IC50 1.66 ± 0.49 µM, 8.00 ±2.01 µM, > 10 µM, 13.5 ± 1.3 µM and 7.62 ± 2.98 µM at P2X1, 
respectively). MT282 also displayed over 20-fold selectivity towards the P2X7 in comparison to 
the P2X1 receptor. Since the human stable P2X3-2 receptor mutant could not be expressed 
successfully in 1321N1 astrocytoma cells after retroviral transfection, a test for species 
selectivity of niclosamide derivatives was not possible. No assumption can be made if 
niclosamide derivatives are also candidates for selective P2X3 receptor ligand development in 
humans. If the selective potency can be confirmed in humans, these five structures could be the 
basis for further drug development. 
Bisacodyl was identified as a very potent and interesting hit at human P2X7 and rat P2X3 
receptors. The initially detected high inhibitory potency at the P2X3 receptor could not be 
confirmed during concentration-response experiments. Bisacodyl was proven to be the most 
potent antagonist at the P2X7 receptor of this drug library. Bisacodyl is a laxative approved for 
the short-term treatment of obstipation and bowel evacuation prior to gastrointestinal surgery 
and diagnostic investigation.362 It is rapidly cleaved to the active metabolite bis(p-
hydroxyphenyl)-pyridyl-2-methane (BHPM) by deacetylases found on the intestinal mucosa and 
then glucuronidated extrahepatically in the gut wall. BHPM is identical to THV-B01, one member 
of the nine bisacodyl derivatives tested in our experiments. It is also the active metabolite of 
sodium picosulfate, a structurally closely related laxative, by cleavage of the sulfate residues by 
desulfatase enzymes of the colonic microflora. Bisacodyl and sodium picosulfate themselves are 
not absorbed into the body after oral application. A single oral dose of 10 mg bisacodyl leads to 
maximal plasma concentrations of 64.6 ng/ml of total BPHM (free and in its glucuronidated 
form). Free BHPM could not be measured in plasma.363 The urinary excretion is reported to be 
3.4 ± 0.5 % up to 9.2 ± 3.3 % when administered as tablet or suppository, and around 50 % of 
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one dose is eliminated as the active metabolite in the faeces. The urinary excretion increases up 
to 43.4 ± 15.0 %, when the drug is administered in solution.364, 365 BHPM is subjected to an 
intensive cycle of metabolism. It is secreted again to the lumen after glucuronidation, where the 
glucuronide is cleaved and resorption in intestinal epithelial cells begins again. The laxative 
effect of bisacodyl is attributed to an increase of prostaglandin E2 (PGE2). This leads to inhibition 
of Na+/K+-ATPase, resulting in raising the osmotic pressure in the intestinal tract. This again is 
associated with an enhanced secretion of sodium and potassium ions and water into the 
intestinal lumen.366, 367 Ikarashi et al. found evidence that bisacodyl indirectly decreases the 
expression of aquaporine water channels, which play a very important role in intestinal water 
transport, by enhancing the secretion of PGE2. The laxative effect was therefore rather 
associated with the inhibition of water resorption due to a deprivation of aquaporine water 
channels in the epithelial mucosa of the intestine than to an increase of osmotic pressure in the 
lumen, as was assumed previously.368 P2X7 receptors have mainly been associated with 
inflammatory processes in the gastrointestinal tract, but not in normal healthy GI tissue in 
rats.369 No information can be found which supports the idea that P2X7 as a channel capable of 
performing pores is also involved in the water resorption process in the colon. It is therefore 
unlikely that the inhibitory effect of bisacodyl detected in this experimental series can contribute 
to the laxative mode of action of the drug. The test of the cleaved and etherified bisacodyl 
derivatives indicates that the ester moieties are essential for successful P2X7 receptor inhibition. 
The derivatization shifts the affinity of the compounds towards the rat receptor mutant P2X3, 
which is another indication that P2X7 receptors are most likely not involved in the mode of 
action of bisacodyl. Furthermore, bisacodyl itself is not the laxative compound, but its 
hydrolyzed metabolite BHPM. THV-B01, which is equivalent to BHPM, did not show inhibitory 
potency at P2X7 higher than 50 %. Concentration-response experiments were not successful. 
Sodium picosulfate, a closely related laxative drug like bisacodyl, did also not show any inhibitory 
potency at the P2X7 receptor at 100 µM. The results show that the P2X7 receptor is not a part of 
the mechanism of action of bisacodyl. 
The active metabolite BHPM (THV-B01) was a potent antagonist at the P2X3 receptor with low 
nanomolar potency, as were the etherified derivatives. Since P2X3 receptors are widely 
expressed in the gastrointestinal nervous system and mainly associated with perception and 
forwarding of pain signals, these findings could be the start for the development of new ligands 
with primarily gastrointestinal located action.370 It is possible that the P2X3 receptor is a 
previously unknown part of the molecular mechanism of bisacodyl efficacy in the colon. 
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Furthermore, most of the compounds seem to be selective for the P2X3 receptor. The 
determination of affinity at the human P2X3 receptor will complete the picture.  
A lot of the drugs were initially identified as potential enhancers at human P2X1, P2X7 and rat 
P2X3 receptor. Most of them were identified as false hits. Only one compound at the P2X3 
(emetine) and four compounds at the P2X7 receptor demonstrated a dose-dependent and 
reproducible ATP-induced enhancement of receptor function. Among those four compounds 
were two antibiotics, one penicillin and one cephalosporin. Furthermore, two additional 
cephalosporin antibiotics, cefaclor and cefatrizine, were demonstrated to enhance ATP-induced 
receptor activity. They were not the first PAMs identified for the P2X7 receptor. Nörenberg et al. 
identified clemastine as a potent and potentially selective positive enhancer at the P2X7 
receptor. The enhancing effect was found to be concentration-dependent, did not occur in the 
absence of agonist, and was caused by an increase of ATP potency and not by an increase of 
maximal receptor activity.197 Clemastine was also part of the drug library tested here. In the 
initial screening, the results of Nörenberg et al. could be confirmed, but concentration-response 
experiments showed inhibition of P2X7 receptor at concentrations above 10 µM and no 
enhancement of ATP activity at all. It is possible that the enhancing effect of clemastine is 
dependent on the ATP concentration used for receptor stimulation. Nörenberg et al describe an 
increased sensitization of P2X7 to its physiological agonist ATP resulting in full receptor 
activation at non-saturating ATP concentrations.197 
Ivermectin was also identified as a PAM at human P2X7, which was not observed in this 
experimental setting.156 Instead, ivermectin was identified as an antagonist at the human P2X1 
and rat P2X3 receptor with inhibitory potency in the low micromolar range, and showed neither 
inhibitory nor enhancing activity at the P2X7 and the P2X2 receptor. The lack of enhancement at 
the P2X7 receptor correlates with previous findings indicating ivermectin to be relatively 
selective towards the P2X4 receptor.101 Other previously identified PAMs of the P2X7 receptor 
are phenothiazine antipsychotics prochlorperazine and trifluoperazine, which were not part of 
the drug library tested in these experiments here.193 The structurally related compounds 
fluphenazine and perphenazine did not show enhancing but weak inhibitory potency at human 
P2X7 receptor. Therefore, the enhancing effect at P2X7 most likely cannot be attributed to all 
phenothiazine compounds per se. Literature demonstrates that positive allosteric modulation of 
P2X receptors is no rarity and can be observed for a variety of drugs and compounds. For further 
confirmation of their enhancing effect, penicillin and cephalosporin antibiotics should be tested 
in an independent experiment to confirm their allosteric enhancing capabilities and further 
characterize their affinity and efficacy. 
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6 Summary 
P2X receptors are widely expressed in the body. They are associated with numerous 
physiological and pathophysiological processes such as cancer, inflammation and pain, which 
make them important targets for drug development. Several selective antagonists have already 
been described for the P2X3 and the P2X7 receptor. The published antagonists for P2X1, P2X2 
and P2X4 receptors either show only moderate potency or are not selective towards one P2X 
subtype.  
 
Characterization of the S15V mutant of the rat P2X3 receptor and use for library screening 
The pharmacological testing of P2X1 and P2X3 receptors is complicated by their fast 
desensitization upon agonist stimulation. In order to enable pharmacological evaluation at the 
rat P2X3 receptor, a stable non-desensitizing receptor mutant was created by exchange of the 
amino acid serine in position 15 to valine (S15V). The mutant (P2X3) was then used for the 
testing of a library of anthraquinone derivatives synthesized by Dr. Younis Baqi by measurement 
of calcium influx. The aim was:  
(i) to determine whether the new mutant is suitable for high throughput screening via 
calcium measurement and  
(ii) the identification of new P2X3 receptor ligands. 
The Z’-factor was calculated for assessing the quality and reliability of the assays. An average 
value of 0.64 ± 0.02 was determined which demonstrates the suitability of the assay using the 
receptor mutant for high-throughput screening experiments. The testing of an anthraquinone 
compound library led to the identification of several antagonists for the P2X3 receptor. The most 
potent compounds shared common structural features. Selected antagonists and their 
respective IC50 values are presented in Figure 6.1. 
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Figure 6.1: Structures and inhibitory potencies of three of most potent newly identified P2X3 
receptor antagonists, the anthraquinone derivatives YB106, YB107 and YB120. 
 
The structure-activity relationships of anthraquinone derivatives are summarized in Figure 6.2. 
ATP curve shift experiments with the antagonist YB120 indicated a competitive mode of 
inhibition. 
 
 
Figure 6.2: Summary of structure-activity relationships of anthraquinone derivatives with 
inhibitory potency at the P2X3 receptor. 
 
Several of the investigated anthraquinone derivatives showed positive allosteric modulation of 
the P2X3 receptor. Structures of positive allosteric modulators (PAMs) differed from those of 
antagonists. Selected potent PAMs are displayed in Figure 6.3. 
 
YB106 
IC50 2.81 ± 0.41 µM 
YB120 
IC50 2.39 ± 1.00 µM 
YB107 
IC50 2.38 ± 0.30 µM 
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Figure 6.3: Selected anthraquinone derivatives that showed positive allosteric modulation of the 
P2X3 receptor. 
 
The enhancing properties were dependent on the compound concentration and on the ATP 
level. The compounds were not active in the absence of ATP. Some of the identified PAMs 
showed a common structural feature. The scaffold and the structure-activity relationships are 
presented in Figure 6.4. 
 
 
Figure 6.4: Structure-activity relationships of anthraquinone derivatives with positive 
modulating properties at the P2X3 receptor. 
 
Our study demonstrated that the S15V mutant of the rat P2X3 receptor is suitable for 
fluorescent measurements of agonist-dependent calcium influx, and that anthraquinone 
derivatives are potent modulators of P2X3 receptors.  
 
YB038 
P2X1: EC50Enhancement 9.07 ± 5.70 µM 
P2X2: > 10 µM 
P2X3: EC50Enhancement 0.897 ± 0.296 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
YB160 
P2X1: IC50 3.18 ± 1.43 µM 
P2X2: IC50 3.32 ± 0.37 µM 
P2X3: EC50Enhancement 2.22 ± 0.45 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
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Inhibitory potency of polyoxometalates at P2X receptors 
POMs are inorganic transition metal clusters with high negative charges and diverse three-
dimensional shapes. They have previously been demonstrated to be potent inhibitors of 
nucleotide-degrading enzymes, namely NPPs, NTPDases and ecto-5’-nucleotidases.221, 271 The 
investigated POM library contained seventeen polyoxotungstates, four rhenium-based 
compounds and two vanadium cluster compounds. The aim of our study was: 
 the determination of inhibitory potency of POMs at P2X receptors 
 to characterize the influence of PEGylation on the potency of POMs 
 to determine the compounds’ selectivity 
 gain further insight into the mechanism of inhibition of P2X receptors by POMs. 
Almost all of the metal cluster compounds were found to be potent antagonists of P2X 
receptors. The most potent compounds are presented in Figure 6.5 and Figure 6.6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Structures and potencies of selected polyoxotungstates at P2X receptors. 
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Figure 6.6: Structures and potencies of selected POMs and related cluster compounds at P2X 
receptors.  
 
Compound selectivity could be demonstrated for some polyoxotungstates versus the P2X4 and 
P2X7 receptors, at which they were less potent. The inhibitory potency at P2X1, P2X2 and P2X3 
receptors was comparable in most cases. The rhenium clusters showed weaker potency at P2X 
receptors than the polyoxotungstates. KB1 and KB2 were the only POMs that preferably 
inhibited the P2X2 over the P2X1 receptor. Of the vanadium-based compounds, the 
(Bu4N)6-PEG 2000, 
(Bu4N)6[H3P2W15O62]-PEG 2000 
P2X7: EC50Enhancement 0.167 ± 0.148 µM 
              (biphasic curve shape) 
K-POM, [HP2W15V3O62]
8- 
P2X7: EC50Enhancement 0.0241 ± 0.0087 µM  
              (biphasic  curve shape) 
KB3, [Re6S8(CH3COO)6]
4- Metavanadate ([VO3]
-) 
P2
X1
P2
X2
P2
X3
P2
X4
P2
X7
4.5
5.5
6.5
7.5
8.5
p
IC
5
0
P2
X1
P2
X2
P2
X3
P2
X4
P2
X7
3
4
5
6
7
8
p
IC
5
0
P2
X1
P2
X2
P2
X3
P2
X4
P2
X7
4.5
5.0
5.5
6.0
6.5
p
IC
5
0
P2
X1
P2
X2
P2
X3
P2
X4
P2
X7
4.5
5.0
5.5
6.0
p
IC
5
0
6 Summary 
-187- 
 
metavanadate was able to inhibit the P2X2 but none of the other P2X subtypes. Orthovanadate 
did not show inhibitory potency at any of the P2X receptor subtypes. The non-PEGylated 
compound K-POM was the most potent antagonist of the library with low nanomolar potency at 
P2X1 and P2X2 receptors. Its PEGylation resulted in only a minor decrease in potency. All 
PEGylated compounds as well as their two non-PEGylated precursors showed biphasic curves at 
the P2X7 receptor with concentration-dependent enhancement of receptor activity followed by 
inhibition. ATP shift curves and subsequent Schild plot analyses indicated that several POMs are 
orthosteric antagonists of P2X receptors. Cell viability assays (MTT) revealed a large separation 
between P2X receptor blocking and cytotoxic concentrations. It could be demonstrated that 
POMs are potent but non-selective antagonists of P2X receptors. 
 
Interaction of approved drugs with P2X receptors 
A library of 440 approved drugs of widespread indications and diverse structures were screened 
at 20 µM final concentration. Compounds inhibiting the receptors by more than 50 % at 1 µM 
were further investigated by recording of concentration-response curves. Selected potent hit 
compounds are presented in Figure 6.7. 
Ambroxol was identified as a selective antagonist of the P2X2 receptor. The drug is approved as 
an expectorant for children and adults. It increases mucin secretion, mucus hydration and the 
production of surfactant in the lung. The drug may be suitable as a lead structure for the 
development of new potent and selective P2X2 receptor antagonists. 
The antipsychotic drug bromperidol, a dopamine D2 antagonist, was identified as a selective 
antagonist at the P2X1 receptor. Due to the high potency and selectivity, the compound might 
be a good candidate for the development of new, selective P2X1 receptor antagonists. 
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Figure 6.7: Structure and inhibitory potency of selected hit compounds of the drug library at P2X 
receptors.  
 
Bisacodyl is approved as a laxative for the treatment of chronic obstipation. We discovered that 
it acts as a potent antagonist of the P2X4 and the P2X7 receptor with eight-fold selectivity for 
the P2X7 versus the P2X4 receptor. Due its high potency, a small library of derivatives based on 
the structure of bisacodyl was synthesized by The-Hung Vu. One of the compounds represents 
the hydrolysis product of bisacodyl, termed BHPM, which is believed to be the biologically active 
laxative agent that is formed from the prodrug bisacodyl in the gut wall. It is an even more 
potent P2X receptor antagonist with high selectivity for the P2X3 receptor subtype 
(IC50 19.4 nM). P2X3 receptor blockade may contribute to the pharmacological effects of 
bisacodyl. The etherification of the phenolic groups led to a reduction of inhibitory potency at 
the P2X3 receptor when compared to BHPM. 
 
Bromperidol 
P2X1: IC50 3.46 ± 0.33 µM 
P2X2: > 20 µM 
P2X3: > 20 µM 
P2X4: > 20 µM 
P2X7: > 20 µM 
Ambroxol 
P2X1: > 20 µM 
P2X2: IC50 5.69 ± 1.06 µM 
P2X3: > 20 µM 
P2X4: > 20 µM 
P2X7: > 20 µM 
Bisacodyl 
P2X1: IC50 > 100 µM 
P2X2: > 20 µM 
P2X3: IC50 > 100 µM 
P2X4: IC50 0.711 ± 0.297 µM 
P2X7: IC50 0.0962 ± 0.0324 µM 
Niclosamide 
P2X1: > 1 µM 
P2X2: > 20 µM 
P2X3: IC50 0.0134 ± 0.0029 µM 
P2X4: IC50 > 100 µM 
P2X7: IC50 0.322 ± 0.129 µM 
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Figure 6.8: Structures and potencies of bisacodyl derivatives at P2X receptors. Data is presented 
as mean ± SEM from 3-4 independent experiments.  
 
Niclosamide was identified as a potent antagonist at both the P2X3 and the P2X7 receptor. It is 
approved as an antihelmintic drug and has recently been reported to also show anti-cancer 
actitivity.346, 351 
 
THV-B01 (BHPM) 
P2X1: > 10 µM 
P2X2: > 10 µM 
P2X3: IC50 0.0194 ± 0.0036 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
THV-B04-1 
P2X1: > 10 µM 
P2X2: IC50 1.55 ± 0.60 µM 
P2X3: IC50 0.452 ± 0.053 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
THV-B04-2 
P2X1: > 10 µM 
P2X2: > 10 µM 
P2X3: IC50 4.14 ± 0.23 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
THV-B05-1 
P2X1: > 10 µM 
P2X2: > 10 µM 
P2X3: > 10 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
THV-B05-2 
P2X1: > 10 µM 
P2X2: > 10 µM 
P2X3: IC50 1.86 ± 0.12 µM 
P2X4: > 10 µM 
P2X7: > 10 µM 
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The structurally closely related benzanilide derivative IMD-0354, part of a commercial TOCRIS 
library, has previously been identified in our group as a potent antagonist of the P2X1 receptor 
by Sabrina Densborn and Dr. Aliaa Abdelrahman (data not yet published). Based on this scaffold, 
a library of hydroxybenzamide derivatives was synthesized by Dr. Maoqun Tian. The results for 
the lead structure IMD-0354 and the most potent compound at both P2X3 and P2X7 receptors 
are presented in Figure 6.9. 
 
 
 
 
 
Figure 6.9: Structure and potency of selected benzanilide derivatives at P2X receptors.  
 
Figure 6.10 summarizes the most important structure-activity relationships of benzanilide 
derivatives for both the P2X3 and P2X7 receptor. 
Bisacodyl, niclosamide and the related compounds MT164 and MT175 were shown by ATP curve 
shift experiments to act as allosteric antagonists of P2X3 and P2X7 receptors.  
 
  
IMD-0354 (MT164) 
P2X1: IC50 0.0192 ± 0.0041 µM 
P2X2: > 10 µM 
P2X3: IC50 0.0147 ± 0.0103 µM 
P2X4: IC50 6.14 ± 2.44 µM 
P2X7: IC50 0.128 ± 0.019 µM 
MT175 
P2X1: IC50 0.0231 ± 0.0036 µM 
P2X2: > 10 µM 
P2X3: IC50 0.0109 ± 0.0052 µM 
P2X4: IC50 6.34 ± 1.56 µM 
P2X7: IC50 0.0513 ± 0.0025 µM 
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(B) 
 
 
 
 
 
 
Figure 6.10: Summary of structure-activity relationships of niclosamide derivatives with 
inhibitory potency (A) at the P2X3 (blue) and (B) the P2X7 receptor (red). 
 
Some approved drugs were found to enhance the maximal activation level of P2X7 receptors in 
the initial screening experiment. The most potent hit compound is presented in Figure 6.11. 
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Figure 6.11: Structure and enhancing potency of medroxyprogesterone acetate at the P2X7 
receptor. The receptor was stimulated with ATP 2.5 mM (half-maximal activation). 
 
The enhancing properties of medroxyprogesterone acetate were concentration-dependent. 
Enhancement was only seen at the stimulated receptor, no agonistic properties of the 
compound itself could be detected. None of the other investigated steroid-based drug was 
identified as a PAM at P2X7 receptor besides medroxyprogesterone acetate. ATP shift curve 
experiments indicate an increase of ATP affinity as cause for the allosteric P2X7 receptor 
modulation.  
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7 Conclusion and Outlook 
Screening assays suitable for high-throughput screening and for the characterization of hit 
compounds and optimized derivatives in in 1321N1 astrocytoma cell lines stably transfected 
with one of the P2X receptor subtypes were established. These allow the use of ATP, the natural 
agonist of P2X receptors, since 1321N1 astrocytoma cells do not show any signal upon ATP 
stimulation – in contrast to other commonly used cell lines. Such an assay system is essential, 
since the effects of allosteric modulators can be highly probe-dependent, leading to different 
results when using a synthetic agonist for activation as compared to applying the physiological 
ligand. 
The first screening campaigns have provided a considerable number of hit compounds, including 
competitive antagonists, allosteric antagonists (negative allosteric modulators, NAMs), and even 
positive allosteric modulators (PAMs). Future studies should be directed towards improving their 
properties, such as potency, selectivity and pharmacokinetic properties by medicinal chemistry 
approaches.  
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Abbreviations 
(Bu4N)
+ Tetrabutylammonium 
2-meSATP 2-Methylthioadenosine-5‘-O-triphosphate 
5-BDBD 5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-
2-one 
5-HT 5-Hydroxytryptamine 
ADP Adenosine 5‘-diphosphate 
AMP Adenosine 5‘-monophosphate 
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APC Adenomatous polyposis coli 
Arg (R) Arginine  
Asn (N) Asparagine 
Asp (D) Aspartic acid 
ATD Amino terminal domain 
ATP Adenosine-5‘-triphosphate 
BBG Brilliant Blue G 
BHPM Bis(p-hydroxyphenyl)-pyridyl-2-methane 
BzATP 2‘(3‘)-O-(4-Benzoylbenzoyl)adenosine-t‘-triphosphate 
CCL21 Chemokine C-C motif ligand 21 
CCR2 C-C chemokine receptor type 2 
cDNA complementary deoxyribonucleic acid 
CFA complete Freund’s adjuvant-induced arthritic rat model 
CK 2 Protein kinase 2 (Casein kinase II) 
CNS Central nervous system 
COX Cyclooxygenase 
ctDNA Calf thymus DNA 
Cys (C) Cysteine 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethyl sulfoxide 
DR Dose ratio 
EC50 Concentration of half-maximal receptor activation 
EDTA Ethylenediaminetetraacetic acid 
eNOS Endothelial nitric oxide synthase 
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FCS Fetal calf serum 
Fluo-4 AM Fluo-4 acetoxymethyl ester 
G418 Geneticin 
GABAA/C γ-Aminobutyric acid receptor subtype A/C 
GI Gastrointestinal 
Glu (E) Glutamic acid 
GP+envAM12 Amphotropic mouse fibroblast packaging cell line 
GPCR G protein-coupled receptor 
GSH/GSSG Glutathione/glutathione disulfide 
HAD High affinity desensitization 
HBSS Hank’s balanced salt solution 
HDAC Histone deacetylase 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
His (H) Histidine 
HIV Human immune deficiency virus 
HTS High-throughput screening 
IC50 Concentration of half-maximal receptor inhibition 
Ile (I) Isoleucine 
IRF8 Interferon regulatory factor 8 
KA Kainic acid 
KB Estimated antagonist affinity constant 
KD Dissociation constant 
Ki Inhibition constant 
LBD Ligand binding domain 
Leu (L) Leucine 
LGIC Ligand-gated ion channel 
Lys (K) Lysine 
max. maximal 
Met (M) Methionine 
MFCA 3-Methyl-flavone-8-carboxylic acid 
mRNA Messenger RNA 
MRSA Methicillin-resistant Staphylococcus aureus 
msec Milliseconds 
mTORC1 Mammalian target of rapamycin complex 1 
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MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
n. c. no convergence 
n. d. not determined 
nACh nicotinic acetylcholine receptor 
NALCN Sodium leak channel 
NAM negative allosteric modulator 
NavAb Voltage-gated sodium channel 
NF023 8,8’-[Carbonyl-bis(imino-3,1-phen-ylenecarbonylimino)]bis-1,3,5-
naphthalene-trisulfonic acid 
NF110 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-
(carbonylimino)))tetra-kis-benzenesulfonic acid 
NF279 8,8’-[Carbonyl-bis(imino-4,1-phenylenecarbonylimino-4,1-
pheylene-carbonyl-imino)]bis-1,3,5-naphthalene trisulfonic acid 
NF449 4,4’,4’’,4’’’-[Carbonylbis-(imino-5,1,3-benzenetriyl-
bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid 
NF770 7,7’-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-
methyl-phenylene)carbonyl-imino))bis-(1-methoxy-naphthalene-
3,6-disulfonic acid 
NMDA N-methyl-D-aspartate 
NSAID Non-steroidal anti-inflammatory drug 
PAM Positive allosteric modulator 
pEC50 negative decadic logarithm of EC50 value 
PEG Polyethylene glycol 
Phe (F) Phenylalanine 
pIC50 negative decadic logarithm of IC50 value 
POM Polyoxometalate 
PPADS Pyridoxalphosphate-6-azophenyl-2‘-4‘-disulfonic acid 
PPARα Peroxisome proliferator-activated receptor α 
PSB-1011 Disodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2-ylamino)-4-
sulfophenylamino]-9,10-dioxo-9,10,dihydroanthracene-2-sulfonate 
PSB-10211 Sodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-1-ylamino)-
phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 
PSB-12054 N-(benzyloxycarbonyl)phenoxazine 
PSB-12062 N-(p-methylphenylsulfonyl)phenoxazine 
Abbreviations 
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pVSV-G Vesicular stomatitis virus-expressing vector 
RB-2 Reactive Blue-2 
RNA Ribonucleic acid 
RSV Anti-respiratory syncytial virus 
RT Room temperature 
S15VrP2X3 Mutant of rat P2X3 receptor with a point mutation in position 15 
(serine was exchanged to valine) 
SARS Severe acute respiratory syndrome 
SEM Standard error of the mean 
Ser (S) Serine 
STAT3 Signal transducer and activator of transcription 3 
TCA Tricyclic antidepressant 
Thr (T) Threonine 
TM Transmembrane α-helix 
TMD Transmembrane domain 
TNP-ATP 2‘-3‘-O-(2, 4,6-Trinitrophenyl)adenosine-5‘-triphosphate 
TRIS Tris(hydroxymethyl)aminomethane 
UDP Uridine 5‘-diphosphate 
UTP Uridine 5‘-triphosphate 
VGCC Voltage-gated calcium channel 
VGIC Voltage-gated ion channel 
VGKC Voltage-gated potassium channel 
VGNC Voltage-gated sodium channel 
VSD Voltage-sensing domain 
YFP Yellow-fluorescent protein 
zfP2X4 Zebrafish P2X4 receptor 
α,β-MeATP α,β-Methylene-adenosine 5‘-triphosphate 
β,γ-MeATP β,γ-Methylene-adenosine 5‘-triphosphate 
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